bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

A SARS-CoV-2 neutralizing antibody protects from
lung pathology in a COVID-19 hamster model
Jakob Kreye1,2,3,4,†,*, S Momsen Reincke1,2,3,5,†, Hans-Christian Kornau1,6, Elisa Sánchez-Sendin1,2,3,
Victor Max Corman7, Hejun Liu8, Meng Yuan8, Nicholas C. Wu8, Xueyong Zhu8, Chang-Chun D. Lee8,
Jakob Trimpert9, Markus Höltje10, Kristina Dietert11,12, Laura Stöffler1,3, Niels von Wardenburg1,3, Scott
van Hoof1,2,3, Marie A Homeyer1,3,5, Julius Hoffmann1,3, Azza Abdelgawad9, Achim D Gruber11, Luca D
Bertzbach9, Daria Vladimirova9, Lucie Y Li2,10, Paula Charlotte Barthel10, Karl Skriner13, Andreas C
Hocke14, Stefan Hippenstiel14, Martin Witzenrath14, Norbert Suttorp14, Florian Kurth14,15, Christiana
Franke3, Matthias Endres1,3,16,17,18, Dietmar Schmitz1,6, Lara Maria Jeworowski7, Anja Richter7, Marie
Luisa Schmidt7, Tatjana Schwarz7, Marcel Alexander Müller7, Christian Drosten7, Daniel Wendisch14,
Leif E Sander14, Nikolaus Osterrieder9, Ian A Wilson8,19, Harald Prüss1,2,3,*

1

German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.

2

Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany.

3

Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member

of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.
4

Department of Pediatric Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität

Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.
5

Berlin Institute of Health (BIH), 10178 Berlin, Germany.

6

Neuroscience Research Center (NWFZ), Cluster NeuroCure, Charité-Universitätsmedizin Berlin, corporate

member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.
7

Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,

Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, and German Centre for Infection
Research (DZIF), Berlin, Germany.
8

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA

92037, USA.
9

Institute of Virology, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany.

1

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

10

Institute of Integrative Neuroanatomy Berlin, Charité-Universitätsmedizin Berlin, corporate member of Freie

Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
11

Institute of Veterinary Pathology, Freie Universität Berlin, Robert-von-Ostertag-Str. 15, 14163 Berlin,

Germany.
12

Veterinary Centre for Resistance Research, Freie Universität Berlin, Robert-von-Ostertag-Str. 8, 14163

Berlin, Germany.
13 Department

of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, corporate member

of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.
14

Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate

member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.
15

Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine and I. Department of

Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
16

Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität

Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.
17

Excellence Cluster NeuroCure Berlin, Charité-Universitätsmedizin Berlin, corporate member of Freie

Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.
18

German Centre for Cardiovascular Research (DZHK), partner site Berlin, Charité-Universitätsmedizin Berlin,

corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin,
Germany.
19
†

The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

These authors contributed equally.

* Correspondence to:
Jakob Kreye & Harald Prüss
German Center for Neurodegenerative Diseases (DZNE) Berlin
c/o Charité – Universitätsmedizin Berlin
CharitéCrossOver (CCO), Charitéplatz 1, 10117 Berlin, Germany
Email: jakob.kreye@dzne.de; harald.pruess@dzne.de.

2

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

ABSTRACT
The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19),
manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virusneutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and
guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from ten COVID-19
patients, we identified 40 strongly neutralizing mAbs. The most potent mAb CV07-209 neutralized
authentic SARS-CoV-2 with IC50 of 3.1 ng/ml. Crystal structures of two mAbs in complex with the
SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2
attachment. Interestingly, some of the near-germline SARS-CoV-2 neutralizing mAbs reacted with
mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters
from SARS-CoV-2 infection, weight loss and lung pathology. Our results show that non-self-reactive
virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.

3

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

INTRODUCTION
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started emerging in humans in
late 2019, and rapidly spread to a pandemic with millions of cases worldwide. SARS-CoV-2 infections
cause coronavirus disease 2019 (COVID-19) with severe respiratory symptoms, but also pathological
inflammation

and

multi-organ

dysfunction,

including

acute

respiratory

distress

syndrome,

cardiovascular events, coagulopathies and neurological symptoms (Helms et al., 2020; Zhou et al.,
2020; Zhu et al., 2020). Some aspects of the diverse clinical manifestations may result from a
hyperinflammatory response, as suggested by reduced mortality in hospitalized COVID-19 patients
under dexamethasone therapy (Horby et al., 2020).
Understanding the immune response to SARS-CoV-2 therefore is of utmost importance. Multiple
recombinant SARS-CoV-2 mAbs from convalescent patients have been reported (Brouwer et al.,
2020; Cao et al., 2020; Ju et al., 2020; Kreer et al., 2020; Robbiani et al., 2020; Rogers et al., 2020;
Wec et al., 2020). mAbs targeting the receptor-binding domain (RBD) of the viral spike protein S1 can
compete with its binding to human angiotensin converting enzyme 2 (ACE2) and prevent viral entry
and subsequent replication (Cao et al., 2020; Ju et al., 2020; Walls et al., 2020). Potent virus
neutralizing mAbs that were isolated from diverse variable immunoglobulin (Ig) genes typically carry
low levels of somatic hypermutations (SHM). Several of these neutralizing mAbs selected for in vitro
efficacy showed prophylactic or therapeutic potential in animal models (Cao et al., 2020; Liu et al.,
2020; Rogers et al., 2020; Zost et al., 2020). The low number of SHM suggests limited affinitymaturation in germinal centers compatible with an acute infection. Near-germline mAbs usually
constitute the first line of defense to pathogens, but carry the risk of self-reactivity to autoantigens
(Lerner, 2016; Liao et al., 2011; Zhou et al., 2007). Although critical for the therapeutic use in
humans, potential potential tissue-reactivity of near-germline SARS-CoV-2 antibodies has not been
examined so far.

4

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Here, we systematically selected 18 strongly neutralizing mAbs out of 598 antibodies from 10 COVID19 patients by characterization of their biophysical properties, authentic SARS-CoV-2 neutralization,
and exclusion of off-target binding to murine tissue. Additionally, we solved two crystal structures of
neutralizing mAbs in complex with the RBD, showing antibody engagement with the ACE2 binding
site from different approach angles. Finally, we selected mAb CV07-209 by its in vitro efficacy and the
absence of tissue-reactivity for in vivo evaluation. Systemic application of CV07-209 in a hamster
model of SARS-CoV-2 infection led to profound reduction of clinical, paraclinical and histopathological
COVID-19 pathology, thereby reflecting its potential for translational application in patients with
COVID-19.

5

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

RESULTS
Antibody repertoire analysis of COVID-19 patients
We first characterized the B cell response in COVID-19 using single-cell Ig gene sequencing of
human mAbs (Fig. 1A). From ten COVID-19 patients with serum antibodies to the S1 subunit of the
SARS-CoV-2 spike protein (Fig. S1, Supplementary Table ST1), we isolated two populations of single
cells from peripheral blood mononuclear cells with fluorescence-activated cell sorting (FACS):
CD19+CD27+CD38+ antibody secreting cells (ASC) reflecting the unbiased humoral immune response
and SARS-CoV-2-S1-labeled CD19+CD27+ memory B cells (S1-MBC) for characterization of antigenspecific responses (Fig. S2A and S2B). We obtained 598 functional paired heavy and light chain Ig
sequences (Supplementary Table ST2). Of 432 recombinantly expressed mAbs, 122 were reactive to
SARS-CoV-2-S1 (S1+), with a frequency of 0.0-18.2% (median 7.1%) within ASC and 16.7-84.1%
(median 67.1%) within S1-MBC (Fig. 1B and 1C). Binding to S1 did not depend on affinity maturation
as measured by the number of SHM (Fig. 1D). Compared to mAbs not reactive to SARS-CoV-2-S1,
S1+ mAbs had less SHM, but equal lengths for both their light and heavy chain complementaritydetermining region 3 (CDR3) (Fig. S2C, S2D and S2E). Within the ASC and S1-MBC population,
45.0% and 90.2% of S1+ mAbs bound the RBD, respectively (Fig. S2F).
S1+ mAbs were enriched in certain Ig genes including VH1-2, VH3-53, VH3-66, VK1-33 and VL2-14
(Fig. S3). We identified both clonally related antibody clones within patients and public and shared
S1+ clonotypes from multiple patients (Fig. S4). Some public or shared clonotypes had been
previously reported, such as IGHV3-53 and IGHV3-66 (Supplementary Table ST3) (Cao et al., 2020;
Yuan et al., 2020a), while others were newly identified, such as IGHV3-11 (Fig. S4C).

Identification and characterization of potent SARS-CoV-2 neutralizing mAbs
We next determined the mAbs with the highest capacity to neutralize SARS-CoV-2 in a plaque
reduction neutralization tests (PRNT) using authentic virus (Munich isolate 984) (Wolfel et al., 2020).
6

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Of 86 mAbs strongly binding to RBD, 40 showed virus neutralization with a half-maximal inhibitory
concentration (IC50) ≤250 ng/ml and were considered neutralizing antibodies (Fig. 1A, Supplementary
Table ST2), from which 18 (Top-18) were selected for further characterization (Supplementary Table
ST4). The antibodies bound to RBD with a half-maximal effective concentration (EC50) of 3.8-14.2
ng/ml (Fig. 1E) and an equilibrium dissociation constant (KD) of 6.0 pM to 1.1 nM (Fig. S5,
Supplementary Table ST4), thereby neutralizing SARS-CoV-2 with an IC50 of 3.1-172 ng/ml (Fig. 1F,
Supplementary Table ST4). The antibody with the highest affinity, CV07-209, was also the strongest
neutralizer (Fig. 1G). We hypothesized that the differences in neutralizing capacity relate to different
interactions with the ACE2 binding site. Indeed, the strongest neutralizing mAbs CV07-209 and
CV07-250 reduced ACE2 binding to RBD to 12.4% and 58.3%, respectively. Other Top-18 mAbs
including CV07-270 interfered only weakly with ACE2 binding (Fig. S6A).
The spike proteins of SARS-CoV-2 and SARS-CoV share more than 70% amino acid sequence
identity, whereas sequence identity between SARS-CoV-2 and MERS-CoV and other endemic
coronaviruses is significantly lower (Barnes et al., 2020). To analyze potential cross-reactivity of
mAbs to other coronaviruses, we tested for binding of the Top-18 mAbs to the RBD of SARS-CoV,
MERS-CoV, and the human endemic coronaviruses 229-E, NL63, HKU1 and OC32. CV38-142
detected the RBD of both SARS-CoV-2 and SARS-CoV, whereas no other mAb was cross-reactive to
additional coronaviruses (Fig. S7). To further characterize the epitope of neutralizing mAbs, we
performed ELISA-based epitope binning experiments using biotinylated antibodies. Co-applications of
paired mAbs showed competition of most neutralizing antibodies for RBD binding (Fig. S6B). As an
exception, SARS-CoV cross-reactive CV38-142 bound RBD irrespective of the presence of other
mAbs, suggesting an independent and conserved target epitope (Fig. S6B).

Near-germline SARS-CoV-2 neutralizing antibodies can bind to murine tissue

7

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Many SARS-CoV-2 neutralizing mAbs carry few SHM or are in germline-configuration (Fig. 1D) (Ju et
al., 2020; Kreer et al., 2020). Such antibodies close to germline might be reactive to more than one
target (Zhou et al., 2007). Prompted by the abundance of near-germline SARS-CoV-2 antibodies and
to exclude potential side-effects of mAb treatment, we next analyzed whether SARS-CoV-2
antibodies can bind to self-antigens.
Therefore, we tested the binding of S1-mAbs to unfixed murine tissues. Surprisingly, four of the Top18 potent SARS-CoV-2 neutralizing mAbs showed anatomically distinct tissue reactivities (Fig. 2,
Supplementary Table ST4). CV07-200 intensively stained brain sections in the hippocampal
formation, olfactory bulb, cerebral cortex and basal ganglia (Fig. 2A). CV07-222 also bound to brain
tissue, as well as to smooth muscle (Fig. 2B). CV07-255 and CV07-270 were reactive to smooth
muscle from sections of lung, heart, kidney and colon, but not liver (Fig. 2C and 2D, Supplementary
Table ST4). None of the Top-18 mAbs bound to HEp-2 cells, cardiolipin or beta-2 microglobulin as
established polyreactivity-related antigens (Jardine et al., 2016) (Fig. S8).

Crystal structures of two mAbs approaching the ACE2 binding site from different angles
For further characterization using X-ray crystallography, we selected two neutralizing mAbs CV07250 and CV07-270 based on differences in the number of SHM, extent of ACE2 competition and
binding to murine tissue. CV07-250 (IC50=3.5 ng/ml) had 33 SHM (17/16 on heavy and light chain,
respectively), strongly reduced ACE2 binding and showed no binding to murine tissue. In contrast,
CV07-270 (IC50= 82.3 ng/ml) had only 2 SHM (2/0), did not reduce ACE2 binding in our assay, and
showed binding to smooth muscle tissue. Using X-ray crystallography, we determined structures of
CV07-250 and CV07-270 in complex with SARS-CoV-2 RBD to resolutions of 2.55 and 2.70 Å,
respectively (Fig. 3, Supplementary Tables ST5 and ST6).
The binding mode of CV07-250 to RBD is unusual in that it is dominated by the light chain (Fig. 3A
and 3D), whereas in CV07-270, the heavy chain dominates as frequently found in other antibodies
8

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

(Fig. 3B and 3E). Upon interaction with the RBD, CV07-250 has a buried surface area (BSA) of 399
Å2 and 559 Å2 on the heavy and light chains, respectively, compared to 714 Å2 and 111 Å2 in CV07270. CV07-250 uses CDR H1, H3, L1, L3, and framework region 3 (LFR3) for RBD interaction (Fig.
3D and Fig. 4A, 4B and 4C), whereas CV07-270 interacts with CDR H1, H3, L1, and L2 (Fig. 3E and
Fig. 4D, 4E and 4F).
The epitope of CV07-250 completely overlaps with the ACE2 binding site with a similar angle of
approach as ACE2 (Fig. 3A, 3C, 4G and 4I). In contrast, the CV07-270 epitope only partially overlaps
with the ACE2 binding site and the antibody approaches the RBD from a different angle compared to
CV07-250 and ACE2 (Fig. 3B, 3C, 4H, 4I), explaining differences in ACE2 competition. Although
CV07-250 and CV07-270 both contact 25 epitope residues, only seven residues are shared
(G446/G447/E484/G485/Q493/S494/Q498). Furthermore, CV07-270 binds to a similar epitope as
SARS-CoV-2 neutralizing antibody P2B-2F6 (Ju et al., 2020) with a similar angle of approach (Fig.
S9). In fact, 18 out of 20 residues in the P2B-2F6 epitope overlap with the CV07-270 epitope,
although CV07-270 and P2B-2F6 are encoded by different germline genes for both heavy and light
chains.
Interestingly, CV07-250 was isolated 19 days after symptom onset, but already acquired 33 SHM, the
highest number among all S1+ MBCs (Fig. S2C). Some non-germline amino acids are not directly
involved in RBD binding, including all five SHMs on CDR H2 (Fig. S10). This observation suggests
that CV07-250 could have been initially affinity-matured against a different antigen.

Prophylactic and therapeutic mAbs in a COVID-19 animal model
Next, we selected mAb CV07-209 for evaluation of in vivo efficacy based on its high capacity to
neutralize SARS-CoV-2 and the absence of reactivity to mammalian tissue. We used the hamster
model of COVID-19, as it is characterized by rapid weight loss and severe lung pathology

9

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

(Osterrieder et al., 2020). In this experimental set-up, hamsters were intranasally infected with
authentic SARS-CoV-2. Nine hamsters per group received either a prophylactic application of CV07209 24 hours before viral challenge, or a therapeutic application of CV07-209 or control antibody
mGO53 two hours after viral challenge (Fig. 5A).
Hamsters under control mAb treatment lost 5.5±4.4% (mean±SD) of body weight, whereas those that
received mAb CV07-209 as a therapeutic or prophylactic single dose gained 2.2±3.4% or 4.8±3.4%
weight after 5 days post-infection (dpi), respectively. Mean body weights gradually converged in the
animals followed up until 13 dpi, reflecting the recovery of control-treated hamsters from SARS-CoV-2
infection (Fig. 5B).
To investigate the presence of SARS-CoV-2 in the lungs, we measured functional SARS-CoV-2
particles from lung tissue homogenates. Plaque forming units were below the detection threshold for
all animals in the prophylactic and in 2 of 3 in the treatment group at 3 and 5 dpi (Fig. 5C and 5D).
qPCR measurements of lung viral genomic RNA copies revealed a 4-5 and 3-4 log decrease at both
time points, indicating a dramatic reduction of SARS-CoV-2 virus particles in both the prophylactic
and therapeutic group. However, genomic viral RNA copy numbers from nasal washes and laryngeal
swaps were similar between all groups (Fig. 5C and 5D).
Additionally, we performed histopathological analyses of infected hamsters. As expected, all lungs
from control-treated animals sacrificed at 3 dpi revealed typical histopathological signs of necrosuppurative pneumonia with suppurative bronchitis, necrosis of bronchial epithelial cells and
endothelialitis (Fig. 6A). At 5 dpi, control-treated animals showed marked bronchial hyperplasia,
severe interstitial pneumonia with marked type II alveolar epithelial cell hyperplasia and endothelialitis
(Fig. 6D). In contrast, animals receiving prophylactic treatment with CV07-209 showed no signs of
pneumonia, bronchitis, necrosis of bronchial epithelial cells, or endothelialitis at 3 dpi. A mild
interstitial pneumonia with mild type II alveolar epithelial cell hyperplasia became apparent 5 dpi.
Animals receiving therapeutic treatment with CV07-209 also showed a marked reduction of
10

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

histopathological signs of COVID-19 pathology, although at both time points one out of three animals
showed mild bronchopulmonary pathology with signs of interstitial pneumonia and endothelialitis.
These qualitative findings were mirrored in the reduction of the bronchitis and edema scores (Fig. 6B,
6E and Supplementary Table ST7).
To confirm the absence of viral particles under CV07-209 treatment, we performed in-situ
hybridization of viral RNA at 3 dpi. No viral RNA was detectable in the prophylactic group, whereas all
animals in the control group and one in the therapeutic group revealed intensive staining of viral RNA
in proximity of bronchial epithelial cells (Fig. 6C). Taken together, these findings show that systemic
application of SARS-CoV-2 neutralizing mAb CV07-209 protects hamsters from COVID-19 lung
pathology and weight loss in both the prophylactic and the therapeutic setting.

11

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

DISCUSSION
Our results add several new aspects to the growing knowledge on the humoral immune response in
SARS-CoV-2 infections. First, we solved the structures of two neutralizing mAbs binding to the RBD
of SARS-CoV-2 at resolutions of 2.55 and 2.70 Å, allowing detailed characterization of the target
epitopes and gaining insight into the mechanism of mAbs neutralizing SARS-CoV-2. SARS-CoV-2
mAbs can compete with ACE2 binding and exert neutralizing activity by inhibiting viral particle binding
to host cells (Barnes et al., 2020; Brouwer et al., 2020; Cao et al., 2020; Ju et al., 2020; Kreer et al.,
2020; Robbiani et al., 2020; Rogers et al., 2020; Wec et al., 2020), a key mechanism previously
identified in SARS-CoV neutralizing antibodies (Prabakaran et al., 2006; ter Meulen et al., 2006).
Steric hindrance of mAbs blocking ACE2 binding to the RBD provides one mechanistic explanation of
virus neutralization (Barnes et al., 2020; Cao et al., 2020; Wu et al., 2020). CV07-250 clearly belongs
to this category of antibodies, as its epitope lies within the ACE2 binding site and it approaches the
RBD from a similar angle as ACE2. In contrast, the epitope of CV07-270 only partially overlaps with
the ACE2 binding site and approaches the RBD ridge from a different angle. In line with these
findings, competition of CV07-270 with ACE2 binding as detected by ELISA was very weak. Its
mechanism of virus neutralization therefore remains elusive. Of note, there have been reports of
neutralizing antibodies targeting epitopes distant to the ACE2 binding site (Chi et al., 2020). Future
research will need to clarify if additional mechanisms like triggering conformational changes in the
spike protein upon antibody binding contribute to virus neutralization, as reported for SARS-CoV
(Walls et al., 2019).
Secondly, the majority of our SARS-CoV-2 mAbs are close to germline configuration, supporting
previous studies (Kreer et al., 2020; Robbiani et al., 2020). Given the increased probability of autoreactivity of near-germline antibodies, we examined reactivity with murine tissue and indeed found
that a fraction of SARS-CoV-2 neutralizing antibodies also bound to with brain, lung, heart, kidney or
gut expressed epitopes. Such reactivity with host antigens should ideally be prevented by

12

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

immunological tolerance mechanisms, but complete exclusion of such antibodies would generate
“holes” in the antibody repertoire. In fact, HIV utilizes epitopes shared by its envelope and mammalian
self-antigens, thus harnessing immunological tolerance to impair anti-HIV antibody responses (Yang
et al., 2013) and impeding successful vaccination (Jardine et al., 2016). To defy viral escape in HIV,
but similarly COVID-19, anergic strongly self-reactive B cells likely enter germinal centers and
undergo clonal redemption to mutate away from self-reactivity, while retaining HIV or SARS-CoV-2
binding (Reed et al., 2016). Interestingly, longitudinal analysis of mAbs in COVID-19 showed that the
number of SHM in SARS-CoV-2-neutralizing antibodies only marginally increased over time (Kreer et
al., 2020). This finding suggests that the self-reactivity observed in this study may not be limited to
mAbs of the early humoral immune response in SARS-CoV-2 infections. Whether self-reactive
antibodies could contribute to extra-pulmonary symptoms in COVID-19, awaits further studies and
should be closely monitored also in vaccination trials.
Finally, we evaluated in detail the in vivo efficacy of the most potent neutralizing antibody CV07-209
in a Syrian hamster model. This model is characterized by a severe phenotype including weight loss
and distinct lung pathology. Our results demonstrated that prophylaxis and treatment with a single
dose of CV07-209 not only led to clinical improvement as shown by the absence of weight loss, but
also to markedly reduced lung pathology. While the findings confirm the efficacy of prophylactic mAb
administration reported by other groups in mice, hamsters and rhesus macaques (Cao et al., 2020;
Liu et al., 2020; Rogers et al., 2020; Zost et al., 2020), our work is the first to demonstrate the efficacy
of post-exposure treatment in hamsters leading to viral clearance, clinical remission and prevention of
lung injury. To our knowledge, data on post-exposure treatment so far were restricted to transgenic
hACE2 mice (Cao et al., 2020) and a mouse model using adenovector delivery of human ACE2
before viral challenge (Liu et al., 2020). Collectively, our results indicate that mAb treatment can be
fine-tuned for exclusion of self-reactivity with mammalian tissues and that mAb administration can
also be efficacious after the infection, which will be the prevailing setting in COVID-19 patients.

13

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

REFERENCES
Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J.,
Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure
solution. Acta Crystallogr D Biol Crystallogr 66, 213-221.
Bailey, L.J., Sheehy, K.M., Dominik, P.K., Liang, W.G., Rui, H., Clark, M., Jaskolowski, M., Kim, Y., Deneka, D., Tang, W.J.,
et al. (2018). Locking the elbow: improved antibody Fab fragments as chaperones for structure determination. J Mol Biol
430, 337-347.
Barnes, C.O., West, A.P., Jr., Huey-Tubman, K.E., Hoffmann, M.A.G., Sharaf, N.G., Hoffman, P.R., Koranda, N., Gristick,
H.B., Gaebler, C., Muecksch, F., et al. (2020). Structures of human antibodies bound to SARS-CoV-2 spike reveal common
epitopes and recurrent features of antibodies. Cell.
Brouwer, P.J.M., Caniels, T.G., van der Straten, K., Snitselaar, J.L., Aldon, Y., Bangaru, S., Torres, J.L., Okba, N.M.A.,
Claireaux, M., Kerster, G., et al. (2020). Potent neutralizing antibodies from COVID-19 patients define multiple targets of
vulnerability. Science 369, 643-605.
Buchholz, U., Muller, M.A., Nitsche, A., Sanewski, A., Wevering, N., Bauer-Balci, T., Bonin, F., Drosten, C., Schweiger, B.,
Wolff, T., et al. (2013). Contact investigation of a case of human novel coronavirus infection treated in a German hospital,
October-November 2012. Euro Surveill 18, 20406.
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020). Potent
neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B
cells. Cell.
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020). A
neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650-655.
Corman, V.M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D.K., Bleicker, T., Brunink, S., Schneider, J., Schmidt,
M.L., et al. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25, 2000045.
Dietert, K., Gutbier, B., Wienhold, S.M., Reppe, K., Jiang, X., Yao, L., Chaput, C., Naujoks, J., Brack, M., Kupke, A., et al.
(2017). Spectrum of pathogen- and model-specific histopathologies in mouse models of acute pneumonia. PLoS One 12,
e0188251.
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60,
2126-2132.
Erickson, N.A., Gruber, A.D., and Mundhenk, L. (2020). The family of chloride channel regulator, calcium-activated proteins
in the feline respiratory tract: a comparative perspective on airway Diseases in man and animal models. J Comp Pathol 174,
39-53.
Gu, Z., Gu, L., Eils, R., Schlesner, M., and Brors, B. (2014). circlize implements and enhances circular visualization in R.
Bioinformatics 30, 2811-2812.
Helms, J., Kremer, S., Merdji, H., Clere-Jehl, R., Schenck, M., Kummerlen, C., Collange, O., Boulay, C., Fafi-Kremer, S.,
Ohana, M., et al. (2020). Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 382, 2268-2270.
Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi,
E., et al. (2020). Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med.

14

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Jardine, J.G., Sok, D., Julien, J.P., Briney, B., Sarkar, A., Liang, C.H., Scherer, E.A., Henry Dunand, C.J., Adachi, Y.,
Diwanji, D., et al. (2016). Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design.
PLoS Pathog 12, e1005815.
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020). Human neutralizing
antibodies elicited by SARS-CoV-2 infection. Nature 584, 115-119.
Kornau, H.C., Kreye, J., Stumpf, A., Fukata, Y., Parthier, D., Sammons, R.P., Imbrosci, B., Kurpjuweit, S., Kowski, A.B.,
Fukata, M., et al. (2020). Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability. Ann
Neurol 87, 405-418.
Kreer, C., Zehner, M., Weber, T., Ercanoglu, M.S., Gieselmann, L., Rohde, C., Halwe, S., Korenkov, M., Schommers, P.,
Vanshylla, K., et al. (2020). Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID19 patients. Cell.
Kreye, J., Wenke, N.K., Chayka, M., Leubner, J., Murugan, R., Maier, N., Jurek, B., Ly, L.T., Brandl, D., Rost, B.R., et al.
(2016). Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis
pathogenesis. Brain 139, 2641-2652.
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020). Structure of the
SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215-220.
Lerner, R.A. (2016). Combinatorial antibody libraries: new advances, new immunological insights. Nat Rev Immunol 16,
498-508.
Liao, H.X., Chen, X., Munshaw, S., Zhang, R., Marshall, D.J., Vandergrift, N., Whitesides, J.F., Lu, X., Yu, J.S., Hwang,
K.K., et al. (2011). Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J
Exp Med 208, 2237-2249.
Liu, L., Wang, P., Nair, M.S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J.F., Sahi, V., Figueroa, A., et al. (2020). Potent
neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. Nature.
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser
crystallographic software. J Appl Crystallogr 40, 658-674.
Minor, W., Cymborowski, M., Otwinowski, Z., and Chruszcz, M. (2006). HKL-3000: the integration of data reduction and
structure solution--from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr 62, 859-866.
Nakamura, T., Karakida, N., Dantsuka, A., Ichii, O., Elewa, Y.H.A., Kon, Y., Nagasaki, K.I., Hattori, H., and Yoshiyasu, T.
(2017). Effects of a mixture of medetomidine, midazolam and butorphanol on anesthesia and blood biochemistry and the
antagonizing action of atipamezole in hamsters. J Vet Med Sci 79, 1230-1235.
Osterrieder, N., Bertzbach, L.D., Dietert, K., Abdelgawad, A., Vladimirova, D., Kunec, D., Hoffmann, D., Beer, M., Gruber,
A.D., and Trimpert, J. (2020). Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters. Viruses 12, E779.
Prabakaran, P., Gan, J., Feng, Y., Zhu, Z., Choudhry, V., Xiao, X., Ji, X., and Dimitrov, D.S. (2006). Structure of severe
acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 281,
15829-15836.
Reed, J.H., Jackson, J., Christ, D., and Goodnow, C.C. (2016). Clonal redemption of autoantibodies by somatic
hypermutation away from self-reactivity during human immunization. J Exp Med 213, 1255-1265.
Reincke, M., Prüss, H., and Kreye, J. (2019). Brain Antibody Sequence Evaluation (BASE): an easy-to-use software for
complete data analysis in single cell immunoglobulin cloning (bioRxiv).

15

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C.C., Wang, Z., Cho, A., Agudelo, M., Barnes, C.O., Gazumyan, A.,
Finkin, S., et al. (2020). Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature.
Rogers, T.F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020).
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science.
Rohrbeck, A., Schroder, A., Hagemann, S., Pich, A., Holtje, M., Ahnert-Hilger, G., and Just, I. (2014). Vimentin mediates
uptake of C3 exoenzyme. PLoS One 9, e101071.
Schritt, D., Li, S., Rozewicki, J., Katoh, K., Yamashita, K., Volkmuth, W., Cavet, G., and Standley, D.M. (2019). Repertoire
Builder: high-throughput structural modeling of B and T cell receptors. Mol Syst Des Eng 4, 761-768.
ter Meulen, J., van den Brink, E.N., Poon, L.L., Marissen, W.E., Leung, C.S., Cox, F., Cheung, C.Y., Bakker, A.Q.,
Bogaards, J.A., van Deventer, E., et al. (2006). Human monoclonal antibody combination against SARS coronavirus:
synergy and coverage of escape mutants. PLoS Med 3, e237.
Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020). Structure, function, and antigenicity
of the SARS-CoV-2 spike glycoprotein. Cell 181, 281-292 e286.
Walls, A.C., Xiong, X., Park, Y.J., Tortorici, M.A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A.,
et al. (2019). Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell 176, 1026-1039
e1015.
Wec, A.Z., Wrapp, D., Herbert, A.S., Maurer, D.P., Haslwanter, D., Sakharkar, M., Jangra, R.K., Dieterle, M.E., Lilov, A.,
Huang, D., et al. (2020). Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731736.
Wolfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Muller, M.A., Niemeyer, D., Jones, T.C., Vollmar, P.,
Rothe, C., et al. (2020). Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465-469.
Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., et al. (2020). A noncompeting pair of
human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274-1278.
Yang, G., Holl, T.M., Liu, Y., Li, Y., Lu, X., Nicely, N.I., Kepler, T.B., Alam, S.M., Liao, H.X., Cain, D.W., et al. (2013).
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 210, 241256.
Yuan, M., Liu, H., Wu, N.C., Lee, C.-C.D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., et al. (2020a). Structural
basis of a shared antibody response to SARS-CoV-2. Science
Yuan, M., Wu, N.C., Zhu, X., Lee, C.D., So, R.T.Y., Lv, H., Mok, C.K.P., and Wilson, I.A. (2020b). A highly conserved cryptic
epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630-633.
Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A
pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.
Zhou, Z.H., Tzioufas, A.G., and Notkins, A.L. (2007). Properties and function of polyreactive antibodies and polyreactive
antigen-binding B cells. J Autoimmun 29, 219-228.
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020). A novel
coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382, 727-733.
Zivcec, M., Safronetz, D., Haddock, E., Feldmann, H., and Ebihara, H. (2011). Validation of assays to monitor immune
responses in the Syrian golden hamster (Mesocricetus auratus). J Immunol Methods 368, 24-35.

16

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Zost, S.J., Gilchuk, P., Case, J.B., Binshtein, E., Chen, R.E., Nkolola, J.P., Schafer, A., Reidy, J.X., Trivette, A., Nargi, R.S.,
et al. (2020). Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature.

Acknowledgments
We thank Stefanie Bandura, Matthias Sillmann and Doreen Brandl for excellent technical assistance,
Christian Meisel for performing a cardiolipin ELISA and Martin Barner for assistance in generating the
circos plot in Fig. S4B. We acknowledge BIAFFIN GmbH & Co KG (Kassel, Germany) for
performance of SPR measurements and Dr. Désirée Kunkel from Flow & Mass Cytometry Core
Facility at Charité - Universitätsmedizin Berlin for support with single cell sorting.

Funding
SMR is participant in the BIH-Charité Junior Clinician Scientist Program funded by the Charité –
Universitätsmedizin Berlin and the Berlin Institute of Health. Work at Scripps was supported by NIH
K99 AI139445 (NCW) and the Bill and Melinda Gates Foundation OPP1170236 (IAW). Use of the
SSRL, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office
of Science, Office of Basic Energy Sciences under Contract No. DE-AC02–76SF00515. The SSRL
Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental
Research, and by the National Institutes of Health, National Institute of General Medical Sciences
(including P41GM103393). This work was supported by COVID-19 grants from Freie Universität
Berlin and Berlin University Alliance to NO and LES; and by the German Research Foundation (DFG)
to ADG, SH, NS, MW and LES (grant SFB-TR84), to ME and DS (EXC2049) and to HP (grant
numbers PR 1274/2-1, PR 1274/3-1, PR 1274/5-1); and by the Helmholtz Association to HCK (grant
ExNet0009) and to HP (grant HIL-A03); and by the Federal Ministry of Education and Research to HP
(Connect-Generate, 01GM1908D) and MW, ACH, SH, NS and LES (PROVID, 01KI20160A and
SYMPATH, 01ZX1906A).

17

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Author Contributions
JK, SMR, HCK, VMC, JT, KD, HL, MY, NCW, IAW, HP designed the study. SMR, LS, JH, SH, MW,
NS, FK, CF, DW and LES collected patient material and led the clinical study PA-COVID-19. JK,
SMR, HCK, ESS, VMC, HL, MY, NCW, XZ, CCDL, JT, MH, KD, LS, NvW, SvH, MAH, JH, AA, LDB,
DV, LYL, PCB, AH, KS, LMJ, AR, MLS, TS and DW carried out experiments. JK, SMR, HCK, ESS,
VMC, HL, MY, NCW, JT, MH, LDB, KD, ADG, ME, DS, ADG, MAM, CD, NO, IAW, HP analyzed and
interpreted acquired data. JK, SMR and HP drafted the manuscript. All authors critically revised and
approved the submitted version.

Competing interests
Related to this work the German Center for Neurodegenerative Diseases (DZNE) and the Charité Universitätsmedizin have filed a patent application on which JK, SMR, HCK, ESS, VMC, MAM, DW,
LES and HP are named as inventors.

Materials availability
Antibodies will be made available by the corresponding authors upon request under a Material
Transfer Agreement (MTA) for non-commercial usage.

Data and Code Availability
X-ray coordinates and structure factors are deposited at the RCSB Protein Data Bank under
accession codes 6XKQ and 6XKP. The raw sequencing data associated with this manuscript will be
deposited together with the analysis using BASE on Code Ocean upon publication and will be shared
upon request during review. The software used for Ig sequence analysis is available on
https://github.com/automatedSequencing/BASE.

18

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

FIGURES

598
sequences

432
expressed

10

5

10

5

0

122

E
RBD binding (OD 450 nm)

40

Top-18
selection

5

0

01 07 23 24 38 48 X1 X2
Patient-ID

F

0

0.6
0.4
CV07-209

0.2

CV07-250
control

10

G
100

Plaque reduction (%)

86
strong RBD
binder

10

0
01 03 05 07 24 38 X1
Patient-ID

S1 binder

SARS-CoV-2
neutralizer

S1 binding (OD ratio)

Monoclonal antibodies

D

10 -2 10 -1 10 0 10 1 10 2 10 3 10 4
mAb (ng/ml)

30

40

10 -9

10 -10

50

0.0

20
SHM

K D (M)

10
patients

C
S1 binding (OD ratio)

B
S1 binding (OD ratio)

A

10 -11
0
10 -1 10 0

10 1 10 2 10 3
mAb (ng/ml)

10 4

1

10
100
IC50 (ng/ml)

Fig.1 | Identification and characterization of potent SARS-CoV-2 neutralizing mAbs.

(A) Diagram depicting the strategy for isolation of 18 potently neutralizing mAbs (Top-18). (B) Normalized binding to S1 of SARS-CoV-2 for
mAbs isolated from antibody secreting cells (▼; blue = S1-binding, grey = not S1-binding). (OD=optical density in ELISA) (C) Normalized
binding to S1 of SARS-CoV-2 for mAbs isolated from S1-stained memory B cells (▲; colors like in (B)) (D) S1-binding plotted against the
number of somatic hypermutations (SHM) for all S1-reactive mAbs.
(E) Concentration-dependent binding of Top-18 SARS-CoV-2 mAbs to the RBD of S1 (mean±SD from two wells of one experiment). (F)
Concentration-dependent neutralization of authentic SARS-CoV-2 plaque formation by Top-18 mAbs (mean±SD from two independent
measurements). (G) Affinity of mAbs to RBDs (KD determined by surface plasmon resonance) plotted against IC50 of authentic SARS-CoV-2
neutralization.

19

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Fig. 2 | SARS-CoV-2 neutralizing antibodies can bind to murine tissue.
Immunofluorescence staining of SARS-CoV-2 mAbs (green) on murine organ sections showed specific binding to distinct anatomical
structures,
(B)

including

staining

of

(A)

staining

bronchial

walls

of
with

hippocampal
CV07-222,

neuropil
(C)

with
staining

CV07-200
of

(cell

vascular

nuclei
walls

depicted
with

in

CV07-255,

blue),
and

(D) staining of intestinal walls with CV07-270. Smooth muscle tissue in (B-D) was co-stained with a commercial smooth muscle actin
antibody (red).

20

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Fig. 3 | Crystal structures of mAbs in complex with SARS-CoV-2 RBD.
(A) CV07-250 (cyan) in complex with RBD (white). (B) CV07-270 (pink) in complex with RBD (white). (C) Human ACE2 with SARS-CoV-2
RBD (PDB 6M0J) (Lan et al., 2020). (D-E) Epitopes of (D) CV07-250 and (E) CV07-270. Epitope residues contacting the heavy chain are in
orange and the light chain in yellow. CDR loops and framework region that contact the RBD are labeled. (F) ACE2-binding residues on the
RBD (blue) in the same view as (D) and (E). The ACE2 interacting region is shown in green within a semi-transparent cartoon
representation.

21

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

A

B

C
L455
F456

Y489
VH Y100b

N487

Y449
G446

VL F32
VH Y100b

VH F100

VH N97
VH S95

VH D96

D

VL G68

VL Y91

E

VL S67

F
VH I100d

Y449

F490
VH W100h
R346
K444

E484

VH W100h

VH D31

G

RBD

VH R100g

VL Y49

VH T28

VH W100k

H

RBD

RBD

I

RBD-ridge

RBD-ridge

RBD-ridge
CV07-250

CV07-270

ACE2

Fig. 4 | Interactions and angle of approach at the RBD-antibody interface.
(A-C) Key interactions between CV07-250 (cyan) and RBD (white) are highlighted. (A) CDR H3 of CV07-250 forms a hydrogen-bond
network with RBD Y489 and N487. (B) VH Y100b (CDR H3), VL F32 (CDR L1), and VL Y91 (CDR L3) of CV07-250 form a hydrophobic
aromatic patch for interaction with RBD L455 and F456. (C) The side chain of VL S67 and backbone amide of VL G68 from FR3 is engaged
in a hydrogen-bond network with RBD G446 and Y449. (D-F) Interactions between CV07-270 (cyan) and RBD (white) are illustrated. (D)
Residues in CDR H1 of CV07-270 participate in an electrostatic and hydrogen-bond network with RBD R346 and K444. (E) VH W100h and
VH W100k on CDR H3 of CV07-270 make π-π stacking interactions with Y449. VH W100k is also stabilized by a π-π stacking interaction
with VL Y49. (F) VH R100g on CDR H3 of CV07-270 forms an electrostatic interaction with RBD E484 as well as a π-cation interaction with
RBD F490. Oxygen atoms are in red, and nitrogen atoms in blue. Hydrogen bonds are represented by dashed lines. (G-I) Zoomed-in views
of the different RBD ridge interactions with (G) CV07-250, (H) CV07-270, and (I) ACE2 (PDB 6M0J) (Lan et al., 2020). The ACE2-binding
ridge in the RBD is represented by a backbone ribbon trace in red.

22

Change of bodyweight (%)

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

A

CV07-209
0
(18 mg/kg)

SARS-CoV-2
infection

prophylatic
(n = 9)
CV07-209
(18 mg/kg)

therapeutic
(n = 9)
mGO53
(18 mg/kg)

-5

control
(n = 9)

viral gRNA
viral PFU
tissue scoring
in-situ hybridization

-1

0

1

2

viral gRNA
viral PFU
tissue scoring

3

4 5 6 7 8
Days post infection

B

Change of body weight (%)

15

tissue scoring

9

10 11 12 13

*

*

10
CV07-209
CV07-209
mGO53

****
* ***
*

5

**
**** ***
****
****
****

**
*

0

-5

-1

0

1

2

3

4 5 6 7 8
Days post infection

C
8

lung tissue

Viral gRNA
(log10 copies)

Viral particles
(log10 PFU)

10 11 12 13

3 days post infection
lung tissue

6
4
2
0

laryngeal swab

nasal wash

6

6

6

4

4

4

2

2

2

0

0

0

D

5 days post infection

8
6
4
2
0

lung tissue

Viral gRNA
(log10 copies)

lung tissue

Viral particles
(log10 PFU)

9

laryngeal swab

nasal wash

6

6

6

4

4

4

2

2

2

0

0

0

Fig. 5 | Prophylactic and therapeutic application of mAb CV07-209 in a COVID-19 hamster model.
(A) Schematic overview of the animal experiment. (B) Body weight of hamsters after virus challenge and prophylactic (pink) or therapeutic
(blue) application of SARS-CoV-2 neutralizing mAb CV07-209 or control antibody (mean±SEM from n=9 animals per group from day -1 to 3,
n=6 from days 4 to 5; n=3 from days 6 to 13; mixed-effects model with posthoc Dunnett’s multiple tests in comparison to control group;
significance levels shown as * (p<0.05), ** (p<0.01), *** (p<0.001), **** (p<0.0001), or not shown when not significant). (C-D) Quantification
of plaque forming units (PFU) from lung homogenates and quantification of SARS-CoV-2 RNA copies per 105 cellular transcripts from
samples and timepoints as indicated. PFU were set to 5 when not detected, RNA copies below 1 were set to 1. Bars indicate mean. Dotted
lines represent detection threshold.

23

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Bronchi 3 dpi
Parenchyma 3 dpi

#

Viral RNA d3

prophylactic

4
3
2
1
0

control

6
4
2
0
prophylactic

therapeutic

control

#
Viral RNA d3

Bronchi 5 dpi

D

therapeutic

4
3
2
1
0

6
4
2
0

E
Bronchitis score

C

Parenchyma 5 dpi

B

control

#

Bronchitis score

therapeutic

Edema score

prophylactic

4
3
2
1
0

Edema score

A

4
3
2
1
0

Fig. 6 | Histopathological analysis of hamsters after SARS-CoV-2 infection.
(A) Histopathology of representative haematoxylin and eosin stained, paraffin-embedded bronchi with inserted epithelium (upper row) and
lung parenchyma with inserted blood vessels (lower row) at 3 dpi. Severe suppurative bronchitis with immune cell infiltration (hash) is
apparent only in the control-treated animals with necrosis of bronchial epithelial cells (diagonal arrows). Necro-suppurative interstitial
pneumonia (upward arrows) with endothelialitis (downward arrows) is prominent in control-treated animals. Scale bars: 200 µm in bronchus
overview, 50 µm in all others. (B) Bronchitis and edema score at 3 dpi. (C) Detection of viral RNA (red) using in situ hybridization of
representative bronchial epithelium present only in the control group. Scale bars: 50 µm. (D) Histopathology of representative lung sections
from comparable areas as in (A) at 5 dpi. Staining of bronchi of control-treated animals showed a marked bronchial hyperplasia with
hyperplasia of epithelial cells (diagonal arrow) and still existing bronchitis (hash), absent in all prophylactically treated and in 2/3
therapeutically treated animals (upper row). Lung parenchyma staining of control-treated animals showed severe interstitial pneumonia with
marked type II alveolar epithelial cell hyperplasia and endothelialitis (insets, downward arrows). Compared to control-treated animals,
prophylactically treated animals showed only mild signs of interstitial pneumonia with mild type II alveolar epithelial cell hyperplasia (upward
arrow), whereas therapeutically treated animals showed a more heterogeneous picture with 1/3 showing no signs of lung pathology, 1/3
animal showing only mild signs of interstitial pneumonia, and 1/3 animal showing a moderate multifocal interstitial pneumonia. Scale bars:
200 µm in bronchus overview, 50 µm in all others. (E) Bronchitis and edema score at 5 dpi.

24

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

MATERIALS AND METHODS
SARS-CoV-2-infected individuals and sample collection
The patients have given written informed consent and analyses were approved by the Institutional
Review Board of Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin. All patients in this study were tested
positive for SARS-CoV-2 infection by RT-PCR. Patient characteristics are described in
Supplementary Table ST1.

PBMC collection and FACS staining
Recombinant SARS-CoV-2-S1 protein produced in HEK cells (Creative Diagnostics, DAGC091) was
covalently labeled using CruzFluor647 (Santa Cruz Biotechnology, sc-362620) according to the
manufacturer’s instructions.
Using fluorescence-activated cell sorting we sorted viable single cells from freshly isolated peripheral
blood mononuclear cells (PBMCs as 7AAD-CD19+CD27+CD38+ antibody-secreting cells (ASCs) or
SARS-CoV2-S1-enriched 7AAD-CD19+CD27+ memory B cells (MBCs) into 96-well PCR plates.
Staining was performed on ice for 25 minutes in PBS with 2 % FCS using the following antibodies: 7AAD 1:400 (Thermo Fisher Scientific), CD19-BV786 1:20 (clone SJ25C1, BD Biosciences, 563326),
CD27-PE 1:5 (clone M-T271, BD Biosciences, 555441), CD38-FITC 1:5 (clone HIT2, BD
Biosciences, 560982), and SARS-CoV-S1-CF647 at 1 µg/ml for patients CV07, CV38, CV23, CV24,
CV 38, CV48, CV-X1, CV-X2 and CV01 (second time point, fig. S1). The first patients (CV01 (first
time point), CV03, and CV05) were stained with a divergent set of antibodies: CD19-PE 1:50 (clone
HIB19, BioLegend, 302207), CD38-PEcy7 1:50 (clone HIT2, BioLegend, 303505), CD27-APC 1:50
(clone O323, BioLegend, 302809) and DAPI as viability dye.

Generation of recombinant human monoclonal antibodies

25

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Monoclonal antibodies were generated following our established protocols (Kornau et al., 2020; Kreye
et al., 2016) with modifications as mentioned. We used a nested PCR strategy to amplify variable
domains of immunoglobulin heavy and light chain genes from single cell cDNA and analyzed
sequences with aBASE module of customized Brain Antibody Sequence Evaluation (BASE) software
(Reincke et al., 2019). Pairs of functional Ig genes were PCR-amplified using specific primers with Q5
Polymerase (NEB). PCR-product and linearized vector were assembled using Gibson cloning with
HiFi DNA Assembly Master Mix (NEB). Cloning was considered successful when sequence identify
>99.5% was given, verified by the cBASE module of BASE software. For mAb expression, human
embryonic kidney cells (HEK293T) were transiently transfected with matching Ig heavy and light
chains. Three days later mAb containing cell culture supernatant was harvested. Ig concentrations
were determined and used for reactivity and neutralization screening, if Ig concentration was above 1
µg/ml. For biophysical characterization assays and in vivo experiments, supernatants were purified
using Protein G Sepharose beads (GE Healthcare), dialyzed against PBS and sterile-filtered using
0.2 µm filter units (GE Healthcare). For in vivo experiments, mAbs were concentrated using Pierce™
3K Protein Concentrator PES (Thermo Scientific).

SARS-CoV-2-S1 ELISA
Screening for SARS-CoV-2-specific mAbs was done by using anti-SARS-CoV-2-S1 IgG ELISAs
(EUROIMMUN Medizinische Labordiagnostika AG) according to the manufacturer’s protocol. mAb
containing cell culture supernatants were pre-diluted 1:5, patient sera 1:100. Optical density (OD)
ratios were calculated by dividing the OD at 450 nm by the OD of the calibrator included in the kit. OD
ratios of 0.5 were considered reactive.

RBD ELISA
Binding to the receptor-binding domain (RBD) of S1 was tested in an ELISA. To this end, a fusion
protein (RBD-Fc) of the signal peptide of the NMDA receptor subunit GluN1, the RBD-SD1 part of
26

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

SARS-CoV2-S1 (amino acids 319-591) and the constant region of rabbit IgG1 heavy chain (Fc) was
expressed in HEK293T cells and immobilized onto 96-well plates from cell culture supernatant via
anti-rabbit IgG (Dianova, 111-035-045) antibodies. Then, human mAbs were applied and detected
using horseradish peroxidase (HRP)-conjugated anti-human IgG (Dianova, 109-035-088) and the
HRP substrate 1-step Ultra TMB (Thermo Fisher Scientific, Waltham, MA). All S1+ mAbs were
screened at a human IgG concentration of 10 ng/ml to detect strong RBD binders and the ones
negative at this concentration were re-evaluated for RBD reactivity using a 1:5 dilution of the cell
culture supernatants. To test for specificity within the coronavirus family, we expressed and
immobilized Fc fusion proteins of the RBD-SD1 regions of MERS-CoV, SARS-CoV and the endemic
human coronaviruses HCoV-229-E, HCoV-NL63, HCoV-HKU1, and HCoV-229E and applied mAbs at
1 µg/ml. The presence of immobilized antigens was confirmed by incubation with HRP-conjugated
anti-rabbit IgG (Dianova). Assays for concentration-dependent RBD binding (Fig. 1E) were developed
using 1-step Slow TMB (Thermo Fisher Scientific). EC50 was determined from non-linear regression
models using Graph Pad Prism 8.
To evaluate the ability of mAbs to interfere with the binding of ACE2 to SARS-CoV-2 RBD, we
expressed ACE2-HA, a fusion protein of the extracellular region of human ACE2 (amino acids 1-615)
followed by a His-tag and a hemagglutinin (HA)-tag in HEK293T cells and applied it in a modified
RBD-ELISA. Captured RBD-Fc was incubated with mAbs at 0.5 µg/ml for 15 minutes and
subsequently with ACE2-HA-containing cell culture supernatant for 1 h. ACE2-HA binding was
detected using anti-HA antibody HA.11 (clone 16B12, BioLegend, San Diego, CA, MMS-101P), HRPconjugated anti-mouse IgG (Dianova, 115-035-146) and 1-step UltraTMB.
For experiments regarding the competition between mAbs for RBD binding, purified monoclonal
antibodies were biotinylated using EZ-Link Sulfo-NHS-Biotin (Thermo Fisher) according to the
manufacturer’s instructions. Briefly, 50-200 µg of purified antibody were incubated with 200-fold molar
excess Sulfo-NHS-Biotin for 30 minutes at room temperature. Excess Sulfo-NHS-Biotin was removed
by dialysis for 16 hours. Recovery rate of IgG ranged from 60-100%. RBD-Fc captured on ELISA
27

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

plates was incubated with mAbs at 10 µg/ml for 15 minutes. Then, one volume of biotinylated mcAbs
at 100 ng/ml was added and the mixture incubated for additional 15 minutes, followed by detection
using HRP-conjugated streptavidin (Roche Diagnostics) and 1-step Ultra TMB. Background by the
HRP-conjugated detection antibodies alone was subtracted from all absorbance values.

Circos plot of public clonotypes
Antibodies which share same V and J gene on both Ig heavy and light chain are considered to be one
clonotype. Such clonotypes are considered public if they are identified in different patients. After
identification of public clonotypes, they were plotted in a Circos plot using the R package circlize (Gu
et al., 2014).

Identification of 18 strongly neutralizing antibodies
To identify the most potent SARS-CoV-2 neutralizing mAb, all 122 S1-reactive mAbs were screened
for binding to RBD. 86 were defined as strongly binding to RBD (defined as detectable binding at 10
ng/ml in an RBD ELISA) and then assessed for neutralization of authentic SARS-CoV-2 at 25 and
250 ng/ml using mAb-containing cell culture supernatants. Antibodies were further selected (i) as the
strongest neutralizing mAb of the respective donor and / or (ii) with an estimated IC 50 of 25 ng/ml or
below and / or (iii) with an estimated IC90 of 250 ng/ml or below. These were defined as the 18 most
potent antibodies (Top-18) and expressed as purified antibodies for detailed biophysical
characterization.

Surface plasmon resonance measurements
The antigen (SARS-CoV-2 S protein-RBD-mFc, Accrobiosystems) was reversibly immobilized on a
C1 sensor chip via anti-mouse IgG. Purified mAbs were injected at different concentrations in a buffer
consisting of 10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% Tween 20. CV-X1-126 and
CV38-139 were analyzed in a buffer containing 400 mM NaCl as there was a slight upward drift at the
28

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

beginning of the dissociation phase due to non-specific binding of to the reference flow. Multi-cyclekinetics analyses were performed in duplicates except for non-neutralizing CV03-191. Ka, Kd and KDvalues were determined using a monovalent analyte model. Recordings were performed on a Biacore
T200 instrument at 25°C.

Plaque reduction neutralization test
To detect neutralizing activity of SARS-CoV-2-specific mAbs, plaque reduction neutralization tests
(PRNT) were done as described before (Wolfel et al., 2020). Briefly, Vero E6 cells (1.6 x105 cells/well)
were seeded in 24-well plates and incubated overnight. For each dilution step, mAbs were diluted in
OptiPro and mixed 1:1 with 200 μl virus (Munich isolate 984) (Wolfel et al., 2020) solution containing
100 plaque forming units. The 400 μl mAb-virus solution was vortexed gently and incubated at 37°C
for 1 hour. Each 24-well was incubated with 200 μl mAb-virus solution. After 1 hour at 37°, the
supernatants were discarded and cells were washed once with PBS and supplemented with 1.2%
Avicel solution in DMEM. After 3 days at 37°C, the supernatants were removed and the 24-well plates
were fixed and inactivated using a 6% formaldehyde/PBS solution and stained with crystal violet. All
dilutions were tested in duplicates. For PRNT-screening mAb dilutions of 25 and 250 ng of IgG/ml
were assessed. IC50 was determined from non-linear regression models using Graph Pad Prism 8.

Immunocytochemistry
Recombinant spike protein-based immunofluorescence assays were done as previously described
(Buchholz et al., 2013; Corman et al., 2020; Wolfel et al., 2020). Briefly, VeroB4 cells were
transfected with previously described pCG1 plasmids encoding SARS-CoV-2, MERS-CoV, HCoVNL63, -229E, -OC43, and -HKU1 spike proteins (Buchholz et al., 2013). For transfection, Fugene HD
(Roche) was used in a Fugene to DNA ratio of 3:1. After 24 hours, transfected as well as
untransfected VeroB4 cells were harvested and resuspended in DMEM/10% FCS to achieve a cell
density of 2.5x105 cells/ml each. Transfected and untransfected VeroB4 cells were mixed 1:1 and 50
29

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

μl of the cell suspension was applied to each incubation field of a multitest cover slide (Dunn
Labortechnik). The multitest cover slides were incubated for 6 hours before they were washed with
PBS and fixed with ice-cold acetone/methanol (ratio 1:1) for 10 minutes. For the immunofluorescence
test, the incubation fields were blocked with 5% non-fat dry milk in PBS/0.2% Tween for 60 minutes.
Purified mAbs were diluted in EUROIMMUN sample buffer to a concentration of 5 µg/ml and 30 μl of
the dilution was applied per incubation field. After 1 hour at room temperature, cover slides were
washed 3 times for 5 minutes with PBS/0.2% Tween. Secondary detection was done using a 1:200
dilution of a goat-anti human IgG-Alexa488 (Dianova). After 30 minutes at room temperature, slides
were washed 3 times for 5 minutes and rinsed with water. Slides were mounted using DAPI
prolonged mounting medium (FisherScientific).

Crystal structure determination of Fab-RBD complexes
The receptor binding domain (RBD; residues 319-541) of the SARS-CoV-2 spike (S) protein was
expressed in High Five cells and purified using affinity and size exclusion chromatography as
described previously (Yuan et al., 2020b). Residues in the elbow region of CV07-250
(112SSASTKG118) were mutated to 112FNQIKP117 to reduce elbow flexibility and facilitate crystal
packing (Bailey et al., 2018). CV07-250 and CV07-270 Fabs were expressed in ExpiCHO cells and
purified using affinity and size exclusion chromatography. The Fab/RBD complexes were formed by
mixing the two components in an equimolar ratio and incubating overnight at 4°C before setting-up
crystal trials. The complexes of CV07-250/RBD and CV07-270/RBD were screened for crystallization
at 20.0 and 12.0 mg/ml, respectively, using 384 conditions of the JCSG Core Suite (Qiagen) on our
robotic CrystalMation system (Rigaku) at The Scripps Research Institute. Crystals appeared after day
3, were harvested after day 7, and then flash-cooled in liquid nitrogen for X-ray diffraction
experiments. Diffraction data were collected at cryogenic temperature (100 K) at Stanford
Synchrotron Radiation Lightsource (SSRL) on the newly constructed Scripps/Stanford beamline 12-1
with a beam wavelength of 0.97946 Å and processed with HKL3000 (Minor et al., 2006). Diffraction
30

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

data were collected from crystals grown in conditions: 0.085 M HEPES pH 7.5, 10% (v/v) ethylene
glycol, 15% (v/v) glycerol, 8.5% (v/v) 2-propanol, 17% (w/v) polyethylene glycol 4000 for the CV07250/RBD complex and 0.1 M sodium cacodylate pH 6.5, 0.2 M sodium chloride, 2 M ammonium
sulfate, 15% (v/v) ethylene glycol for the CV07-270/RBD complex. The X-ray structures were solved
by molecular replacement (MR) using PHASER (McCoy et al., 2007) with MR models for the RBD
and CV07-270 Fab from PDB 6W41 (Yuan et al., 2020b) and 4FQH, respectively. The MR model for
CV07-250 Fab was generated using Repertoire Builder (Schritt et al., 2019). Iterative model building
and refinement were carried out in COOT (Emsley and Cowtan, 2004) and PHENIX (Adams et al.,
2010), respectively. In the CV07-250 + RBD structure, residues 319-337, 357- 366, 371-374, 383396, 516-541 were not modeled due to paucity of electron density. The N and C terminal regions are
normally disordered in the SARS CoV-2 RBD structures. These flexible regions are not involved in
any other contacts, including crystal lattice contacts, and are on the opposite side of the RBD to the
epitope, which is well ordered. In the CV07-270 + RBD structure, Fab residues in a region of the
heavy-chain constant domain also have greater mobility as commonly found in Fabs. Likewise, the N
and C- terminal residues of 319-333 and 528-541 in both RBD molecules of the asymmetric unit are
disordered. Epitope and paratope residues, as well as their interactions, were identified by accessing
PDBePISA at the European Bioinformatics Institute (https://www.ebi.ac.uk/pdbe/prot_int/pistart.html).

Murine tissue reactivity screening
Preparations of brain, lung, heart, liver, kidney and gut from 8-12 weeks old C57BL/6J mice were
frozen in -50°C 2-methylbutane, cut on a cryostat in 20 µm sections and mounted on glass slides. For
tissue reactivity screening according to established protocols (Kreye 2016 Brain), thawed unfixed
tissue slices were rinsed with PBS then blocked with blocking solution (PBS supplemented with 2%
Bovine Serum Albumin (Roth) and 5% Normal Goat Serum (Abcam)) for 1 hour at room temperature
before incubation of mAbs at 5 µg/ml overnight at 4°C. After three PBS washing steps, goat antihuman IgG-Alexa Fluor 488 (Dianova, 109-545-003) diluted in blocking solution was applied for 2
31

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

hours at room temperature before additional three washes and mounting using DAPI-containing
Fluoroshield. Staining was examined under an inverted fluorescence microscope (Olympus CKX41,
Leica DMI6000) or confocal device (Leica TCS SL). For co-staining, tissue was processed as above,
but sections were fixed with 4% PFA in PBS for 10 minutes at room temperature before blocking. For
co-staining, the following antibodies were used: mouse Smooth Muscle Actin (clone 1A4, Agilent, 172
003), goat anti-mouse IgG-Alexa Fluor 594 (Dianova, 115-585-003). For nuclei staining DRAQ5™
(abcam, ab108410) was used.

HEp2 cell assay
HEp-2 cell reactivity was investigated using the NOVA Lite HEp-2 ANA Kit (Inova Diagnostics)
according to the manufacturer’s instructions using mAb containing culture supernatant (screening of
all S1+ mAbs) or purified mAbs at 50 µg/ml (polyreactivity testing of CV07-200, CV07-209, CV07-222,
CV07-255, CV07-270 and CV38-148) and examined under an inverted fluorescence microscope.

Polyreactivity screening ELISA
Purified mAbs were screened for reactivity against cardiolipin and beta-2 microglobulin at 50 µg/ml
using routine laboratory ELISAs kindly performed by Christian Meisel (Labor Berlin).

Hamster model of SARS-CoV-2 infection
The animal experiment was approved by the Landesamt für Gesundheit und Soziales in Berlin,
Germany (approval number 0086/20) and performed in compliance with relevant national and
international guidelines for care and humane use of animals. In vitro and animal work was conducted
under appropriate biosafety precautions in a BSL-3 facility at the Institute of Virology, Freie
Universität Berlin, Germany. Twenty-seven six-week old female and male golden Syrian hamsters
(Mesocricetus auratus; outbred hamster strain RjHan:AURA, Janvier Labs) were kept in groups of 3
animals in enriched, individually ventilated cages. The animals had ad libitum access to food and
32

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

water and were allowed to acclimate to these conditions for seven days prior to prophylactic
treatment and infection. Cage temperatures and relative humidity were recorded daily and ranged
from 22-24°C and 40-55%, respectively.
Virus stocks for animal experiments were prepared from the previously published SARS-CoV-2
München isolate (Wolfel et al., 2020). Viruses were propagated on Vero E6 cells (ATCC CRL-1586)
in minimal essential medium (MEM; PAN Biotech) supplemented with 10% fetal bovine serum (PAN
Biotech) 100 IU/ml Penicillin G and 100 µg/ml Streptomycin (Carl Roth). Stocks were stored at -80°C
prior to experimental infections.
For the SARS-CoV-2 challenge experiments, hamsters were randomly distributed into three groups:
In the first group (prophylaxis group), animals received an intraperitoneal (i.p.) injection of 18 mg per
kg bodyweight of SARS-CoV-2 neutralizing mAb CV07-209 24 hours prior to infection. In the second
and third group (treatment and control group, respectively), animals were given the identical mAb
amount two hours after infection, either with 18 mg/kg of CV07-209 (treatment group) or with 20
mg/kg of non-reactive isotype-matched mGO53 (control group). Hamsters were infected intranasally
with SARS-CoV-2 infected as previously described (Osterrieder et al., 2020).
On days 2, 5 and 13 post infection, three hamsters of each group were euthanized by exsanguination
under general anesthesia as described (Nakamura et al., 2017). Nasal washes, tracheal swabs, and
lungs (left and right) were collected for histopathological examinations and/or virus titrations and RTqPCR. Body weights were recorded daily and clinical signs of all animals were monitored twice daily
throughout the experiment.

Histopathology and in situ hybridization
For histopathological examination and in situ hybridization (ISH) of lung tissues, the left lung lobe was
carefully removed and immersed in fixative solution (4% formalin, pH 7.0) for 48 hours. Lungs were
then embedded in paraffin and cut in 2 μm sections. For histopathology, slides were stained with
33

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

hematoxylin and eosin (HE) followed by blinded microscopic evaluation by board‐certified veterinary
pathologists as previously described (Dietert et al., 2017; Osterrieder et al., 2020). The following
parameters were evaluated to assess three different scores: (1) the bronchitis score that includes
severity of bronchial inflammation and epithelial cell necrosis of bronchi; (2) the regeneration score
combining the presence of hyperplasia of bronchial epithelial cells and alveolar type II epithelial cells;
and (3) the edema score including alveolar and perivascular edema.
ISH was performed as reported previously (Erickson et al., 2020; Osterrieder et al., 2020) using the
ViewRNA™ ISH Tissue Assay Kit (Invitrogen by Thermo Fisher Scientific) following the
manufacturer's instructions with minor adjustments. Probes for the detection of the Nucleoprotein (N)
gene RNA of SARS-CoV-2 (NCBI database NC_045512.2, nucleotides 28,274 to 9,533, assay ID:
VPNKRHM), and the murine housekeeping gene eukaryotic translation elongation factor-1α (EF1a;
assay ID: VB1-14428-VT, Affymetrix, Inc.), that shares 95% sequence identity with the Syrian
hamster, were designed. Lung sections (2 µm thickness) on adhesive glass slides were dewaxed in
xylol and dehydrated in ethanol. Tissues were incubated at 95°C for 10 minutes with subsequent
protease digestion for 20 minutes. Sections were fixed with 4% paraformaldehyde in PBS (Alfa Aesar,
Thermo Fisher) and hybridized with the probes. Amplifier and label probe hybridizations were
performed according to the manufacturer's instructions using fast red as the chromogen, followed by
counterstaining with hematoxylin for 45 s, washing in tap water for 5 minutes, and mounting with
Roti®-Mount Fluor-Care DAPI (4, 6-diaminidino-2-phenylindole; Carl Roth). An irrelevant probe for
the detection of pneumolysin was used as a control for sequence-specific binding. HE-stained and
ISH slides were analyzed and images taken using a BX41 microscope (Olympus) with a DP80
Microscope Digital Camera and the cellSens™ Imaging Software, Version 1.18 (Olympus).

Virus titrations, RNA extractions and RT-qPCR
To determine virus titers from 25 mg lung tissue, tissue homogenates were serially diluted and titrated
on Vero E6 cells in 12-well-plates. Three days later, cells were formalin-fixed, stained with crystal
34

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

violet and plaques were counted. RNA was extracted from homogenized lungs, nasal washes and
tracheal swabs using the innuPrep Virus DNA/RNA Kit (Analytik Jena) according to the
manufacturer’s instructions. We quantified RNA using a one-step RT qPCR reaction with the NEB
Luna Universal Probe One-Step RT-qPCR kit (New England Biolabs) and previously published
TaqMan primers and probes (SARS-CoV-2 E_Sarbeco and hamster RPL18) (Corman et al., 2020;
Zivcec et al., 2011) on a StepOnePlus RealTime PCR System (Thermo Fisher Scientific).

Statistical Analysis
All statistical tests were performed using GraphPad Prism, version 8.4. For comparison of SHM
number, ordinary one-way ANOVA tests with posthoc Tukey's multiple comparisons tests were used.
Statistical significance of bodyweight changes from hamster experiments was tested using a mixedeffects model (two-way ANOVA) with posthoc Dunnett's multiple comparisons test in comparison to
control group.

35

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

SUPPLEMENTARY MATERIALS
Title: SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19
hamster model
Jakob Kreye†,*, S Momsen Reincke†, Hans-Christian Kornau, Elisa Sánchez-Sendin, Victor Max
Corman, Hejun Liu, Meng Yuan, Nicholas C. Wu, Xueyong Zhu, Chang-Chun D. Lee, Jakob Trimpert,
Markus Höltje, Kristina Dietert, Laura Stöffler, Niels von Wardenburg, Scott van Hoof, Marie A
Homeyer, Julius Hoffmann, Azza Abdelgawad, Achim D Gruber, Luca D Bertzbach, Daria
Vladimirova, Lucie Y Li, Paula Charlotte Barthel, Karl Skriner, Andreas C Hocke, Stefan Hippenstiel,
Martin Witzenrath, Norbert Suttorp, Florian Kurth, Christiana Franke, Matthias Endres, Dietmar
Schmitz, Lara Maria Jeworowski, Anja Richter, Marie Luisa Schmidt, Tatjana Schwarz, Marcel
Alexander Müller, Christian Drosten, Daniel Wendisch, Leif E Sander, Nikolaus Osterrieder, Ian A
Wilson, Harald Prüss*

†

These authors contributed equally.

* Correspondence to:
Jakob Kreye & Harald Prüss
German Center for Neurodegenerative Diseases (DZNE) Berlin
c/o Charité – Universitätsmedizin Berlin
CharitéCrossOver (CCO), Charitéplatz 1, 10117 Berlin, Germany
Email: jakob.kreye@dzne.de; harald.pruess@dzne.de.

36

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

S1 binding (OD ratio)

CV01

CV03

CV23

CV07

CV05

10

10

10

10

10

5

5

5

5

5

*

0
-10

0

0

0

-10

10 20 30

0

CV24

10 20 30

0

0

-10

0

CV38

10 20 30

-10

0

-10

10 20 30

CV-X1

CV48

10

10

10

10

5

5

5

5

5

0
-10

0

10 20 30

0
-10

0

10 20 30

0

-10

0

10 20 30

10 20 30

CV-X2

10

0

0

0

-10

0

10 20 30

-10 10 30 50 70 90

Days since diagnosis

Fig. S1 | SARS-CoV-2-S1 serum IgG response from COVID-19 patients.
Serum IgG response determined as the normalized optical density (OD) in a SARS-CoV-2-S1 ELISA in relation to the time point of
diagnosis defined by the first positive qPCR test. Upward arrowhead denotes the appearance of first symptoms. Downward arrowhead
denotes the PBMC isolation. From patient CV01, PBMC samples were isolated at two time points as indicted by the second downward
arrow with an asterisk (*).

37

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

A

B

C
p = 0.0002
5

0

3

10

4

10

SHM per mAb V genes

0

10

3

10

4

SARS-CoV-2-S1-CF647

10

3

(1.98%)

10

5

10

4

10

ASC

0

CD27-PE

80

S1-MBC (1.3%)

0

5

10

CD38-FITC

D

3

10

4

10

60

p = 0.0232

40

20

0

5

10

E

F
S1-

S1+RBD-

S1+RBD+

10

20

S1-MBC

CDR3 length IGK/IGL

20

ASC

30

30
CDR3 length IGH

S1-MBC

ASC

CD38-FITC

10

0

50

100

50

100

0

0
ASC

S1-MBC

ASC

S1-MBC

0

Frequency (%)

Fig. S2 | Flow cytometry gating and characteristics of immunoglobulin sequences.
(A-B) A representative flow cytometry plot from patient CV38 indicating gating on (A) CD19+CD27+antibody-secreting cells (ASC) and (B)
SARS-CoV-2-S1-stained memory B cells (S1-MBC). Cells were pre-gated on live CD19+ B cells. (C) Comparison of somatic hypermutation
(SHM) count within immunoglobulin V genes combined from heavy and light chains of S1-reactive (S1+, blue) and non-S1-reactive (S1-,
grey) mAbs. Statistical significance was determined using a one-way ANOVA (F = 19.22) with posthoc Tukey's multiple comparisons tests.
(ASC: n = 20 S1+, n = 260 S1-; S1-MBC: n = 102 S1+, n = 50 S1-). All expressed mAbs are displayed. Each triangle represents a S1+
(blue) or S1- (grey) mAb, isolated from an ASC (pointing downwards) or a S1-MBC (pointing upwards). (D-E) Length comparison of
complementarity-determining region (CDR) 3 amino acid sequences between S1+ and S1- mAbs within (D) heavy and (E) light chains.
Symbols and colors have the same meaning as in (C). (F) Frequency of RBD-binder (S1+RBD+) and non-RBD-binder (S1+RBD-) relative
to all expressed mAbs (upper lanes) and relative to S1+ mAbs (lower lanes).

38

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

IGKV 3-20

IGHV 3-23

IGKV 3-15

IGHV 3-30

IGKV 1-39

IGHV 4-59

IGKV 1-5

IGHV 3-7

IGKV 2-30
IGKV 3-11

IGHV 4-31

IGKV 2-28

IGHV 1-2

IGKV 4-1

IGHV 4-39

IGKV 1-9

IGHV 3-48

IGKV 1-12
IGKV 1-27

IGHV 1-69

IGKV 1-6

IGHV 4-4

IGKV 2D-29

IGHV 3-21

IGKV 1-33

IGHV 3-15

IGKV 3D-20
IGKV 3D-15

IGHV 3-33

IGKV 2-24

IGHV 4-30-4

IGKV 1D-16

IGHV 3-9

IGKV 1D-12

IGHV 3-74

IGKV 1-17
IGKV 1-16

IGHV 3-30-3

IGKV 1-NL1

IGHV 3-11

IGKV 1-13

IGHV 5-51
IGHV 1-18

0

5
10
15
Gene usage (%)

20

0

10
20
Gene usage (%)

30

IGHV 3-49
IGHV 1-8

IGLV 2-14

IGHV 3-53

IGLV 1-40

IGHV 1-46

IGLV 1-44
IGLV 2-8

IGHV 4-34

IGLV 3-1

IGHV 4-38-2

IGLV 3-21

IGHV 3-66

IGLV 2-23

IGHV 3-64

IGLV 1-47

IGHV 1-3

IGLV 6-57
IGLV 2-11

IGHV 5-10-1

IGLV 4-69

IGHV 4-30-2

IGLV 1-51

IGHV 3-73

IGLV 3-25

IGHV 1-24

IGLV 8-61
IGLV 3-10

IGHV 1-58

IGLV 7-46

IGHV 6-1

IGLV 4-60

0

10

20

30

40

Gene usage (%)

IGLV 5-45
IGLV 5-37
IGLV 3-9
IGLV 3-27

S1- mAbs

S1+ mAbs

IGLV 2-18
IGLV 9-49

39

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Fig. S3. | Comparison of variable gene usage.
Comparison of gene usage between SARS-CoV-2-S1-reactive (S1+) and non-reactive (S1-) mAbs is shown for immunoglobulin (A) variable
heavy (IGHV), (B) variable kappa (IGKV) and (C) variable lambda (IGLV) genes. Bars depict percentage of gene usage of all expressed
mAbs within each group.

40

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

ASC

A
CV01

CV03

CV05

CV07

CV24

CV38

CV-X1

n=53

n=55

n=58

n=30

n=22

n=38

n=24

CV01

CV07

CV23

CV24

CV38

CV48

CV-X1

S1+ mAbs from
expanded clones

unique S1+ mAbs
CV-X2

S1-MBC

unique S1- mAbs
n=6

n=75

n=5

n=44

n=5

n=6

n=5

n=6

S1- mAbs from
expanded clones

B

C
Patient

mAb

Reactivity

IGHV

IGHJ

CDR H3

CV07
CV23
CV38
CV03
CV07
CV-X1
CV01
CV38
CV38

HL CV07-255
HL CV23-121
HL CV38-186
HK CV03-191
HK CV07-209
HK CV-X1-143
HL CV01-273
HL CV38-119
HL CV38-180

RBD
S1RBD
RBD
RBD
RBD
RBD
RBD
n.exp.

1-2*02
1-2*02
1-2*02
3-11*06
3-11*01
3-11*05
4-4*02
4-4*02
4-4*02

4*02
4*02
4*02
4*02
4*02
4*02
4*02
4*02
4*02

ARDSRFSYVNGEFDY
ARELGSWDGRFDY
ARDQSPDILKSPFDY
ARDLGYNRRFDY
ARDGVIPPRFDY
ARDLGYSTRFDY
ARGWGKGPPLGY
ARAWNFDY
ARRAAAGPRPYDY

IGKV/

IGKJ/

IGLV
2-23*02
2-23*02
2-23*03
1-33*01
1-33*01
1-33*01
2-23*01
2-23*01
2-23*01

IGLJ
3*02
3*02
3*02
4*01
4*01
4*01
3*02
3*02
3*02

CDR L3
CSYAGHSTWV
CSYAGSSTWV
CSYAGSSTFG
QQYDNLPLT
QQYDNLPLT
QQYDNLPLT
YSYAGSSTWV
CSYAGSSNWV
CSYAGFSTWV

Fig. S4 | Clonal expansion and public clonotypes.
(A) Pie charts represent clonal relationship of all expressed mAbs from each donor separately for antibody secreting cells (ASC) and S1stained memory B cells (S1-MBC). mAbs were considered S1-reactive (S1+) or non-S1-reactive (S1-) based on SARS-CoV-2-S1 ELISA
measurements. Antibodies were considered to be clonally expanded when they were isolated from multiple cells. (B) Circos plot displays all
isolated mAbs from ten donors. Interconnecting lines indicate relationship between mAbs that share the same V and J gene on both Ig
heavy and light chain. Such public or shared clonotypes in which more than 50% of mAbs are S1-reactive are represented as colored lines.
Small black angles at the outer circle border indicate expanded clones within the respective donor. (C) Properties of public clonotypes from

41

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

S1+ mAbs according to the colors used in (B) with sequence similarities between mAbs isolated from different donors, also within
complementarity-determining region (CDR) three. IGHV, IGHJ IGKV, IGKJ, IGLV, IGLJ = V and J genes of immunoglobulin heavy, kappa,
lambda chains; n.exp. = not expressed.

42

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

8

CV03-191 (5 – 0.04 nM)

6
4
2
0
0

200

Response Units (RU)

CV07-222 (2.5 – 0.01 nM)

12
10
8
6
4
2
0

600

200

400

600

200

400

600

12
10
8
6
4
2
0

800

400

600

200

400

600

CV07-200 (10 – 0.02 nM)

0

12
10
8
6
4
2
0

300

600

CV07-262 (20 – 0.039 nM)

800

0

200

400

600

600

300

600

12
10
8
6
4
2
0

600

900 1200

200

400

600

800

CV38-139 (100 – 0.39 nM)
10
8
6
4
2
0

900 1200

0

12
10
8
6
4
2
0

300

CV07-283 (10 – 0.02 nM)

0

800

CV38-113 (20 – 0.039 nM)

CV38-183 (20 – 0.078 nM)

0

0

900 1200

10
8
6
4
2
0
300

CV07-209 (2.5 - 0.01 nM)
10
8
6
4
2
0

800

CV07-315 (5 – 0.01 nM)

0

12
10
8
6
4
2
0

200

14
12
10
8
6
4
2
0

CV07-250 (20 – 0.039 nM)

0

800

CV38-142 (100 – 0.39 nM)

0

14
12
10
8
6
4
2
0

900 1200

CV07-287 (20 – 0.039 nM)

0

12
10
8
6
4
2
0

300

CV05-163 (20 – 0.039 nM)

0

400

10
8
6
4
2
0
0

12
10
8
6
4
2
0

200

400

600

800

0

CV38-221 (100 – 0.39 nM)

900 1200

600

1200

1800

CV-X1-126 (100 – 0.39 nM)
10
8
6
4
2
0

0

200

400

600

800

0

600

1200

1800

Time (s)

Fig. S5 | Binding kinetic measurements of mAbs to RBD.
Binding kinetics of mAbs to RBD were modeled (black) from multi-cycle surface plasmon resonance (SPR) measurements (blue, purple,
orange). Fitted monovalent analyte model is shown. For CV07-200, neither a bivalent nor a monovalent analyte model described the data
accurately (no model is shown). Three out of the 18 selected mAbs for detailed characterization (Top-18) were not analyzed using multicycle-kinetics: CV07-270 was excluded as it interacted with the anti-mouse IgG reference surface on initial qualitative measurements.
CV07-255 and CV-X2-106 were not analyzed since they showed biphasic binding kinetics and relatively fast dissociation rates in initial
qualitative measurements. Non-neutralizing CV03-191, a mAb not included in the Top-18 mAbs, was included in the multicycle experiments
as it has the same clonotype as strongly neutralizing CV07-209 (Fig. S4C). All measurements are performed by using a serial 2-fold dilution
of mAbs on reversibly immobilized SARS-CoV-2-S1 RBD-mFc.

43

ACE2 binding to SARS-CoV-2-RBD
(% control without competing mAb)

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

100

50

C

V0
C 5-1
V0 6
3
C 7-2
V0 0
0
C 7-2
V0 0
9
C 7-2
V0 2
2
C 7-2
V0 5
0
C 7-2
V0 5
5
C 7-2
V0 6
2
C 7-2
V0 7
0
C 7-2
V0 8
3
C 7-2
V0 8
7
C 7-3
V3 1
5
8
C -1
V3 1
3
8
C -1
V3 3
9
8
C -1
V3 4
2
8
C -1
V 8
C 38- 3
V- 22
X
C 1- 1
V- 12
X2 6
-1
06

0

100
CV07-200
CV07-209

Competing mAb

CV07-222
CV07-250
50
CV07-262
CV38-113
CV38-142
CV38-183

C

V0
720
0
C
V0
720
9
C
V0
722
2
C
V0
725
0
C
V0
726
2
C
V3
811
3
C
V3
814
2
C
V3
818
3

0

Detection mAb

Fig. S6 | Competition of mAbs for RBD binding with ACE2 and between SARS-CoV-2 mAbs.
(A) ELISA-based measurements of human ACE2 binding to SARS-CoV-2 RBD after pre-incubation with the indicated neutralizing mAbs.
Values are shown relative to antibody-free condition as mean+SD from three independent measurements. (B) Competition for RBD binding
between combinations of potent neutralizing mAbs is illustrated as a heat map. Shades of green indicate the degree of competition for RBD
binding of detection mAb in presence of 100-fold excess of competing mAb relative to non-competition conditions. Green squares indicate
no competition. Values are shown as mean of two independent experiments.

44

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

A

SARS2-CoV-2

MERS-CoV

B

HCoV-HKU1

HCoV-NL63

HCoV-229E

RBD binding (OD 450 nm)

3

HCoV-OC43

CV07-209
CV38-142
anti-rabbit IgG

2

1

SA

R
SAS-C
RS oV
-C -2
M oV-RB
E - D
22RS-RB
D
N 9E RB
H L63-RBD
K - D
SA OCU1- RBD
RS 43 RB
-R D
SA -C
RS oV BD
-C -2
M oV-RB
E - D
22RS-RBD
N 9E RB
H L63-RBD
K - D
SA OCU1- RBD
4 3 RB
R
-R D
SAS-C
RS oV BD
-C -2M o V RB
E - D
22RS-RB
D
N 9E RB
H L63-RBD
K
O U1-RBD
C4 -R D
3- BD
R
BD

0

Fig. S7 | Binding specificity of mAbs within coronaviruses.
(A) Representative immunofluorescence staining on VeroB4 cells overexpressing spike protein of indicated coronavirus with SARS-CoV-2
mAb CV07-209 at 5 µg/ml. For all other 17 of the selected 18 mAbs (Top-18, Supplementary Table ST4), similar results were obtained. (B)
Binding of indicated mAbs to fusion proteins containing the RBD of indicated coronaviruses and the constant region of rabbit IgG revealed
by ELISA. For all other Top-18 mAbs, similar results were obtained as for CV07-209. Values indicate mean+SD from two wells of one
experiment.

45

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Positive control

CV38-148

CV07-209

Fig. S8 | Representative staining on HEp-2 cells of selected S1-reactive antibodies.
Representative HEp-2 cell staining with a commercial anti-nuclear antibody as positive control revealed nuclear binding (left). S1-reactive
non-neutralizing mAb CV38-148 exhibited cytoplasmatic binding (middle). Neutralizing mAb CV07-209 showed no binding (right). All mAbs
selected for detailed characterization (Top-18, Supplementary Table ST4) revealed similar results like CV07-209 when used at 50 µg/ml.

46

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

A

B

C

Fig. S9 | Structural comparison of CV07-270/RBD and P2B-2F6/RBD complexes.
(A) Structure of CV07-270 (pink) in complex with RBD (white). (B) Structure of P2B-2F6 (blue) in complex with RBD (white) (PDB 7BWJ)
(Ju et al., 2020) (C) Structures of CV07-270/RBD and P2B-2F6/RBD were superimposed based on the RBD.

47

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Fig. S10 | Comparison of sequences of CV07-250 and CV07-270 to their putative germline sequences.
(A) Alignment of CV07-250 with the germline IGHV1-18 sequence (nucleotide SHM rate 5.8%) and IGLV2-8 (nucleotide SHM rate 5.4%).
(B) Somatic mutations VH S31H, VL G29A, VL N31H, VL Y32F, VL S34T, and VL L46V are located in the CV07-250 paratope with other

48

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

somatic mutations in all of the CDRs that may affect overall CDR conformation and interactions. Hydrogen bonds are represented by
dashed lines. Distances between atoms are shown in solid lines. CV07-250 heavy chain is in dark cyan and light chain is in light cyan.
SARS-CoV-2 RBD is in light grey. (C) Alignment of CV07-270 with the germline IGHV3-11 sequence (nucleotide SHM rate 0.7%) and
IGLV2-14 (nucleotide SHM rate 0%). The regions that correspond to CDR H1, H2, H3, L1, L2, and L3 are indicated. Residues that differ
from the germline are highlighted in red. Residues that interact with the RBD are highlighted in yellow. Residue positions in the CDRs are
labeled according to the Kabat numbering scheme.

49

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplementary Table ST1 | Description of patient cohort.

General

Patient
history

Patient ID
(gender, age)

CV01
(m, 21)

CV03
(m, 46)

CV05
(m, 61)

CV07
(m, 32)

CV23
(f, 44)

CV24
(m, 64)

CV38
(m, 70)

CV48
(m, 48)

CV-X1
(m, 46)

CV-X2
(m, 57)

Pre-existing
conditions

N

CVD,
Crohn’s
disease

N

N

atopic
dermatitis,
hypthyreosis

CVD

CVD

N

N

N

Smoking

N

N

N

Y

N

N

Y (10 PY)

N

Y (7 PY)

N

fever

fever,
cough,
dyspnea,
emesis

fever,
dyspnea,
renal
failure,
atrial
fibrillation

fever,
cough,
dyspnea,
diarrhea

fever,
cough,
dyspnea,
respiratory
failure,
diarrhea

fever,
cough,
epistaxis

loss of
smell

N

N

n/a

loss of
smell

Pulmonary
and general
symptoms

fever,
cough,
emesis

fever,
cough,
dyspnea,
emesis

Neurological
symptoms

loss of
smell,
muscle
twitches

loss of
smell,
mood
impairment,
paresthesia

Symptoms

Date
17.02.2020 29.02.2020
symptom
onset
Days until
diagnosis /
13 / 13
10 / 11
hospitalization

Disease
course

Follow Up

SARS-CoV-2
serum IgG at
PBMC
isolation

fever,
fever, cough,
cough,
dyspnea,
dyspnea,
superinfection respiratory
failure

N

loss of
smell

n/a

27.02.2020

08.03.2020

20.03.2020

3 / 13

5/6

0/0

7/8

6 / 14

10 / 9

11 / 12

2/-

13.03.2020 12.03.2020 14.03.2020 15.03.2020 18.03.2020

2.0 / 3.8

6.4

5.7

6.6

1.2

n/a

8.9

6.4

n/a

n/a

34 / 0

14 / 0

9/0

15 / 2

34 / 0

8/2

15 / 0

17 / 2

15 / 6

0/0

N/0

N/0

N/0

Y/0

N/0

Y/0

Y/0

Y/0

Y/3

N/0

Medication

N

N

AB, ACT

N

N

AB, ACT

AB, ACT,
APT,
Digitoxin

AB, ACT,
APT, HCQ

AB, HCQ

N

Outcome

discharged

discharged

discharged

discharged

discharged

Days in
hospital / on
ICU
Oxygen
demand /
days
ventilation

discharged discharged discharged discharged discharged

PBMCs from ten COVID-19 patients were included in immunoglobulin repertoire studies. General information, patients’ history, symptoms of
SARS-CoV-2 infection, disease course and outcome are listed for each donor. SARS-CoV-2 IgG is given as a ratio of optical density from
time point of PBMC isolation (± one day).
Abbreviations: m = male, f = female, Y = yes, N = no, n/a = not available, CVD = cardiovascular disease, PY = pack years, AB = antibiotics,
ACT = anticoagulation therapy, APT = antiplatelet therapy, HCQ = hydroxychloroquine.

50

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

1-44

3

AAWDDSLNGWV

25

2-14

3

SSYTLDSTVV

ASC

IgA1

1-69

4

ASGWGMEYSSSSADY

0

3-11

2

QQRSNWPPYT

1

ASC

IgM

1-18

4

ARADETMVQGVIPNFDY

4

2-8

2

SSYAGSNNVV

3

0.1

ASC

IgA2

3-74

6

ARGRDCGGSSCYGYPYYGMDV

7

2-28

2

MQALHTPYT

4

n.exp.

ASC

IgG2

3-7

4

ARAGSVGVVDY

12

2-30

1

MQGTHWPWT

8

0.1

ASC

IgA1

3-7

4

VRDRGYCVGDVCYTVLDY

27

1-6

4

LHDYNYPPT

13

0.09

ASC

IgM

3-15

1

TTWFYYDIRDH

24

3-11

2

QQRSNWPPFT

11

0.09

ASC

IgM

1-18

4

ARADDTMVQGVIPNFDY

14

2-8

3

SSYAGSNNVV

2

0.03

ASC

IgM

3-15

4

ASIYYDF

13

1-17

2

LHYNSVPYT

ASC

IgM

1-2

4

ARGDAVARTLNLDY

8

1-44

2

AAWDDSLNGV

3

ASC

IgM

3-7

4

ARAGNIGAVDY

14

2-30

1

MQGTHWPWT

1

0.02

ASC

IgA1

3-49

4

GLSYYYDNGGYYSVPPIDV

20

2-8

3

SSYADSNNLV

9

n.exp.

3-9

3

HK CV01-103
HL CV01-104

1-2

HK CV01-107
HK CV01-109

1-3

HK CV01-110
HK CV01-111
HL CV01-112

1-2

HK CV01-113
HL CV01-114
HK CV01-116

1-3

HL CV01-117
HK CV01-118

0.09

18 n.exp.
0.09

ASC

IgM

AKNSPSCADAVCYFDV

10

4-1

1

QQYYSAPRT

8

n.exp.

HK CV01-120

ASC

IgA1 4-30-4 3

AREGVLITIFGVARDAFDI

1

3-20

2

QQYGSSPRT

1

0.09

HK CV01-121

ASC

IgA1 4-38-2 4

SIWGGVQGVLQDY

22

3-15

2

QQYNDWPRT

7

0.09

ASC

IgG2

ARAGSIASVDY

11

2-30

1

MQGTHWPWT

8

n.exp.

HK CV01-123

ASC

HK CV01-124

ASC

HK CV01-122

HL CV01-125

1-1

12 n.exp.

1-3

1-2

HL CV01-126

3-7

4

IgM

3-7

4

AKGGWRYFDY

16

3-11

4

QQRSSWPLT

9

0.08

IgM

3-23

4

AKYGSITIFGVVIIGYFYFDY

1

3-20

2

QQYGSSPAT

0

0.08

ASC

IgA1

1-18

4

ARADYTMVQGVIPNFDY

7

2-8

2

SSYAGSNNVL

10

0.1

ASC

IgA2

5-51

6

AGHVRYCISTNCYHYGMDV

5

5-45

3

MIWHTSAWV

6

0.10

HK CV01-128

1-3

ASC

IgG2

3-7

4

ARAGDRGAVDY

13

2-30

1

MQGTHWPWT

8

0.11

HL CV01-129

1-2

ASC

IgA1

1-18

4

ARADYTMVQGVIPNFDY

0

2-8

2

SSYAGSNNVV

4

n.exp.

HK CV01-130

ASC

IgM

3-7

3

ARPGYSGNNWGEAFDI

0

4-1

1

QQYYDTLWT

13

0.09

HK CV01-132

ASC

IgG1 4-59

6

ARDRGYNWNYYYYYGMDV

0

3-20

1

QQYGSSPST

2

0.1

ASC

IgG2

3-7

4

ARAGSRGSVDY

21

2-30

1

MQGTHWPWT

13

0.1

HK CV01-134

ASC

IgM

3-30

6

AKEKLDCSSTSCYFGFIYYYYYMDV

0

1-12

2

QQANSFPLT

1

0.09

HK CV01-133

1-3

HL CV01-135

ASC

IgG1 3-11

4

ARESYEGSSFDY

10

6-57

3

QSYDSSNRRV

3

0.1

HK CV01-137

ASC

IgG2

3-7

4

ARDYGRCGDY

18

3-11

2

QQGGNWPRT

9

0.11

HK CV01-138

ASC

IgA1

4-39

5

ARHGYITIFGVVIIPGWFDP

0

3-15

1

QQYNNWPPWT

2

0.07

HL CV01-139

ASC

IgM

4-39

4

ARHPDNELLPFDY

0

3-21

1

QVWDSSSDSYV

2

0.11

HK CV01-140

ASC

IgM 3-30-3 2

ARDPRNYCHSNTCPVWYFDL

17

3-20

2

QQYGSSPRT

6

0.08

HL CV01-141

ASC

IgG1 3-33

AREGNYGDYGGSFDY

0

3-10

3

YSTDSSGNHRV

0

n.exp.

HL CV01-142

ASC

IgM 4-30-4 2

ARGPRITIFGVVIYWYFDL

0

1-40

2

QSYDSSLSGSGV

1

0.09

HL CV01-144

ASC

IgG1 3-30

4

ARRDRIFEFGATREALDF

22

1-40

1

QSYDSSLSGYV

15

0.08

HK CV01-145

ASC

IgM

3-23

5

AKVTWTTTGDS

19

1-5

1

QQYNSYPWT

7

0.10

ASC

IgG1

3-7

4

ARAGDRGAVDY

17

2-30

1

MQGTQWPWT

10

0.09

ASC

IgG1 3-30-3 5

ARERVNGRWLQLLTP

20

1-5

4

QQYDAYLS

16

0.09

ASC

IgM

3-7

4

ARAGDRGAVDY

10

2-30

1

MQGTHWPWT

2

0.08

ASC

IgM

1-18

4

AGYPRYNWNYDNRYYFDF

7

1-39

5

QQSYSAPIT

9

n.exp.
0.07

HK CV01-146

1-3

HK CV01-147
HK CV01-148

1-3

HK CV01-149
HL CV01-151

ASC

IgM

1-18

4

ARADDTMVQGVIPNFDY

2

2-8

2

SSYAGSNNVV

4

HK CV01-152

ASC

IgA1

1-3

6

ARGVGATIPYYYYYYMDV

2

1-5

1

QQYNSYSWT

1

0.1

HK CV01-153

ASC

IgG1

4-4

6

AKVGGGNADHGPGYYYYYMDV

37

1-9

2

QELNRYPRT

17

0.07

HK CV01-154

1-2

4

ASC

IgM

3-9

3

AKNSASCADDLCYFDI

15

4-1

1

QQYYSGPRT

7

0.08

HK CV01-155

1-1

ASC

IgM

3-11

4

ARALPGGITIFGVVITEYYFDY

0

3-20

2

QQYGSSSYT

2

0.08

HL CV01-158

ASC

IgG2 3-21

3

ARGDDYGEYTGAFDA

2

3-1

2

QAWDSSTVV

3

0.09

HK CV01-159

ASC

IgA1

4

ARGGETQQRLVWDQKTDD

23

1-17

4

LQYNSYPLT

12

0.11

1-46

51

(ng/ml)

7

ARSGGYSGYDYSHRIDY

Estimated IC50

CDR L3

ARGSSNLFDI

4

RBD reactivity

IGKJ/IGLJ gene

3

(OD ratio)

IGKV/IGLV gene

S1 reactivity

SHM IGHV

3-74

IgG1 3-21

CDR H3

IgM

ASC

Source cell
ASC

HL CV01-102

Clonality

HL CV01-101

mAb

IGHJ gene

0.1

IGHV gene

4

Ig isotype

SHM IGKV/ IGLV

Supplementary Table ST2 | Immunoglobulin sequence and functional screening data of all isolated mAbs.

CDR L3

SHM IGKV/ IGLV

0.08

4

QQYYSTPLT

8

n.exp.

HL CV01-168

ASC

IgA1

5-51

4

VWTSRGYFDH

6

7-43

3

LFYYGGAWV

9

n.exp.

HL CV01-169

ASC

IgM

3-30

4

ARDLSSGWSLDS

3

2-14

3

SSYTSSNTWV

4

0.07

HL CV01-170

ASC

IgM

4-4

6

ARYCSSTSCYGYYYYGMDV

0

2-8

1

SSYAGSISYV

2

0.08

HK CV01-171

ASC

IgG1

4-4

3

AKGGGSGWYYDAFDI

17

3-15

1

QQYNNWLRT

12

0.11

HL CV01-174

ASC

IgM

1-18

4

ARDDWNYARGNFDY

3

2-14

2

SSYTSSSSVV

1

0.14

HK CV01-175

1-3

ASC

IgM

3-7

4

ARAGGVGTVDY

11

2-30

1

MQGTLWPWT

2

0.1

HL CV01-176

1-2

ASC

IgA1

1-18

4

ARADHTMVQGVIPNFDY

3

2-8

2

SSYTGRKNVV

6

0.1

HK CV01-180

1-3

ASC

IgM

3-7

4

ARCDMAGTTDY

5

2-30

1

MQGTLWPWT

2

0.1

HK CV01-181

ASC

IgG1 3-21

2

ARDLEGVETIFGVVIIPAYWYFDL

0

2-28

4

MQALQTRLT

3

0.08

HL CV01-182

ASC

IgG1 3-23

4

AKDLKIGTLGWYYDFWSGYLPDPSNKIFDY

0

1-40

3

QSYDSSLSGWV

0

0.1

HL CV01-183

ASC

IgM

3-73

3

TRVNPIQGAFYDALDI

6

1-51

2

GTWDSSLSVVV

7

0.11

HK CV01-184

ASC

IgG2 4-59

4

ARFSSAAGVWALDH

11

4-1

2

QQYYTTPFT

7

n.exp.

HL CV01-185

ASC

IgA1

1-69

6

ACDMVQGVAVLDV

13

2-14

2

SSYTSSSTVV

9

0.13

HK CV01-186

ASC

IgG2 4-59

5

ARHGKSIPYSNYDWFDP

0

1-39

3

QQSYSTLPFT

0

0.09

HK CV01-188

ASC

IgM

3-72

4

ARDLGANGDRFGN

4

4-1

1

QQYYSTPLT

2

0.08

HK CV01-193

ASC

IgA1

3-15

4

ATDLGDYGDYMRS

13

1-12

2

QQANSFPYT

7

0.11

HL CV01-194

ASC

IgM

4-59

4

AKKADPHSAFDY

6

2-11

1

CSYAGSYTYV

6

0.09

HL CV01-195

ASC

IgM

3-7

1

VRELVVGRAEYFQD

0

1-44

2

AAWDDSLNGRV

1

3.37

HK CV01-196

ASC

IgG1 3-30

3

AKDPGMLYPSAFDM

14

3-15

4

QQYNNWPPLT

13 n.exp.

HL CV01-197

ASC

IgM

3-23

4

AKDQDGHYGGNPDMDH

10

2-8

3

SSYAGSNKMV

11 n.exp.

HL CV01-198

ASC

IgG2 3-15

4

ATLTYGYSPY

11

2-14

1

SSYTSSTTYV

63 n.exp.

HK CV01-199

ASC

IgA1

4

ASNFNRNDGY

14

2-30

4

IQSTHWPPN

13 n.exp.

HK CV01-202

ASC

IgG1 4-30-4 4

ARMGNMFGYSVVDF

22

1-39

2

LQTYSAPYT

20 n.exp.

HL CV01-203

ASC

IgA2

3-30

6

AKSEGKFYFYGVDV

9

1-47

1

AACDDSLSGHV

3

n.exp.

HK CV01-205

ASC

IgG1 5-51

5

AREARWSFPSWFDP

6

3-15

2

QQYNNWPRF

7

n.exp.

HK CV01-211

ASC

IgA1

5-51

4

ARLSSGWYGGFNFDY

0

3-20

2

QQYGSSPVYT

0

n.exp.

HL CV01-212

ASC

IgM

3-30

4

AKCSYTSICKGWDGAH

14

2-14

2

SSFTTSYTLV

11 n.exp.

HK CV01-213

ASC

IgG1 3-64

4

ARLQGTGYLDY

12

3-20

2

HQYGSSPRT

9

n.exp.

HL CV01-215

ASC

IgM

3-48

5

ARQWAVNWFVP

7

2-14

2

SSHTSSSTVV

8

n.exp.

HK CV01-220

ASC

IgA1

3-48

6

ARDVGTYESTSTGMDV

7

3-11

5

QQRGNWPPAT

HL CV01-221

ASC

IgA1 3-30-3 4

ARGAPVDY

6

2-8

7

N/A

9

n.exp.

HL CV01-222

ASC

IgA1

3-23

4

AKPGGEWYSSGWRFDY

2

1-47

2

AAWDDSLSGPV

0

n.exp.

HL CV01-223

ASC

IgM

3-23

3

AKCGRTSCRVDAFDI

27

8-61

3

VLSMGGGVWV

13 n.exp.

HL CV01-225

ASC

IgA1

3-53

3

ARDGGGSYPHRAFDI

1

2-14

2

SSYTSSSTSDVV

2

n.exp.

HL CV01-226

ASC

IgG1 4-39

6

ARHATGTPPYYYYYMDV

2

3-1

1

QAWDSSTACV

3

n.exp.

HL CV01-227

ASC

IgA1

3-30

4

AKGSPLLGFGGVDY

0

5-39

3

AIWYSSSLV

1

n.exp.

HK CV01-228

ASC

IgA1

3-7

4

ARVGASDYDYVWGTRTLDS

11

4-1

1

QQCLTTPPWT

ASC

IgG2 5-51

4

ARPYGAGTAHYFDY

9

4-1

4

QQYYGTPHT

8

n.exp.

ASC

IgA1

4-39

6

ARHFHPGNYYYYYMDV

6

3-1

2

QAWDSSTYVV

3

n.exp.

HL CV01-232

ASC

IgM

4-39

4

ARKYGDLHFDY

1

8-61

3

VLYMGSGISV

3

n.exp.

HL CV01-233

ASC

IgM

4-39

3

ARSDARFLEWLFPDAFDI

3

2-23

2

CSYAGSTTFVV

3

n.exp.

HL CV01-234

ASC

IgM

3-30

5

ARGSPFGGIRSGLGP

20

1-27

1

QKYNSAPWT

11 n.exp.

HK CV01-229
HL CV01-231

HL CV01-238

1-4

1-4

3-74

11 n.exp.

12 n.exp.

ASC

IgG1 4-39

6

ARHPTGSGSYQYYYYYIDV

3

3-1

2

QAWDSSTVV

2

n.exp.

HL CV01-241

ASC

IgA1

3-66

3

ARDRGYDSSGYTAADAFDI

2

1-5

1

QQYNSYST

6

n.exp.

HL CV01-242

ASC

IgG1 4-31

5

ARGGYRNWFDP

3

2-11

3

CSYAGSYTWV

2

n.exp.

HK CV01-244

S1-MBC IgG1 5-10-1 6

ARLKGSVPPYYYNYMDV

18

2-28

4

MQGLQTPFI

7

n.exp.

HK CV01-249

S1-MBC IgA1 3-30-3 3

ARHNRAQGPSFDV

21

1-39

5

QQTYSVPTT

32

0.08

HK CV01-254

S1-MBC IgM

ASLLGGTVVNDY

4

4-1

2

QQYYSTQYT

2

0.09

3-7

4

52

++

>250

(ng/ml)

IGKJ/IGLJ gene

16

4-1

IgA1

Estimated IC50

IGKV/IGLV gene

MQGTHWPWT

11

ASC

RBD reactivity

SHM IGHV

1

TTEKGRYHLGGVFAN

1-3

(OD ratio)

CDR H3

2-30

4

HK CV01-163

S1 reactivity

IGHJ gene

22

3-15

Ig isotype

ARAGSVGTVDY

IgA1

Source cell

4

ASC

Clonality

3-7

HK CV01-166

mAb

IGHV gene

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

IGKV/IGLV gene

IGKJ/IGLJ gene

CDR L3

SHM IGKV/ IGLV

S1 reactivity

3-20

2

QQYGSSLNT

2

7

3-21

2

QVWDNSIDHVV

5

0.08
0.14

10.92

++

>250

-

>250

++

>250

-

n.t.

-

n.t.

++

>250

HL CV01-260

S1-MBC IgA2

1-8

4

ARGREYYDFWSGYYN

3

2-14

3

SSYTRSNTVV

6

HK CV01-266

S1-MBC IgA1

3-15

3

TSERWLDAFDI

28

1-39

5

QQSYRSPPIT

24 n.exp.

HL CV01-273

S1-MBC IgA1

4-4

4

ARGWGKGPPLGY

2

2-23

3

YSYAGSSTWV

4

7.10

HK CV01-274

S1-MBC IgM

3-30

4

AKDNGDYACFDY

0

4-1

4

QQYYSTPLT

0

0.07

HL CV01-276

S1-MBC IgA1

n.exp.

1-2

6

ARDPFEYYDFWSGYYRGGMDV

2

2-14

3

SSYTSSSTRV

1

HK CV03-101

ASC

IgG1

1-2

4

ARGLITWYYYYDSSAVDY

0

3-20

1

QQYGSSPWT

0

0.1

HK CV03-103

ASC

IgM

3-21

5

ARDPDGHRSGWFDWFDP

3

QQANSFPIT

4

n.exp.

HL CV03-104

1D-12 5

ASC

IgG1 1-18

6

ARDSHYYDSSGYYYLYYYYGTDV

1

3-25

1

QSADSSGTYV

0

0.09

HK CV03-106

3-2

ASC

IgG1 4-31

3

ARGRTIFGVVSGAFDI

0

3-20

4

QQYGSSPLT

1

0.02

HK CV03-107

3-2

ASC

IgG1 4-31

3

ARGRTIFGVVSGAFDI

0

3-20

4

QQYGSSPLT

2

0.10

HL CV03-108

ASC

IgG1 3-15

6

TKTKNPPAYDFWSGYYRGRPPYYKYGMDV

20

1-40

1

QSYDNSLSEYDDV

10

0.1

HL CV03-109

ASC

IgG1 5-10-1 4

ARHVGVGATHSPPFDY

0

1-40

2

QSYDSSLSGPTV

0

0.12

HK CV03-110

ASC

IgG1 3-48

4

ARDLGSWYYLLDFDY

1

1-5

1

QQYNSYPRT

0

0.08

HK CV03-112

ASC

IgG1 3-48

5

GRSSSWRYNWFDP

20

3-15

1

QQYNNWPPWT

13

0.03

HL CV03-113

ASC

IgG1 3-15

4

TTDPYYEISSGYSPDY

44

2-11

2

N/A

34

0.09

HL CV03-116

ASC

IgA1

4-59

6

ARVQGRGSGSYYSAYYYGMDV

0

1-40

1

QSYDSSLSGV

1

LRDGISTFGVVNHYYAMDV

16

2-14

1

SSYTSSSTVV

HL CV03-117

3-3

ASC

IgG1 1-46

6

HL CV03-118

3-3

ASC

IgG1 1-46

6

ARDGISTFGVVKHYYAMDV

26

2-14

1

SSYTTTTTLV

0.1
11 n.exp.
26 n.exp.

ASC

IgG1 3-21

6

ARDSLITIFGVVIEAPDDYGMDV

0

2-14

2

SSYTSSSTVV

2

n.exp.

ASC

IgG1 3-23

4

AKDYFVIPPAALYDY

0

1-51

2

GTWDSSLSAGV

3

n.exp.

HL CV03-123

ASC

IgG1 3-23

5

VKELDDQLTLGGWFDP

36

2-23

3

CSYVGTATVV

26

0.11

HL CV03-124

ASC

IgG1 5-51

4

ASSVRYFDWFDFDY

0

1-44

1

AAWDDSLNGYV

0

n.exp.

HK CV03-129

ASC

IgG1 1-69

4

ARARRPTYSSSWGTFDY

0

1-39

1

QQSYSTPWT

0

0.09

HK CV03-130

ASC

IgG1 4-59

4

ASGTYGGPYLFDY

19

1-5

1

QKYNTYPGT

12 n.exp.

HK CV03-131

ASC

IgM

3-11

4

ARAGDMIVVAAFDY

0

3-20

4

QQYGSSPLT

0

0.08

HK CV03-132

ASC

IgG1

3-7

6

ARGPQMVYALFPYYYYYGMDV

0

1-27

1

QKYNSAPWT

0

0.1

HK CV03-135

ASC

IgG1 3-64

3

VMELYGSDVFDL

22

1-39

1

QQSYSTSWT

18

0.1

HL CV03-138

ASC

IgM

3-74

4

ASYTWGRI

1

2-14

2

SSYTRSSTLVV

2

0.08

HK CV03-139

ASC

IgM

4-39

6

ASQGPLPPILYDILTGYYLGDYYYGMDV

2

2-28

4

MQALQTPLT

1

0.09

HK CV03-140

ASC

IgG1 3-49

4

TRDAYYYGSGSYSEGGH

0

3-11

3

QQRSNWPPLFT

0

0.09

HK CV03-141

ASC

IgG1 4-38-2 6

ARDVTGYDNEDYYYYYGLDV

24

4-1

1

QQYYSSPRT

9

0.08

HL CV03-142

ASC

IgM

3-53

4

AREGPDSGYLDY

7

4-69

3

QTWGTGIRV

6

0.11

HK CV03-143

ASC

IgG1 3-48

4

ARDSGFWSGYYPGNFNY

0

1-33

4

QQYDNLPPLT

1

6.43

HK CV03-144

ASC

IgG1 1-18

6

ARDPWIELRPPRNYYYNGMDV

11

2-28

1

MQALQTPRT

4

0.08

HL CV03-145

ASC

IgG1 1-46

4

ARDSSDCSGGSCYRFDY

0

1-44

1

AAWDDSLNGYV

0

n.exp.

HK CV03-146

ASC

IgM

3-23

4

AKDRTVTKTGLFYLDDC

10

1-39

5

QQSYSTPIT

6

0.08
4.2

HL CV03-120
HL CV03-121

3-1

HL CV03-147

3-4

ASC

IgA1

3-23

4

ASQTGTGEVDY

0

3-1

1

QAWDSSTGV

0

HL CV03-148

3-1

ASC

IgG1 3-23

4

AKGPRLLWFGELSPFDY

1

1-51

2

GTWDSSLSALV

1

HL CV03-150

3-5

ASC

IgA1

3-23

6

VKGSGDIERMVSTLRYYFYGLEV

22

1-47

3

AVWDDSLSAWV

HL CV03-151

3-5

ASC

IgA1

3-23

6

VKGSGDIERMVSTLRYYFYGLDV

17

1-47

3

AVWDDSLSAWV

4.58
12 n.exp.
10 n.exp.

HL CV03-152

ASC

IgG1 3-30

4

AKSGEVFWFGRFRRDYLDY

11

1-44

2

AAWDDRLNGVV

12

0.1

HK CV03-153

ASC

IgM

3-74

4

ARDSCTSTSCYESMK

7

1-5

1

QHYNSYPWM

5

0.12

HK CV03-154

ASC

IgG1 1-24

6

ATSTVIAAAGTVHYYYYYGMDV

0

2-24

2

MQATQFPYT

0

0.11

HK CV03-155

ASC

IgG1 3-33

6

ARDEKAYDFWSGYLSYYYYGMDV

1

2-30

2

MQGTHWPPYT

0

0.09

HK CV03-156

ASC

IgG1 5-10-1 4

ARLLYYYDSSGYYLPSPIDY

0

1-33

4

QQYDNLLLT

0

0.54

ASC

IgA1

VKGSGDIERMVSTLRYYFYGLDV

16

1-47

3

AVWDDSLSAWV

10

0.1

HL CV03-158

3-5

3-23

6

HL CV03-160

ASC

IgM 5-10-1 4

ARLGADSSGYYLPSGGIGY

1

1-40

3

QSYDSSLSGSKV

0

0.09

HL CV03-161

ASC

IgG1 4-39

ARQRKGWLQLRGNWYFDL

2

3-10

2

YSTDSSGNQVV

0

0.09

2

53

(ng/ml)

Estimated IC50

SHM IGHV
5

ARAVHGVDTGMVTYYYHYYMDV

RBD reactivity

CDR H3
ARHPWDDYGDYYYYYMDV

6

(OD ratio)

IGHJ gene
6

Ig isotype

3-48

S1-MBC IgG1 4-59

Source cell

S1-MBC IgM

HL CV01-258

Clonality

HK CV01-257

mAb

IGHV gene

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

IGKJ/IGLJ gene

SHM IGKV/ IGLV

S1 reactivity

2

QTWGIGTHDVI

6

0.07

1-47

3

AAWDDSLSAWV

15

1.17

HK CV03-166

ASC

IgA1

4-4

5

TRLYCSSGACYLGP

26

3-20

1

QQYGRSPT

12

0.08
0.11

HL CV03-167

ASC

IgG1 1-46

5

ARGRDWFDP

1

2-23

3

CSYAGSSTWV

5

HK CV03-168

ASC

IgG1 1-69

6

AREAFYDILTGYSSTPNHYYYGMDV

0

2-28

1

MQALQTPWT

0

0.1

HK CV03-169

ASC

IgG1 3-74

4

ARDFYYDSSGFDY

0

1-39

1

QQSYSTPPWT

0

7.53

HL CV03-170

ASC

IgG3

4-4

3

ARDTIGGHAFDI

0

3-21

3

QVWDSSSDHRV

2

0.09

HL CV03-172

ASC

IgG1 1-24

5

ATSTLFSSVVPASWFDP

0

2-14

2

SSYTSSSTPVV

0

0.09

HK CV03-173

ASC

IgM

1-2

3

ARILPSDYFWSGYYSIQETDAFDI

0

1-5

2

QQYNSYSSS

0

0.08

HK CV03-174

ASC

IgG1 5-51

4

1

2-28

1

MQALQTPWT

0

2.68

HL CV03-175

ASC

IgG1 4-31

0

1-51

2

GTWDSSLSAVV

3

0.1

ASC

IgG1 3-23

ARQVFIAVAGTGFDY
5 ARDFVSGPLMTENVPIYDSSGYYLTRYNWFD
P
4
AKDSGSYLLN

0

3-1

1

QAWDSSTYV

1

3.3

ASC

IgG1

1-2

6

AREDGSSPLGGGMDV

0

3-1

1

QAWDSSTYV

1

0.09

HL CV03-177

3-4

HL CV03-179

ASC

IgA1

3-23

6

VKGSGDIERMVSSLRYYFYGLDV

15

1-47

3

AVWDDSLSAWV

12

0.09

HK CV03-181

HL CV03-180

ASC

IgG1 1-69

4

ASTGHHQDASDY

0

3-11

3

QQRSNWPPRVT

0

0.07

HL CV03-182

ASC

IgG1

1-2

4

ARERLAAAGTDFDY

1

1-40

1

QSYDSSLSDYV

2

0.09

ASC

IgA1

3-23

6

VKGSGDIERMVSSLRYYFYGLDV

15

1-47

3

AVWDDSLSAWV

10

0.13

HL CV03-185

ASC

IgG1

4-4

6

ARRGHTLLWYYYYGMDV

0

1-51

7

GTWDSSLSAGAV

2

1.82

HL CV03-186

ASC

IgG1 3-48

6

ARGQRGLPFYYYYGMDV

0

1-40

1

QSYDSSLSGSV

0

0.12

HL CV03-183

HL CV03-188

3-5

3-5

3-5

-

n.t.

-

n.t.

-

> 250

-

n.t.

-

> 250

(ng/ml)

IGKV/IGLV gene
4-69

27

Estimated IC50

SHM IGHV
11

VKGSGDIERMVDALRYYFYGMDV

RBD reactivity

CDR H3
ARGGGTVVTPGPDY

6

3-5

(OD ratio)

IGHJ gene
4

HL CV03-163

CDR L3

IGHV gene
3-74

IgG1 3-23

HL CV03-162

Source cell

IgM

ASC

Clonality

ASC

mAb

Ig isotype

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

ASC

IgA1

3-23

6

VKGSGDIERMVSTLRYYFYGLDV

16

1-47

3

AVWDDSLSAWV

14

0.08

HK CV03-190

ASC

IgG1

4-4

6

ARGMGYDFWSGYSSYYGMDV

0

1-16

4

QQYNSYPLT

0

0.35

-

> 250

HK CV03-191

ASC

IgM

3-11

4

ARDLGYNRRFDY

0

1-33

4

QQYDNLPLT

1

6.16

++

> 250

HK CV03-192

ASC

IgG1 3-15

6

TTDPLRYYDSSGYLYYGMDV

1

2-28

4

MQALLTPST

1

0.12

HL CV03-193

ASC

IgM

3-53

3

ARGGSWPNVFDI

11

8-61

3

VLYMGSGIWV

8

0.1

HL CV03-195

ASC

IgG1 1-18

6

ARDRLRVRGVIKYYYYGMDV

0

3-25

3

QSADSSGTHWV

2

ASC

IgA1

3-30

4

AKDRGYSSSWFSYLDS

13

3-20

4

QQYGSLRLT

0.17
n.exp.

ASC

IgM

1-3

3

AREDTFSVFGVVTRGNAYDV

26

3-20

1

QQYGVSPRT

9
18 n.exp.

++

> 250

-

n.t.

HK CV05-101
HK CV05-102

5-1

HK CV05-104

ASC

IgA1

5-51

4

ARLGRSLQPNLGFDL

28

2-30

4

MQGSHWPLT

23

0.14

HK CV05-107

ASC

IgG1 3-21

4

ARDSESAWNRIGNFYFDL

34

3-15

5

QQYNDWLIT

19

0.07

HK CV05-108

ASC

IgG1 5-10-1 6

ARHHLKRGYATRYGMDV

0

1-39

1

QQSYSTPWT

0

0.12

HK CV05-109

ASC

IgA1

4-31

4

ASLEGPYCSDTTCYEGGQGLDY

11

3-11

1

HQRGNWWT

6

0.09

ASC

IgG1

1-3

3

AREDTFSVFGVVTRGNAYDV

26

3-20

1

QQYGVSPRT

18

0.08

HL CV05-111

ASC

IgA1

3-33

6

ARDLDGDYVTYYYGMDV

1

2-14

2

SSYTSSSTPVV

1

8.39

HK CV05-113

ASC

IgG1 3-30

2

ASGDGYRNFWYFDI

31

2-28

4

MQALQTPT

13

0.09

HK CV05-110

5-1

HL CV05-114

ASC

IgG1 3-30-3 4

HK CV05-115

ASC

IgG1 3-48

HL CV05-116

ASC

IgA1 4-38-2 1

HK CV05-117

6

ARTVGDYGDY

0

3-1

2

QAWDSSTVV

0

0.27

ARDRGGYSGYGPYYYGMDV

0

1-39

1

QQSYSTPWT

0

5.17

N/A

58

2-23

3

CSYAGAGSSNVV

18 n.exp.

ASC

IgM

3-23

6

AKEKTSWLVAYYYGLDV

31

1-9

2

QQVNSHPHT

13

0.11

ASC

IgA1

4-31

3

ARDYPFCGADCPWVDVFDI

23

3-15

1

QQYSNWPRT

30

0.09

HK CV05-119

ASC

IgG1 3-30

4

AKPVGSSGYYEGGKPIDY

0

1-5

1

QQYNSYWT

3

0.12

HL CV05-119

ASC

IgG1 3-30

4

AKPVGSSGYYEGGKPIDY

0

3-21

3

QVWDSSSDHWV

2

0.1

HL CV05-120

ASC

IgG1 5-51

4

ARNRAGVIDY

0

6-57

3

QSYDSSNLWV

1

0.09

HL CV05-121

ASC

IgA1

1-8

3

VRERIDYDHSGVSTSAFEF

27

1-44

1

GGWDDSLNGYV

17

0.09

HL CV05-122

ASC

IgG1 3-23

6

AKGGYCSGGNCKMAHSYYGLDV

21

1-47

3

AAWDDSLSGHWV

7

0.07

HK CV05-125

ASC

IgM

4-39

5

ASSNTASTMIVVVVQRNWFDP

0

3-15

5

QQYNNWPPIT

1

0.1

HK CV05-126

ASC

IgG1 3-48

4

ARDRARAKWLAYSNYFDY

0

3-15

5

QQYNNWPL

0

0.11

ASC

IgG1 3-33

4

ARDRVSSWEYYFDY

0

3-10

2

YSTDSSGNHRGV

1

ASC

IgG1 4-59

6

ARDRVSGGMDV

0

3-21

2

QVWDSSSDHVV

2

0.12
n.exp.

HL CV05-131

ASC

IgA2

3-23

4

ARGYIGYCSGSTCTTNGGGDY

23

1-51

2

VTWDSSLSAGV

8

n.exp.

HL CV05-134

ASC

IgA1

3-23

3

AKAGIRGGISMVRAHFDI

6

2-8

1

SSYAGSNNFV

1

0.08

HK CV05-118

5-2

HL CV05-127
HL CV05-129

5-3

54

CDR L3

SHM IGKV/ IGLV

S1 reactivity

QQSYSTHT

0

0.11

2

QAWDSSNVV

2

0.1

HK CV05-136

ASC

IgG1 1-69

6

ARGRDIVVESTDQDPMDV

14

4-1

5

QQYYSTSSIT

6

0.07

HK CV05-138

ASC

IgA1

4-31

3

ARDYPFCGADCPWVDVFDI

15

3-15

1

QQYNNWPRT

12

0.06

HL CV05-139

ASC

IgG3 3-23

6

AKDFSGANGDYYYYGMDV

0

3-25

3

QSADSSGTWV

2

0.09

HK CV05-140

ASC

IgG1 4-59

4

AAGGGSGFYYF

30

1-5

2

QQYKSSSST

19

0.09

HL CV05-143

ASC

IgG1 4-59

4

ARDRVAAGVDY

1

3-21

2

QVWDSSSDHVV

2

0.09

HL CV05-144

ASC

IgG1 3-30-3 6

ARTPGDGMDV

0

3-10

2

N/A

1

0.1

HL CV05-145

ASC

IgG1 5-10-1 4

ARHAIYCSGGSCYAYFDY

1

1-41

2

N/A

3

n.exp.

HK CV05-146

5-2

ASC

IgA1

4-31

3

ARDYPFCGADCPWVDVFDI

22

3-15

1

QQYNNWPRT

24

0.09

HK CV05-148

ASC

IgG1 4-39

4

ARQRTHTIFGVVVHFDY

1

4-1

1

QQYYSTPWT

1

0.1

HK CV05-149

ASC

IgA1

4-59

6

ARGWGFPGSTNVHFYFYGLDV

29

1-9

1

QQLNSYRT

16

0.1

HL CV05-151

ASC

IgM

4-59

6

AAGEVVTAISYYYYGMDV

0

3-1

2

QAWDSSSVV

2

0.4

HK CV05-152

ASC

IgM

3-15

4

TTERIYDYVWGSYRYSDY

1

3-20

3

QQYGSSPVT

1

0.09

HK CV05-153

ASC

IgA1

4-4

4

ARDLNV

28

3-15

3

QQYVNWPFT

26

0.07

HK CV05-155

ASC

IgM

1-2

6

ARALRITMIVVVTHYGMDV

0

3-20

2

QQYGSSPYT

0

0.1

HK CV05-157

ASC

IgG1 3-48

4

ARDKSDFWSGNFDY

15

1-33

2

QQYDNLLVT

7

0.1

HL CV05-159

ASC

IgG1 4-38-2 4

ARDKVDYYPYYFDY

1

3-21

2

QVWDSSSDHRV

2

0.08

HK CV05-162

ASC

IgG2 3-21

4

ARDQWSGTTVTSMGH

15

1-5

2

QQYDSNWYT

15

0.09

HK CV05-163

ASC

IgG1

1-2

6

AREVMVRGALPPYGMDV

0

3-11

4

QQRSNWPPVT

0

10.44

ASC

IgA1

4-31

3

ARDYPFCGADCSWVDVFDI

21

3-15

1

QQYNNWPRT

13

0.1

HK CV05-164

5-2

5-2

HK CV05-165

ASC

IgA1

3-74

4

AREGGDGFDY

13

1-5

4

QQYQSYPLA

14

0.1

HK CV05-167

ASC

IgG1 1-69

3

ARGVEMATILPDDAFDI

0

3-15

4

QQYNNWPPVT

0

0.09

HL CV05-169

ASC

IgA1

1-69

4

ARGSTHNNLFVMDY

22

7-46

2

FLSYSGVRGLFVV

17

0.06

HL CV05-170

ASC

IgG1

1-2

6

ARVDTTGTTFWLYYYYGMDV

0

3-1

2

QAWDSSTALVV

1

0.11

HK CV05-171

ASC

IgG1 4-30-4 4

ARLHGDYYYFDY

0

1-39

2

QQSYSTHT

5

n.exp.

HL CV05-171

ASC

IgG1 4-30-4 4

ARLHGDYYYFDY

0

3-1

2

QAWDSSVV

0

0.09

HK CV05-172

ASC

IgM 4-30-4 5

ARLSMTTVTRGNWFDP

0

1-39

2

QQSYSTHT

0

0.08

HL CV05-174

ASC

IgG1

1-2

4

ARDLSNSGSSFDY

0

3-1

2

QAWDSSTADVV

0

0.11

HK CV05-175

ASC

IgG1 1-46

3

VQDLGVRGGRRALDV

22

2-28

2

FQALQTPYT

7

0.11

HK CV05-176

ASC

IgG1 3-53

5

ARGYPGGP

0

1-33

4

QQYDNLLT

0

0.18

HK CV05-178

ASC

IgA2

3-23

3

AKDALGFCSGTSCYGEGAFDI

19

1-5

2

QQYNSYPYT

10

0.07

HL CV05-178

ASC

IgA2

3-23

3

AKDALGFCSGTSCYGEGAFDI

19

2-23

3

CSYAGSSTWV

2

n.exp.

ASC

IgG1 3-30-3 6

ARDLQYYDFWSGYLGTPGRYYYYGMDV

0

3-20

1

QQYGSSPPWT

0

0.07

ASC

IgG1 4-59

ARDRVSGGMDV

0

3-21

2

QVWDSSSDHVV

1

n.exp.

HK CV05-183

ASC

IgG1 3-30-3 6

ARDLRFLEWLFNVPYYYYYGMDV

0

1-9

2

QQLNSYPYT

0

0.11

HL CV05-183

ASC

IgG1 3-30-3 6

ARDLRFLEWLFNVPYYYYYGMDV

0

2-23

3

CSFAGGITLV

14 n.exp.

HK CV05-185

ASC

IgM

3-15

4

TTDRTYDYVWGSYRYRDY

0

1-39

4

QQSYSTLPRT

1

0.06

HK CV05-187

ASC

IgG2 3-73

4

TTIGSGYGFGH

10

1-39

2

QQSYSTHT

1

n.exp.

HL CV05-187

ASC

IgG2 3-73

4

TTIGSGYGFGH

10

2-11

2

CSYGGTYVL

11

0.1

HL CV05-189

ASC

IgG1

6

AKAHSDPNYDFWSPDYYGMDV

1

2-14

2

SSYSTSSTKEV

5

0.10

HL CV05-190

ASC

IgG1 3-30-3 4

ARGVYGDSGVDY

1

3-21

1

QVWDSSSDHLYV

1

0.08

HK CV05-191

ASC

IgG2 3-11

6

ARDTSQSHMDV

15

2-30

2

MQGTHWPPYT

6

0.08

ASC

IgG1

1-3

3

AREDTFSVFGVVTRGNAYDV

26

3-20

1

QQYGVSPRT

20

0.11

HL CV05-194

ASC

IgG1 3-74

1

ARDRHTYSLEYFQH

0

6-57

3

QSYDSSNQV

1

0.08

HL CV05-195

ASC

IgG1 3-30

4

AKEGSKGWLQSSCYFDY

0

3-25

2

QSADSSGTYQV

2

0.1

HK CV07-102

ASC

IgG1 1-18

6

ARDLARVGWTWWYYYYGMDV

2

2-30

1

MQGTHWPRT

0

n.exp.

HK CV05-181
HL CV05-182

HK CV05-192

5-3

5-1

3-9

6

HL CV07-103

ASC

IgM

3-23

4

AKVYGSNTHTPVDY

5

2-8

2

SSYAGSNNVV

4

0.09

HK CV07-104

ASC

IgG1

3-7

6

ARDAARYYGMDV

24

1-39

2

QQSYSTPRT

10

0.09

HK CV07-107

ASC

IgG3 3-23

6

AKDRRTMIVVVITNKYYYGMDV

0

1-5

4

QQYNSYPLT

0

0.11

55

-

>250

++

25-250

(ng/ml)

IGKJ/IGLJ gene
2

3-1

Estimated IC50

IGKV/IGLV gene
1-39

0

RBD reactivity

SHM IGHV
0

AREDTAMVQRFDY

(OD ratio)

CDR H3
AREDTAMVQRFDY

4

IGHV gene

4

IgG1 3-33

Ig isotype

IgG1 3-33

ASC

Source cell
ASC

HL CV05-135

Clonality

HK CV05-135

mAb

IGHJ gene

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

SHM IGHV

IGKV/IGLV gene

IGKJ/IGLJ gene

CDR L3

SHM IGKV/ IGLV

S1 reactivity

TTDADTSPVV

4

4-69

3

QTWDTGIRV

7

0.08

4

ARSLRMG

7

3-20

1

HQYGSIPRT

12 n.exp.

HK CV07-113

ASC

IgA1

4-59

6

ARASFKMGTNYHYGMDV

13

1-27

3

QNYNSVPFT

12

0.08

HK CV07-114

ASC

IgG1

1-2

4

TTLTAVVTPLGY

40

2-30

1

MQGTHWPRT

1

HL CV07-118

ASC

IgM

3-15

3

TTDEQRNYCTSPNCRGGAFDI

7

4-69

3

QTWGTGIRV

7

0.07
n.exp.

HK CV07-121

ASC

IgG1 4-39

5

MRQGDWNYSYYFDA

35

2-30

4

VQGTLWPLT

12 n.exp.

HK CV07-127

ASC

IgA1

6

ARHPLALITIFGVSRQYGMDV

0

1-12

1

QQANSFPWT

1

0.1

HL CV07-128

ASC

IgG2 3-30-3 4

ARELGTSGTLDS

23

2-14

3

LSHSTFTTPQWV

21

0.08

HL CV07-129

ASC

IgG1 3-48

3

ASIASYDYVWGTNRPNDAFDI

17

2-23

1

CSYGGPRNLYV

15

0.09

HL CV07-132

ASC

IgM

4-4

4

ARDRQYRGSDYNYYFDY

3

1-44

3

ATWDDSLNGRV

5

0.09

HK CV07-133

ASC

IgG2 4-39

4

ARHQRPVTTFIDY

29

3-15

3

QHYKDWPPFFT

19

0.08

HK CV07-134

ASC

IgG1 3-23

6

AKVMRDDFWSGYYNDYYYGMDV

6

3-20

2

QQYGRT

0

0.09

HK CV07-136

ASC

IgG1 4-59

6

ARDNYSSRRYYYYYGMDV

0

3-20

1

QQYGSSPTWT

0

0.10

HL CV07-137

ASC

IgM 4-30-4 5

ARLSMTTVTRGNWFDP

0

1-47

3

AAWDDSLSGWV

0

HK CV07-138

ASC

IgA2

3-23

2

VKDFPFGGCTSTTTNCDLFFAL

21

2-24

1

MQATQFPRA

HK CV07-139

ASC

IgG2 4-59

5

AGYLRNDNLDP

11

3-11

4

QQRSDWPLT

0.10
11 n.exp.
9 n.exp.

HK CV07-140

ASC

IgA1

3-64

4

AREYYGLLTGYYLDL

19

1-39

1

QQSYSIPWT

24

ASC

IgG1 3-23

4

AKEFSIGWGLFDS

17

3-11

5

QQRNNWPVT

HK CV07-147

ASC

IgG1

1-2

6

ARDLYYDILTGYYMPMDV

4

3-11

5

HK CV07-151

ASC

IgG1 1-58

3

AADPGGVGYCSGGSCYRAFDI

1

HL CV07-152

ASC

IgG1 1-69

3

ARLRVPLTAHDAFDI

0

1-40

HL CV07-154

ASC

IgG1 1-69

6

ARAYCSGGSCYSYYYGMDV

2

HK CV07-155

ASC

IgM

4-59

6

ARVPREWLSPLYYG

HL CV07-156

ASC

IgG1

3-9

4

HL CV07-159

ASC

IgG2 3-48

HK CV07-161

ASC

HK CV07-163

HK CV07-143

7-3

4-39

3D-15 4

QQRGNWPPIT

++

>250

(ng/ml)

CDR H3

4

3-48

Estimated IC50

IGHJ gene

3-15

IgM

RBD reactivity

IGHV gene

IgM

ASC

(OD ratio)

Ig isotype

ASC

Clonality

HL CV07-108
HK CV07-110

mAb

Source cell

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

0.08
13 n.exp.
4 n.exp.

QQYNNWPPALT

0

0.09

3

QSYDSSVGV

3

0.09

3-1

2

QAWDSSTA

0

0.11

2

1-5

1

QQYNSYQWT

0

0.09

VKDNARTRRGSFDY

15

2-23

1

CSYAGSNTYV

13

0.09

3

AREGELSNYDAFDI

18

2-11

1

CSYAGTHSYV

9

0.08

IgG1 3-30

4

AKEGSKGWLQSSCYFDY

1

2-28

5

MQAFEPPAIT

40

0.12

ASC

IgM

3-33

4

ARDWAVAGNFDY

14

3-20

5

QQYGASPPTT

7

0.09

HL CV07-164

ASC

IgA1

1-46

4

ARDGSHWDFDY

22

2-14

3

SSYVSSDAWV

4

HL CV07-165

ASC

IgM

3-53

4

ARRAASGWNFDY

9

2-23

3

CSYLGSATYV

HK CV07-166

ASC

IgG1 1-18

6

ARDTWDIVIVPAASAYYGMDV

21

2-28

2

MQALQTHT

HK CV07-172

ASC

IgM

3-15

4

TTDRTYDYVWGSYRYRDY

0

1-39

1

QQTFSSPPWT

27

0.07

HK CV07-173

ASC

IgM

3-30

6

SKGFLEWLLRRYYYGMDV

3

1-9

3

QQLNSYPFT

0

HK CV07-176

ASC

IgA1

5-51

6

ARHFGGSGSYYNGHWIPAYYYHGMDV

7

2-28

4

MQARQTPPLT

4

0.07
n.exp.
n.exp.

0.09
19 n.exp.
1 n.exp.

HL CV07-176

ASC

IgA1

5-51

6

ARHFGGSGSYYNGHWIPAYYYHGMDV

7

2-8

2

SSYAGSTNLV

4

HK CV07-178

ASC

IgG2 4-31

3

ARDRTMVVWNAFDI

17

1-39

1

QQSHSPSRT

13

0.18

HL CV07-179

ASC

IgA1

3-7

5

ARESRLGIAIFDRRLRSWFGA

0

2-14

1

SSYTSSSTRV

0

n.exp.

HK CV07-180

ASC

IgM

3-15

4

TTQHYDFWSGNYKPFAF

12

2-28

5

MQALQTLT

3

0.11

HL CV07-181

ASC

IgA1

3-33

4

ARDEAAEYYFDY

1

3-25

3

QSADSSGTFWV

1

HK CV07-183

ASC

IgG1 3-30

4

AKEGSKGWIQNSCYFDY

12

4-1

1

QQYYSTPPT

3

0.11
n.exp.

HK CV07-185

ASC

IgA1

3-23

4

VKDPNWANGY

30

2-30

4

VQGTHWPLT

16 n.exp.

HK CV07-186

ASC

IgA1

1-46

4

AKGRSTIFGVIVNQGDCYDY

9

1-27

4

QKYNSAPLT

4

0.10

HK CV07-189

ASC

IgG1 3-23

4

AKDPHFDFWSGNYFDY

5

1D-12 4

QQANSFPLT

0

0.06

HK CV07-190

ASC

IgM

4-31

3

ARDRGVTIFGVVIIDAFDI

1

3-20

4

QQYGSSPLT

0

0.05

HK CV07-191

ASC

IgG1 1-18

6

SREGDLTIFGSVTNAYYYFGMDF

3

1-39

5

QQSYSTPIT

1

n.exp.

2-8

3

SSYAGSNNWV

2

2.06

QQYNSYPRT

0

0.07

HL CV07-196

7-1 S1-MBC IgM

1-2

4

ARDLGIGVAGNLDH

4

HK CV07-199

S1-MBC IgM

4-59

5

ARDRDSSGWYPNWFDP

2

HL CV07-200

7-2 S1-MBC IgG1

1-2

6

ARGPFYYDNSGTLGGLDV

5

2-14

1

SSYTSSSTYV

1

8.57

++

25

HL CV07-201

7-4 S1-MBC IgM

1-2

6

ATDRLVNTGVYTTGSMDV

8

2-23

1

CSYGGSSDYV

2

4.03

++

>250

HK CV07-202

S1-MBC IgG1 3-53

6

ARDLYYYGMDV

4

1-9

4

QQLNNYSVT

2

8.87

++

25-250

HL CV07-203

S1-MBC IgM

6

ARKQQPSSLSYYYYGMDV

1

1-40

3

QSYDSSLSGSWV

3

0.06

1-2

56

1D-16 1

IGKJ/IGLJ gene

CDR L3

SHM IGKV/ IGLV

S1 reactivity

3

QSYDSSIWV

2

0.09

1-39

1

QQSYSTPNT

0

HL CV07-205

S1-MBC IgM

3-23

4

AKEYGYDSSGSGGDY

0

2-23

3

CSYAGSSTWV

2

0.07
n.exp.

HK CV07-206

S1-MBC IgM

1-2

6

AREGYYDFWSGYYTVYYYGMDV

0

1-5

1

QQYNSYWT

9

n.exp.

HL CV07-206

S1-MBC IgM

1-2

6

AREGYYDFWSGYYTVYYYGMDV

0

2-14

3

SSYTSSSTRV

1

3.98

HL CV07-208

7-2 S1-MBC IgM

1-2

6

ARGPFYYDSSGTLGGMDV

3

2-14

1

SSYTSRNTYV

5

n.exp.

HK CV07-209

S1-MBC IgG1 3-11

4

ARDGVIPPRFDY

2

1-33

4

QQYDNLPLT

1

12.06

HL CV07-210

S1-MBC IgM

3-21

4

VSSGNYRFHY

8

2-14

1

SSYMSSSTPYV

4

0.18

HL CV07-213

7-5 S1-MBC IgM

1-8

4

ARGPSWNGYYYYFDY

6

1-44

2

ASWDDRLNGVV

7

0.1

HK CV07-214

S1-MBC IgG1

6-1

3

AREENAFDI

0

3-15

2

QQYSNWLLYT

4

7.69

HK CV07-215

S1-MBC IgM

3-48

3

AREGHAFDI

2

3-20

1

QQYGSSPSWT

1

0.08

HK CV07-216

S1-MBC IgM

3-7

4

VAWGTTPLGTSENN

16

2-30

2

MQHTHWPHT

11

0.08

HL CV07-217

7-5 S1-MBC IgM

1-8

4

ARGPSWNGYYYYFDY

6

1-44

2

ASWDDSLNGVV

8

0.12

HL CV07-218

S1-MBC IgM

3-23

4

AKRMGGNRFNPPVEY

12

1-40

3

HSYDSSLSASV

6

n.exp.

S1-MBC IgG2 3-11

HK CV07-219

6

ARDGIGQLWDDSYYYGLDV

15

2-30

2

MQGAHWPPYT

10

3.68

7-4 S1-MBC IgM

3-30

6

AKKAGYSSGWYTDYYYNGMDV

1

1-40

3

QSYDSSLRGV

4

0.15

HL CV07-222

S1-MBC IgG1

1-2

3

ARGPYYYDSSGSLGAFDI

5

2-23

1

CSYAGGSTSYV

2

12.03

HL CV07-223

7-5 S1-MBC IgM

1-8

4

VRGPSWNGYYYYFDY

6

1-44

2

ASWDDSLNGVV

3

0.08

HL CV07-221

HL CV07-224

S1-MBC IgM

5-51

6

ARLGPYYSSSSNGMDV

2

2-23

3

CSYAGSSTRV

3

0.08

HK CV07-225

S1-MBC IgG1 4-31

6

ARDTPPGYNWNYGPYGMDV

9

3-15

2

QQYNNWPPGYT

4

4.78

HL CV07-226

S1-MBC IgM

3-30

6

AKKAGYSSGWYTDYYYNGMDV

1

2-8

3

SSYTASNRG

++

250

++

<25

++

>250

++

>250

++

<25

++

>250

++

>250

+

n.t.

n.t.

(ng/ml)

IGKV/IGLV gene
6-57

0

Estimated IC50

SHM IGHV
0

AKEYGYDSSGSGGDY

RBD reactivity

CDR H3
ALCGYSYGSNYYYYGMDV

4

(OD ratio)

IGHJ gene
6

3-23

Ig isotype

4-39

S1-MBC IgM

Source cell

S1-MBC IgM

Clonality

HL CV07-204
HK CV07-205

mAb

IGHV gene

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

41 n.exp.

HL CV07-230

S1-MBC IgM

3-9

4

AKEISGYYFDY

7

4-69

3

QTWGTGIHWV

14

0.08

HL CV07-231

7-4 S1-MBC IgM

3-30

6

AKKAGYSSGWYTDYYYNGMDV

1

1-40

3

QSYDSSLRGV

4

0.07

HL CV07-235

S1-MBC IgM

3-23

6

AKSTYGDYYYYYGMDV

7

2-14

3

NSYTSNSSLGV

8

6.16

HK CV07-236

S1-MBC IgM

3-53

4

AREYSSGWYDY

0

3-15

4

QQYNNWPLT

3

0.09

HL CV07-237

7-2 S1-MBC IgA1

1-2

6

ARGPFYYDSSGTLGGMDV

3

2-14

1

SSYTSSSTYV

0

5.58

HL CV07-238

S1-MBC IgM

1-8

6

ARTNWNYYYYYYGMDV

0

1-44

1

AAWDDSLNGYV

2

0.09

HL CV07-239

S1-MBC IgM

4-34

3

ARGRWYHDNNGYRSDAFDV

17

1-44

3

AAWDDSLNEV

9

0.07

HL CV07-241

S1-MBC IgM

3-74

4

ITSMFNNGFY

7

2-11

2

SSYAGSYTV

7

0.08

HL CV07-242

S1-MBC IgM

3-15

5

TTLWRLDP

46

7-46

3

LLTHTDSRV

11 n.exp.

HL CV07-249

7-1 S1-MBC IgM

1-2

4

ARDLGIGVAGNLDH

1

2-8

3

SSYAGSNNWV

3

2.87

+

S1-MBC IgG1 1-18

6

AGSDNYGFPYNGMDV

17

2-8

2

SSYAGNNDFV

16

8.27

++

25

3-23

4

AKEFSIGWGLFDY

9

3-11

5

QQRNNWPVT

8

8.79

++

25-250

HK CV07-252

S1-MBC IgG1 1-46

6

ARDKHWNNANYYYYGMDV

1

1-5

4

QQYNSYL

2

6.03

++

>250

HL CV07-254

S1-MBC IgM

1-2

4

ARDQGGAALVGHSNY

10

2-23

2

CSYAGSSTWV

3

6.71

++

>250

HL CV07-255

S1-MBC IgG1

1-2

4

ARDSRFSYVNGEFDY

3

2-23

3

CSYAGHSTWV

5

9.54

++

25

HL CV07-262

S1-MBC IgG1

1-2

6

ARVGWYDFGTPGDYYYYYGMDV

6

2-23

1

CSYAGTSTFV

3

10.2

++

< 25

HK CV07-263

S1-MBC IgG1

1-2

6

ADSGYWGSHYYYGMDV

3

MQSIQLPLT

0

7.87

++

25-250

HL CV07-264

7-1 S1-MBC IgA2

1-2

4

ARDLGIGVAGNLDH

1

2-8

3

SSYAGSNNWV

2

7.08

++

250

S1-MBC IgG1 3-48

6

ARRRYSSSWYYYYGMDV

2

1-9

4

QQLNSYPLT

0

6.41

-

n.t.

ATDRLVNTGVYTTGSMDV

8

2-23

1

CSYGGSSDYV

2

4.62

++

>250

HL CV07-250
HK CV07-251

HK CV07-265

7-3 S1-MBC IgM

HL CV07-266

7-4 S1-MBC IgG1

1-2

6

HL CV07-267

7-6 S1-MBC IgA1

2D-29 1

1-2

6

ARVFGPGLDCSSTSCYTYGMDV

2

2-23

3

CSYAGSSSWV

1

8.47

++

250

HL CV07-270

S1-MBC IgG3 3-11

5

ARARGSSGWYRIGTRWGNWFDP

2

2-14

2

SSYTSSSNVV

0

8.53

++

25-250

++

>250
>250

HL CV07-271

S1-MBC IgA1

1-2

6

ARVPFAYCSSTSCDRGTPYYYYYGMDV

0

2-14

2

SSYTSSSTLV

3

8.28

HK CV07-272

S1-MBC IgM

3-64

4

ARGLDNNGYYSGY

16

3-20

1

QQYGSSPRT

5

0.08

HL CV07-274

7-7 S1-MBC IgM

1-2

4

ARDQKNDILTGLGDY

4

2-8

3

SSYAGSNNWV

1

3.97

++

S1-MBC IgG1 3-66

4

ARDYYDSSGYYSSGGLGY

0

2-8

1

SSYAGSNNFV

0

4.51

++

>250

ARGPFYYDSSGTLGGMDV

2

2-14

1

SSYTSSSTYV

0

7.29

++

25-250

HL CV07-275
HL CV07-280

7-2 S1-MBC IgA1

1-2

6

HL CV07-281

7-2 S1-MBC IgM

1-2

6

ARGPFYYDSSGTLGGMDV

2

2-14

1

SSYTSSSTYV

0

5.07

+

n.t.

HL CV07-283

7-2 S1-MBC IgA1

1-2

6

VRGPFYYDSSGPLGGMDV

7

2-14

1

SSYTSSSTYV

2

9.89

++

25

57

CDR H3

SHM IGHV

IGKV/IGLV gene

IGKJ/IGLJ gene

CDR L3

SHM IGKV/ IGLV

S1 reactivity

(OD ratio)

RBD reactivity

Estimated IC50

ASGGDYPYGMDV

5

1-44

3

AAWDDSLSAWV

1

0.87

++

>250

6

ARGPFYYDNSGTLGGLDV

5

2-14

1

SSYTSSSTYV

1

9.3

++

25

HL CV07-286

S1-MBC IgG1

3-9

6

AKGGRYCSGTNCYEYYFFAMDV

8

2-8

2

SSYAGSNNNVV

3

0.09

HK CV07-287

S1-MBC IgG1 1-58

3

AAPYCSSTNCYDAFDI

0

3-20

1

QQYGSSPWT

0

9.25

++

25-250

HK CV07-289

S1-MBC IgM

1-2

6

ARGAAMVTGYTYYYGLDV

3

3-20

5

QQYGSSPIT

2

0.07

HL CV07-290

7-7 S1-MBC IgM

1-2

4

ARDQKNDILTGLGDY

0

2-8

3

SSYAGSNNWV

0

3.02

++

>250

HL CV07-292

7-7 S1-MBC IgM

1-2

4

ARDQKNDILTGLGDY

3

2-8

3

SSYAGSNNWV

0

7.92

++

250

HK CV07-293

S1-MBC IgM

3-11

6

ARCNGGGACFYGMDV

10

4-1

5

QQYYSTLT

3

0.07

HL CV07-293

S1-MBC IgM

3-11

6

ARCNGGGACFYGMDV

10

2-14

3

SSYTISSTWV

4

0.07

HL CV07-294

7-2 S1-MBC IgM

1-2

6

ARGPFYYDSSGTLGGMDV

2

2-14

1

SSYTSSSTYV

0

5.69

++

>250

HL CV07-297

S1-MBC IgM

3-53

4

ARRSASGWNFDY

13

2-8

3

SSYAGSNNLV

8

0.08

2-14

3

SSYTSSSTVWV

250

HL CV07-299

S1-MBC IgM

5-51

4

ATSHGYSGYELGY

9

HK CV07-301

S1-MBC IgG1

1-2

6

ARVDTTGTTFWLYYYYGMDV

2

HL CV07-301

S1-MBC IgG1

1-2

6

ARVDTTGTTFWLYYYYGMDV

0

HK CV07-302

S1-MBC IgA1

3-9

6

AKDKGPYYYYGMDV

0

HL CV07-303

7-1 S1-MBC IgM

1-2

4

ARDLGIGVAGNLDH

4

2-8

3

HL CV07-304

7-6 S1-MBC IgA1

1-2

6

ARVFGPGLDCSSTSCYTYGMDV

1

2-23

3

2D-29 3
2-23

3

2D-29 1

(ng/ml)

IGHJ gene
6

1-2

Ig isotype

5-51

7-2 S1-MBC IgA1

Source cell

S1-MBC IgM

HL CV07-285

Clonality

HL CV07-284

mAb

IGHV gene

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

29 n.exp.

N/A

0

0.17

CSYAGSSTWV

2

n.exp.

MQSIQLPQT

0

1.51

++

SSYAGSNNWV

3

4.71

++

250

CSYAGSNSWV

2

8.08

++

>250

HL CV07-305

7-1 S1-MBC IgM

1-2

4

ARDLGIGVAGNLDH

2

2-8

3

SSYAGSNNWV

2

0.93

++

>250

HK CV07-306

S1-MBC IgA1

1-2

4

ARGTLYYDILTGSPNPPKLDY

0

1-39

1

QQSYSTPWT

0

8.25

++

250

HL CV07-307

7-2 S1-MBC IgA2

1-2

6

ARGPFYYDNSGTLGGLDV

5

2-14

1

SSYTSSSTYV

1

9.27

++

25

HL CV07-309

7-2 S1-MBC IgM

1-2

6

ARGPFYYDNSGTLGGLDV

5

2-14

1

SSYTSSSTYV

1

8.62

++

25-250

HL CV07-310

7-2 S1-MBC IgA1

1-2

6

ARGPFYYDSSGTLGGMDV

3

2-14

1

SSYTSSSTYV

0

5.11

+

n.t

HL CV07-312

S1-MBC IgM

1-2

6

ARIPIFGVVSTPGQYYYYGMDV

6

2-14

3

ISYTSSSTWV

1

0.18

25

HL CV07-313

7-4 S1-MBC IgA1

1-2

6

ATDRLVNTGVYTTGSMDV

9

2-23

1

CSYGGSSDYV

2

0.09

HK CV07-315

S1-MBC IgG1

3-9

6

AKDFLWDLHPPRYYGMDV

0

1-39

2

QQSYSTHA

1

0.16

HL CV07-315

S1-MBC IgG1

3-9

6

AKDFLWDLHPPRYYGMDV

0

1-51

3

GTWDSSLNGV

1

11.4

++

HL CV07-316

7-2 S1-MBC IgA1

1-2

6

ARGPFYYDSSGTLGGMDV

2

2-14

1

SSYTSSSTYV

1

3.12

+

n.t

HL CV07-317

7-7 S1-MBC IgM

1-2

4

ARDQKNDILTGLGHY

0

2-8

3

SSYAGSNNWV

0

++

>250

HK CV07-319

S1-MBC IgM

1-2

5

ARGPFFFEVVVAEGFGWFDP

28

3-15

5

QQYNNWPPIT

1

2.53
n.exp.

HL CV07-319

S1-MBC IgM

1-2

5

ARGPFFFEVVVAEGFGWFDP

28

2-8

1

SSYAGSNVYV

0

n.exp.

HL CV07-323

7-6 S1-MBC IgA1

1-2

6

ARVFGPGLDCSSTSCYTYGMDV

0

2-23

3

CSYAGSSSWV

1

7.39

++

>250

HL CV07-324

7-2 S1-MBC IgA1

1-2

6

ARGPFYYDSSSTLGGMDV

4

2-14

1

SSYTSSSTYV

3

11.02

++

25-250

HK CV23-101

S1-MBC IgM

3-30

4

ARDWEYYGSGTKAFDY

9

1-13

4

QHFNSYPLT

>250

S1-MBC IgA1

1-2

4

N/A

47

2-14

2

SSYTRSTAVV

9
4.33
19 n.exp.
3 n.exp.

++

HL CV23-103
HL CV23-113

S1-MBC IgM

5-51

4

ATTRGYSDYEFAY

11

2-8

3

SSYAGSNNFPWV

HK CV23-114

S1-MBC IgM

4-31

5

ARDLGPRSDFGSGSGVGVIDP

10

3-15

1

QQYHNWPPWT

5

n.exp.

HL CV23-115

S1-MBC IgM

1-2

3

ARGYYDILIGYATTHDAFDL

8

2-14

3

SSYTDSSTWV

6

n.exp.

HK CV23-116

S1-MBC IgM

3-21

6

ARASLVTMVRGAGNYMDV

0

3-11

5

QQRSNWPLT

0

0.11

HL CV23-116

S1-MBC IgM

3-21

6

ARASLVTMVRGAGNYMDV

0

2-23

3

CSYAGSRV

2

0.09

HL CV23-121

S1-MBC IgM

1-2

4

ARELGSWDGRFDY

0

2-23

3

CSYAGSSTWV

0

0.10

HK CV23-126

S1-MBC IgM

4-59

6

ARDTTSYCSGGSCYYNYGMDV

7

2-28

3

MQALQTPRT

3

0.07

HL CV24-198 24-1 S1-MBC IgA1

1-2

3

ARDLAYSMVRGISGI

7

2-23

3

CSYAGSNTWV

7

5.48

++

250

HL CV24-201 24-1 S1-MBC IgA1

1-2

3

ARDLAYSMVRGISGI

7

2-23

3

CSYAGSNTWV

9

5.79

++

>250

HK CV24-220

S1-MBC IgA2

3-48

4

ARDRGSGWSLDESYFDH

15

1-39

2

QQSKSIPYT

HL CV24-223 24-5 S1-MBC IgM

4-39

4

ARLRWLRGEFDY

0

6-57

3

QSYDSSTYWV

0

8.83

++

>250

HL CV24-226 24-5 S1-MBC IgM

4-39

4

ARLRWLRGEFDY

0

6-57

3

QSYDSSTYWV

0

8.77

++

>250

HL CV24-236

3-49

4

IRGGYGGNSGFDY

5

1-51

2

GTWDSSLSAVV

3

0.15

S1-MBC IgM

17 n.exp.

HL CV24-243

ASC

IgM

3-7

4

ARLYSGNYFDY

6

4-69

3

QTWDTAIWV

14 n.exp.

HK CV24-247

ASC

IgA1

3-48

5

ARGFYDILTGYYSFHFDL

16

1-5

1

QQYNTYWT

7

0.35

HK CV24-248 24-2

ASC

IgG1 3-33

6

ARREGVADYYYYYGMDV

8

1-6

1

LQVYNYPWT

6

0.09

58

CDR L3

SHM IGKV/ IGLV

S1 reactivity

YSAADNMGV

1

0.08

1

QHYSAATWT

14

0.09

HL CV24-253 24-3

ASC

IgA1

1-2

4

ARVFHGVITPFDY

12

5-37

2

MIWPSSAVV

7

0.07

HK CV24-255

ASC

IgG1 4-34

4

ARGRLGFEELFRGVFFYYFDY

21

1-39

2

QQTFNSPRT

22

0.07

HK CV24-256 24-4

ASC

IgM

3-49

5

TRAQEEKITMIRRIISWFDP

5

3-20

5

QQYGSSPIT

6

0.1

HL CV24-260

ASC

IgG1 4-59

6

ARLLKSCTGGICQTYFYYAMDV

21

1-40

1

QSYDGSLSESAV

20

0.1

HK CV24-262

ASC

IgA1

4-31

4

ARGTTYTIFGVVISPFDY

0

3-20

4

QQYGSSPLT

0

0.09

HK CV24-265

ASC

IgG1 4-34

5

ARGAPGT

30

1-5

2

QHYSTFPYT

15

0.1

HK CV24-268

ASC

IgG1

3-9

4

TTGYCRSNNCLTFYAF

20

1-39

2

QQSYRAPVT

13

0.08

HL CV24-269

ASC

IgM

4-31

6

ARDYFGRSGSGSSLYYYYGMDV

0

3-1

2

QAWDSSTV

0

5.39

HK CV24-271

ASC

IgG1 3-21

4

ARVAAAGQKYYFDY

0

1-9

4

QQLNS

0

0.12

HL CV24-275

ASC

IgG1 3-30

6

AKVANVFMLYPRGSWGMDV

14

1-47

3

AAWDDSLSGWV

14

0.09

HK CV24-280

ASC

IgG1 3-48

6

AAGSSTSPSPV

0

3-15

1

QQYNNWPRT

0

0.16

HK CV24-282

ASC

IgG1 3-23

6

AKDRGRRLTHLGVAPDV

23

1-39

2

QQSYTTPYT

19

0.15

HK CV24-283

ASC

IgM

3-66

4

CGGYGSSWYLDY

20

3-11

2

QQRSNWPYT

10

0.15

HL CV24-284

ASC

IgG1 4-31

4

ARGGLSSRNGGNRSYSSSSFPLGRQDY

0

2-14

1

SSYTSSSTLYV

1

0.15

HL CV24-285

ASC

IgM

5-51

4

ARFLSFVTSPTRYDY

6

2-14

1

SSYTSSSTLV

8

0.14

HK CV24-286

ASC

IgG1 1-69

3

ARHLPLSGYYAFDV

22

3-20

2

QQYGSSPYT

13

0.19

HK CV24-287

ASC

IgM

3-23

3

AKDRSGGILAGGSGGALDI

26

1-5

1

QQYSSYSRT

14

0.16

HL CV24-290

ASC

IgG1 4-39

4

ARASEDISLERAYNYGLTIDF

10

3-9

2

QVWDSSTVV

6

HL CV24-293

ASC

IgA1

3-7

6

ARENYDSSGYYYAYYYYGMDV

0

3-25

1

QSADSSGTYV

3

0.16
n.exp.

HK CV24-294

ASC

IgM

3-9

4

ARGDLGIRYFDY

5

3-15

5

QQYNNWPPIT

1

n.exp.

HL CV24-294

ASC

IgM

3-9

4

ARGDLGIRYFDY

5

2-23

3

CSYAGSSTWV

2

n.exp.

HK CV24-296

ASC

IgG3 1-18

1

N/A

11

4-1

2

QQYHSTPPA

4

n.exp.

HL CV24-296

ASC

IgG3 1-18

1

N/A

11

2-23

3

CSYAGSSTWV

2

n.exp.

HK CV24-298

ASC

IgG1 3-33

3

ARGWGGDGYTVDAFDV

19

2-28

2

MQALQPPYI

HK CV24-301

ASC

IgG1 1-46

5

ARSLYSGSYGAYNWFDP

19

3-11

4

LQRINWLT

HK CV24-309

ASC

IgG1 4-61

6

AREQVLDPGLYYGIDV

29

1-39

2

QQSYSTHT

HL CV24-309

ASC

IgG1 4-61

6

AREQVLDPGLYYGIDV

29

3-1

2

QAWDSDTVI

HL CV24-310 24-3

ASC

IgG1

1-2

4

ARVFHGVITPFDF

19

5-37

2

MIWPSSDVV

23 n.exp.
4 n.exp.

HL CV24-311

ASC

IgG1

1-2

4

ARGADIFITIFGVVIKENDY

0

2-18

2

SSYTSSSTLV

2

-

n.t.

(ng/ml)

IGKJ/IGLJ gene
3

3-20

Estimated IC50

IGKV/IGLV gene
3-27

19

RBD reactivity

SHM IGHV
0

VRVSGPFHDYFLYAMDV

(OD ratio)

CDR H3
AREYDYSNPNYYYYYGMDV

6

IGHV gene

6

IgG1 3-74

Ig isotype

IgG1 1-18

ASC

Source cell
ASC

Clonality

HL CV24-249
HK CV24-252

mAb

IGHJ gene

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

9 n.exp.
13 n.exp.
1 n.exp.

n.exp.

12 n.exp.
17 n.exp.

HL CV24-314

ASC

IgM

3-30

4

ARGKNYGYSDDDLFQHFDY

3

7-43

3

LLHYGSSQLGV

HK CV24-316

ASC

IgG1 1-69

6

ARALGLSGHGMDV

29

1-39

2

QHSYSTPHT

HL CV24-317

ASC

IgG1

4-4

3

AKESWLELWLQGAGFDI

16

2-11

2

CSYGGSYTFVV

HL CV24-319

ASC

IgG1 1-46

6

ARDLWMEYEYNDSGIQKTADQGMDV

16

3-1

3

QAWDINTVV

12 n.exp.
17 n.exp.

HK CV24-321

ASC

IgM

3-33

3

ARDMVRGPNDASDI

10

1-12

4

QQANSFPLT

4

n.exp.

HL CV24-322

ASC

IgG1 4-39

4

ARQRTHTIFGVVVHFDY

1

3-25

1

QSADSSGTYDV

3

n.exp.

HK CV24-323 24-4

ASC

IgM

3-49

5

TRAQEEKITMIRRIISWFDP

5

3-20

5

QQYGSSPIT

6

n.exp.

HK CV24-325 24-4

ASC

IgM

3-49

5

TRAQEEKITMIRRIISWFDP

5

3-20

5

QQYGSSPIT

8

n.exp.

HK CV24-329

ASC

IgM

3-33

3

ARDMVRGPNDASDI

10

3-15

5

QQYNNWPPVT

3

n.exp.

HK CV24-330 24-4

ASC

IgM

3-49

5

TRAQEEKITMIRRIISWFDP

5

3-20

5

QQYGSSPIT

HL CV24-331

ASC

IgG1 3-23

6

AKEVPDIIVVAVAVGMDV

21

1-47

2

ASWDDSLSGVL

HL CV24-332

ASC

IgG1

1-2

6

ARETRETYYDILTGYPFYYYFGMDV

9

1-51

2

GTWDGSLSAAV
VLYMGSDIWA

11 n.exp.
12 n.exp.
11 n.exp.
12 n.exp.

HL CV24-333

ASC

IgM

3-15

4

SSDLPKWGSGMADY

13

8-61

3

HK CV24-336 24-4

ASC

IgM

3-49

5

TRAQEEKITMIRRIISWFDP

5

3-20

5

QQYGSSPIT

HK CV24-344 24-2

ASC

IgG1 3-33

6

ARREGVADYSYSCGMDV

10

1-6

1

LQVYNYPWT

HK CV24-346

ASC

IgG1 1-69

3

ARSDDSSGYYYLKEENDAFDI

0

2-30

2

MQGTHWREYT

8 n.exp.
11 n.exp.
1 n.exp.

HL CV24-347

ASC

IgG3

1-2

6

ARDRLYCSSTSCYTPYYYYYYGMDV

0

3-25

3

QSADSSGTYGV

3

HL CV38-102

S1-MBC IgG1 3-23

2

AKVETRGVGFDL

1

3-1

2

QAWDSSTVV

1

8.7

-

n.t.

HK CV38-103

S1-MBC IgA1

4

ARDWNLSGYYGGGR

1

1-16

4

QQYNSYPLT

0

5.84

++

>250

3-11

59

n.exp.

IGKV/IGLV gene

IGKJ/IGLJ gene

CDR L3

SHM IGKV/ IGLV

S1 reactivity

RBD reactivity

Estimated IC50

7

0.26

SSYAGSNNYV

0

0.58

+

n.t.

HK CV38-113

S1-MBC IgG1 3-53

4

ARGGRLADAAGDY

1

1-33

2

QQYDNLPSWT

1

11.47

++

25

HK CV38-114

S1-MBC IgM

5-51

4

ARAGNDNSLDY

1

1-39

2

QQSYTTPYT

18

0.17

HL CV38-114 38-4 S1-MBC IgM

5-51

4

ARAGNDNSLDY

1

9-49

3 GADHGSGSNFVQKV

1

8.13

++

>250

HL CV38-115

S1-MBC IgG1

3-7

5

ARDLYYYDSSGNGVNWFDP

3

1-40

1

QSYDSSLSGSYV

1

8.04

++

n.t.

HL CV38-117

S1-MBC IgG1 4-30-4 4

ARVTRIYGSGSYCFDY

0

2-23

2

CSYVGSSTFVV

2

9.55

++

>250

HK CV38-118

S1-MBC IgA1

4-59

4

ARAWSSSWYLDY

3

3-11

4

QQRSNWPPVT

0

0.51

+

n.t.

HL CV38-119

S1-MBC IgA1

4-4

4

ARAWNFDY

0

2-23

3

CSYAGSSNWV

1

5.56

++

>250

HL CV38-122

S1-MBC IgG1 3-23

3

AKVLDI

0

2-14

1

SSYTSSSTPYV

HK CV38-124

S1-MBC IgG1 4-59

6

ATYYYDSSGYPYGMDV

1

1-9

3

HL CV38-125 38-4 S1-MBC IgG1 5-51

4

ARHQGYSSSSLGY

1

9-49

HK CV38-127

S1-MBC IgG1 3-33

4

ARDPEIVVGGVDY

0

HK CV38-128

S1-MBC IgA1

3-11

4

ARDWNLSGYYGGGR

HK CV38-129

S1-MBC IgG1 4-31

3

HK CV38-131

S1-MBC IgA1

3-11

4

HK CV38-132

S1-MBC IgG1 4-31

HK CV38-134

(ng/ml)

SHM IGHV

LQNYNFPRT

1

S1-MBC IgG1 3-74

HL CV38-107 38-1 S1-MBC IgA1

(OD ratio)

CDR H3

1

2-8

IGHV gene

1-6

0

Ig isotype

22

ARDGAQYILTGDFDY

Source cell

ARQRVARRRGFGESPFYYGLDV

4

HK CV38-105

Clonality

6

1-2

mAb

IGHJ gene

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

2

n.exp.

3

6.07

++

>250

1

8.53

++

>250

2-30

QQLNSYPG
3 GADHGSGSNFVYM
V
2
MQGTHWPYT

0

3.45

++

>250

0

1-39

2

QQSYTTPYT

18

0.15

ARDQGASASWDAFDI

0

3-20

4

QQYGSSLT

0

2.24

++

>250

ARDHSVRFLEWLLPY

0

1-9

1

QQLNSYPWT

3

1.93

+

n.t.

4

ARAERSITIFGVVTSAFDY

1

4-1

2

QQYYSTPYT

0

1.24

+

n.t.

S1-MBC IgG1 4-34

4

ASSGWYYPDY

3

3-20

4

QQYGSSPNT

0

7.98

++

>250

HL CV38-135

S1-MBC IgG1 3-23

3

AKVTGLGNAFDI

3

3-1

2

QAWDSSTVV

0

7.19

-

n.t.

HL CV38-136

S1-MBC IgG1

4-4

5

ARSSGRGRVVALGSFDP

1

2-23

3

CSYAGSSTWV

0

8.52

-

n.t.

HK CV38-139

S1-MBC IgG1 3-53

4

ARGHYDLFDY

3

1-9

3

QQLNSYPPGT

0

8.33

++

25-250

HK CV38-140

S1-MBC IgA1

4-31

4

ARAYDSSGYYPDY

0

1-39

4

QQSYSTLT

0

2.56

++

>250

HK CV38-142

S1-MBC IgG1 5-51

4

ARIRGVYSSGWIGGDY

4

1-39

1

QQSYSTPRQWT

0

9.39

++

25

1-2

4

ARDGAQYILTGDFDY

0

2-8

1

SSYAGSNNYV

0

2.30

+

n.t.

HK CV38-146

S1-MBC IgG1 1-69

5

ARAATYYYDSSGYTPNWFDP

1

1-39

2

QQSYSTLYT

0

2.17

++

>250

HL CV38-147

S1-MBC IgG1

3-9

4

AKDRRIAVAGTGEDYYFDY

4

3-21

2

QVWDSSSDQVV

1

11.7

++

250

HL CV38-148

S1-MBC IgG1 3-66

4

ARSAPLVGAYSGIYFDY

2

9-49

2

GADHGSGSNFVV

1

7.26

++

>250

1-6

4

LQDYNYPLT

1

0.73

-

n.t.

2D-29 1

MQSIQLWT

0

11.04

-

n.t.

+

n.t.

-

n.t.

HL CV38-143 38-1 S1-MBC IgM

HK CV38-149 38-3 S1-MBC IgM

3-9

4

AKNRVAGTIFGVGPFDY

0

HK CV38-150

S1-MBC IgG1 3-30

3

AKSQWLVLRHAFDI

0

HL CV38-156

S1-MBC IgG1 4-59

4

ARFSQYYYDSSGYDFDY

0

2-23

3

CSYAGSSSWV

3

0.42

HK CV38-158

S1-MBC IgM

3-15

6

TTDRWFGELFSAYYYYYGMDV

0

3-11

3

QQRSNWPPIFT

0

0.17

HL CV38-159

S1-MBC IgG1

1-2

4

ARGNTVFWSGPPLDY

0

2-14

1

SSYTSSSTYV

0

4.27

HL CV38-160

S1-MBC IgG1 3-23

3

AKVAGRGNAFDI

3

7-43

2

LLYYGGAL

3

n.exp.

HK CV38-165

S1-MBC IgG3

4-4

4

ARRSLGNYDSSGYDH

1

3-15

5

QQYNNWPPAIT

1

5.09

HL CV38-165

S1-MBC IgG3

4-4

4

ARRSLGNYDSSGYDH

1

1-44

1

AAWDDSLNGYV

0

0.15

HL CV38-173

S1-MBC IgG3 3-30-3 4

ARDYGGYNYN

4

3-1

2

QAWDSSTVV

0

9.92

-

n.t.

HK CV38-177 38-3 S1-MBC IgG1

3-9

4

AKDMVVVAIFGVGPFDY

1

1-6

4

LQDYNYPLT

1

-

n.t.

HK CV38-179

S1-MBC IgM

5-51

3

ARQRRPPGKRVLTMIVVVYNDAFDI

1

1-33

3

QQYDNLLFT

0

10.77
n.exp.

HL CV38-179

S1-MBC IgM

5-51

3

ARQRRPPGKRVLTMIVVVYNDAFDI

1

1-40

2

QSYDSSLSGSV

2

n.exp.

HL CV38-180

S1-MBC IgG1

4-4

4

ARRAAAGPRPYDY

2

2-23

3

CSYAGFSTWV

6

n.exp.

HK CV38-181

S1-MBC IgA1

1-2

3

ARDLGYSYLYGAFDI

1

3-11

4

QQRSNWPT

4

6.17

++

>250

HL CV38-182

S1-MBC IgA1

1-69

2

AKELGYSGYGAHRYFDL

3

1-40

2

QSYDSSLSGVV

0

11.73

++

250

HL CV38-183

S1-MBC IgG1 3-53

6

ARGDGWDNYYYGMDV

0

1-40

2

QSYDSSLSGSV

2

11.06

++

<25

HK CV38-184

S1-MBC IgG1 4-39

5

ARGLGWFDP

0

QQYYSTPPRT

0

1.89

++

250

HL CV38-186

S1-MBC IgG1

1-2

4

ARDQSPDILKSPFDY

1

2-23

3

CSYAGSSTFG

0

6.51

++

250

HL CV38-193

S1-MBC IgA1

3-11

4

ARDISRNLHDFRPYYFDY

2

7-46

3

LLSYSGARV

1

1.53

+

n.t.

HL CV38-194

S1-MBC IgG1 4-59

3

ARHDVYSSGWYGEGAFDI

2

1-40

3

QSYDSSLSGSWV

3

0.09

1-NL1 2

HL CV38-199

ASC

IgG3 4-59

4

ARYYQDFDY

0

1-44

1

AAWDDSLNGPYV

1

0.07

HK CV38-201

ASC

IgG1 3-30

4

AKDIVLVPAAIPVPIFDY

2

3-11

5

QQRSNWPPT

1

0.07

HL CV38-202

ASC

IgG1 3-33

3

ARDSSQQQLAYAFDI

2

3-1

2

QAWDSSIVV

1

0.1

60

SHM IGKV/ IGLV

S1 reactivity

22

2-14

3

SSYTNTNTLV

20

0.09

ASC

IgM

4-39

2

AHQSGNSGPWYFDL

0

8-61

2

VLYMGSGIVV

1

0.08

HL CV38-210

ASC

IgG1 4-39

4

ARHVEPDYGGNSFDY

0

1-40

1

QSYDSSLSGYV

1

0.11

HL CV38-211

ASC

IgG1

3-9

6

AKDISNKWLRLTQPYSYYGLDV

3

2-8

1

SSYAGSNIPYV

7

0.08

HL CV38-213

ASC

IgG1 3-23

3

AKVLIRNGYDILTGYPYDAFDI

0

2-14

2

SSYTSSSTLV

0

3.15

HL CV38-215

ASC

IgA1 3-30-3 4

ARDGYSAYDFGY

20

8-61

3

VLFMGSGTWV

HK CV38-217

ASC

IgA1 4-30-2 4

ASGPAWELFDY

17

3-15

3

QSYHNWPL

15

HK CV38-219

ASC

IgA1

4-39

4

ARQMRIGTIVVVPAALDY

2

3-20

1

QQYYSSPWT

5

0.07

HK CV38-221

ASC

IgG1 3-66

4

ARGFGDYYFDY

4

3-20

2

QQLYT

1

10.74

HK CV38-222

ASC

IgG1 4-30-4 6

ARDPWQVTIFGVVIRYGMDV

0

1-9

2

QQLNSYPRT

3

0.09

HL CV38-225

ASC

IgM

3-11

5

ARDLWFGRYWGNWLDP

10

1-51

3

GTWDNSLSAAV

7

0.09

HL CV38-227

ASC

IgA1

3-66

6

ASEGRTTGTIVAYYYFAMDV

15

2-8

2

SSYAGRSNVV

15

0.09

HK CV38-228 38-6

ASC

IgA1

4-31

4

AREKGTGDYYLDY

16

3-15

1

QQYNSWPRA

17

0.08

HL CV38-229 38-5

ASC

IgA1 4-30-4 3

AKIRVRAGFRWAFDI

23

2-14

3

SSYTNTNTLV

20

0.09

HL CV38-230

ASC

IgG1 3-53

4

ARDNSSNWYYFDS

8

3-25

1

QSADSSGTYV

10 n.exp.

HL CV38-231

ASC

IgG1 3-33

6

ARDGLDDDYIWGSFKIRYYYMDV

1

2-8

3

SSYSGTTNFAQ

19

HL CV38-232

ASC

IgA1

3-23

4

ASGTYRLGDY

26

1-44

3

AAWDDSLDGPV

15 n.exp.

16

2-11

3

CSYAGTYTYWL

12

IgA2

HL CV38-207 38-5

ASC

HL CV38-208

3-7

6

HL CV38-233

ASC

IgG1

4-4

5

VTGGRWRFDP

HK CV38-235 38-2

ASC

IgA1

3-23

4

VRDLSSSDPWYFDF

HK CV38-236

ASC

IgG1 3-64

6

ARGGYEIVVVPDYYYYGMDV

0

HK CV38-238 38-7

ASC

IgM

3-30

6

AKDPLNCSSTRCYTAWIYYYYGMDV

0

2D-29 4

HK CV38-240 38-7

ASC

IgG1 3-30

6

AKDSVKGYSSGWYYYYYGMDV

0

2D-29 4

HK CV38-242 38-2

ASC

IgA1

3-23

4

ARDLSSSDPWYFDF

14 3D-20 1

HK CV38-243

ASC

IgM

3-21

4

ARDRSGWYRNLFDY

1

2-28

5

HK CV38-245

ASC

IgG2 3-49

3

TRDFDHADSFDI

24

2-28

HK CV38-248

ASC

IgG2 3-30

4

AKGFYDSGP

12

HL CV38-251

ASC

IgA2

3-23

6

AKDQTVSFFYYGMDV

HK CV38-252

ASC

IgM

1-3

4

15 3D-20 1
3-20

4

QQYGDSPRT

5.74
0.09

MQSIQLPLT

0

0.09

QQYGDSPRT

11

0.08

MQALQASIT

0

0.08

2

MQALHTPRYT

9

0.09

2-30

2

MQGTHWKT

3

0.10

5

1-47

1

ATWDDSLSGYV

10

0.07

ARDNTNTWFGSIEY

36

4-1

3

QQNYATPLT

IgG2

3-9

4

VREATRGAHFDC

32

2-8

1

SSYVGFNNLDNFV

IgM

4-34

2

ARRIYYGDLGNWNFDL

24

1-16

4

QQYNSYPLT

19

ASC

IgG1 1-69

4

ATLGYCSGGSCFPTGVFGY

0

7-46

3

LLSYSGARSWV

1

0.05

ASC

IgA1

4-31

4

AREKGTGDYYLDS

21

3-15

1

QQYNSWPRA

21

0.09

HK CV38-265

ASC

IgG1 3-23

6

AKDGHSMVRGVTMWGEFYYYYGMDV

0

3-15

2

QQYNNWPPYT

0

0.1

HK CV38-270

ASC

IgG2

3-9

3

VRSRWQLTSSAFDM

33

1-9

4

QQLNKYPIT

HK CV38-271 38-6

ASC

IgA1

4-31

5

AREKGTGDYYLDP

22

3-15

2

QQYNSWPRA

21

HL CV38-273

ASC

IgG1

1-2

6

ARTYYYDSSGYRNYYYYGMDV

4

2-18

1

SLYTSSSTYV

0

0.18

HK CV38-275

ASC

IgG1 3-15

4

TTDRGNSITIFGVVIIDRPY

0

3-20

2

QQYGSS

0

n.exp.

HL CV38-276

ASC

IgA1

6

ARDEGSPGLDYYGMDV

1

2-14

2

SSYTSNTTLVV

4

0.08

HL CV38-278 38-5

ASC

IgA1 4-30-4 3

AKIRVRAGFRWAFDI

21

2-14

3

SSYTNTNTLV

22

0.08

HL CV38-281

ASC

IgG1 3-11

4

ARDMNYKYYYDSSGYPLLDY

0

1-44

3

AAWDDSLNGWV

0

0.15

HK CV38-284

ASC

IgA1

3-49

4

IRARYYYDSSATFDY

18

1-39

4

QQCYSLPST

>250

25 n.exp.
0.09

18 n.exp.

HL CV38-286

ASC

IgA2

3-30

6

AKDASSPVYDFWSGYYNHLGMDV

0

3-21

3

QVWDSSSDQGV

2

HK CV38-288

ASC

IgM

3-66

6

ARDYTVTTGGVDGMDV

0

3-11

1

QQRSNWPPWT

0

HK CV38-289

ASC

IgA1

3-23

4

VSRAAVGQPEY

HK CV48-103

S1-MBC IgG1 3-49

6

SRFYDYWNTFGLLLGSGLTFYHMDV

22

4-1

HL CV48-104

S1-MBC IgG1 1-69

5

ARDGQQLVRGWFDP

0

2-14

HL CV48-107

S1-MBC IgG1 4-39

4

ASENDYGEHDY

0

HL CV48-109

S1-MBC IgG1 3-30

4

VKGDTSAYWPSSLLIS

34

61

++

0.07

20 n.exp.

HL CV38-259

0.11
n.exp.

QQAYTLPRVT

35 n.exp.

1

QQYCYTPWT

13

0.07

1

SSYTSSSTLYV

2

6.93

4-60

2

ETWDSNTRKVV

1

0.1

2-14

2

GSYATGSSPVV

17

0.10

44) 1D-12 3

n.t.

21 n.exp.

HK CV38-263 38-6

3-21

-

0.08

11 n.exp.
0

ASC

25-250

0.08

0

ASC

++

0.10

QQYKD

HL CV38-255

n.t.

18 n.exp.

MQSIQLPLT

HK CV38-257

+

(ng/ml)

CDR L3

AKIRVRAGFRWAFDI

IgG1 4-30-2 6

ASC

Estimated IC50

IGKJ/IGLJ gene

0.08

IgA1 4-30-4 3

ASC

RBD reactivity

IGKV/IGLV gene

0.09

1

HL CV38-205
HK CV38-206

(OD ratio)

SHM IGHV

1

LQYNSYSWYT

IGHJ gene

QSYDSSTVV

2

IGHV gene

2

1-5

Ig isotype

6-57

3

Source cell

0

ARKGNAIDV

Clonality

ARDHYPYYYYGMDV

mAb

CDR H3

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

CDR L3
QQYKGSSWAT

2

QTWGTGINVV

1

0.08

HL CV48-119

S1-MBC IgA2

3-23

4

AKTDRHWNHCD

18

2-14

2

SSYTGSSTLVA

18

0.08

HL CV48-123

S1-MBC IgM

1-3

4

ARNGGGLDQ

21

2-14

2

CSSTTSSTAV

12 n.exp.

HK CV-X1-102

S1-MBC IgG1 1-69

6

ARSPRPLIVVAEDGMDV

1

3-20

3

QQYGSSPFT

1

6.81

HL CV-X1-109

S1-MBC IgG1

1-2

4

ARGPLFWDTAMANFDY

0

2-14

3

N/A

4

0.12

HK CV-X1-111

S1-MBC IgM

3-49

4

NRELHNSVVVGVMGY

17

4-1

2

HHYYSPPYA

7

0.16

HK CV-X1-112

S1-MBC IgM

3-23

4

AKVGSGWYAFDY

16

3-15

1

QQYNKWPRT

5

0.09

HL CV-X1-119

S1-MBC IgG1 4-59

6

ARDRIMPLSYYYYYGMDV

0

1-44

3

AAWDDSLNGWV

0

0.17

HK CV-X1-126

S1-MBC IgG1 3-53

6

ARDLSEGGMDV

2

1-12

4

QQANGFPPL

2

11.78

HK CV-X1-128

S1-MBC IgG1 5-51

6

ARTYDFWSGFDYYGMDV

3

3-11

3

QQRSNWPT

0

0.13

HL CV-X1-131

S1-MBC IgG1 3-30

4

ARMATTYPEHDPSLY

2

3-21

3

QVWDSSSDHWV

2

10.74

5

AAWRGFAATGFDS

21

1-9

3

QQLKSYPLT

7

0.1

IgA1

1-8

3

ATEGTILTTMTAGAFDL

26

1-12

2

QQTDNFPYT

18

0.17

IgA1

1-69

4

ARFGGTSQSSGYYGFDN

23

2-28

2

MQPLQTPYT

11

0.08

ASC

IgG1 3-23

6

VTHDFPDWPPGGGMDV

18

6-57

3

QSYDWSNQGV

10

0.16

HK CV-X1-142

ASC

IgG2 1-18

4

STRGMAPHDY

28

1-39

1

HQTYDTWT

33 n.exp.

HK CV-X1-143

ASC

IgG1 3-11

4

ARDLGYSTRFDY

0

1-33

4

QQYDNLPLT

0

6.76

HK CV-X1-145

ASC

IgG1 5-51

4

AREDLTGPDY

8

2-30

2

MQGTHWPNT

1

0.16

HL CV-X1-146

ASC

IgG1 3-23

4

ANNYYDNSGPDY

30

6-57

3

QSNDGSPSWV

20

0.15

HL CV-X1-150

ASC

IgG1 5-51

4

ARHLVCGGSCYPFDY

0

3-21

3

QVWDSSSDHQV

1

0.33

HL CV-X1-153

ASC

IgG3 3-33

4

ARDWFWRLGGVDY

0

8-61

2

VLYMGSGLVV

2

0.16

HL CV-X1-157

ASC

IgA1

3-48

6

ATSYYDPSSAYSAHYAMDV

32

2-14

2

TSYTSLSPVV

20

0.09

HK CV-X1-164

ASC

IgG1

1-2

6

ARSFGGFGGNYGMDV

3

1-39

5

QQSYSTPIT

0

0.13

HL CV-X1-165

ASC

IgA2

3-48

4

ARDPIGTGSDY

13

1-51

2

GTWDSSLNAGV

9

0.13

HK CV-X1-167

ASC

IgA2

3-74

5

ARAHSTTLYGWFDP

17

3-20

1

QHYVSSPLT

13

0.09

HL CV-X1-171

ASC

IgA2

4-34

4

ARGFRKGSTFN

13

2-14

3

SSYTTSNTRE

15

0.09

HK CV-X1-172

ASC

IgG1 3-48

6

ARDRLTIFGVAIDYYGMDV

0

1-12

4

QQANSFPALT

0

0.1

HK CV-X1-173

ASC

IgG1 3-30

3

AKDYDSALCTGGTCTFDAFDF

27

1-27

1

QNYNSAPPWT

11

0.24

ASC

IgM

HK CV-X1-137

ASC

HK CV-X1-140

ASC

HL CV-X1-141

HL CV-X1-174

ASC

IgG1 3-21

6

ATVQGDYVAGRAYYYGMDV

0

3-1

2

QAWDSSTAV

0

0.10

HK CV-X1-175

ASC

IgG1 1-69

4

ARGLQGTHLDC

1

4-1

3

QQYYSTGFT

1

1.99

HL CV-X1-177

ASC

IgG1 3-30

4

ARAETPASEIDY

0

3-1

2

QAWDSSHVV

1

0.08

HK CV-X1-178

ASC

IgA1

3-49

6

TRDRPIDYGDLHIYYYGLDV

22

2-28

2

MQALQTPPT

8

0.1

HK CV-X1-180

ASC

IgA1

4-39

5

LKDRTLQGNWFDP

26

3-11

5

QQRRDWPPVT

14

0.09

HL CV-X1-183 X1-1

ASC

IgG1 3-30

4

ASKSPERGSFDY

26

2-14

1

SSYTNGSSLYV

7

n.exp.

HL CV-X1-188

ASC

IgM

4-4

5

AKGGGPIVA

14

4-60

2

ETWDSNTRL

8

0.08

HL CV-X1-189

ASC

IgG1 3-23

6

AKGRRYYDFWSGPMPYGMDV

1

2-14

3

SSYTSSSTLGV

10

0.09

HL CV-X1-190 X1-1

ASC

IgG1 3-30

4

ANTSPGRGSFDY

9

2-14

1

SSYTNSSTLYV

13

HK CV-X1-191

ASC

IgG1 4-31

4

ARQLRFLEWQYFDY

0

1-33

4

QQYDNLLT

0

0.08
n.exp.

ASC

HK CV-X1-195

>250

++

25-250

++

>250

++

>250

-

n.t.

>250

10 n.exp.

4-31

HK CV-X1-136

++

(ng/ml)

IGKJ/IGLJ gene
1

4-69

Estimated IC50

IGKV/IGLV gene
1-5

0

RBD reactivity

SHM IGHV
17

ARDGLDDDYIWGSFKIRYYYMDV

(OD ratio)

CDR H3
ARDARYSAYELPDYFFDL

6

S1 reactivity

IGHJ gene
4

Ig isotype

3-33

S1-MBC IgG1 3-33

Source cell

S1-MBC IgA1

HL CV48-113

Clonality

HK CV48-110

mAb

IGHV gene

SHM IGKV/ IGLV

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

11 n.exp.

IgA1

3-64

4

VKGWGVKASSLGGDY

20

3-11

4

HQRSDWPRLT

HK CV-X2-103

S1-MBC IgA1

3-15

5

TTWRLGQDWFDP

17

1-39

4

QQSYSAPLT

14

0.81

++

HL CV-X2-105

S1-MBC IgA1

3-73

6

TRRFDPNQRNDYYYALDF

12

1-44

1

SAWDDSLNGYV

9

3.48

+

n.t.

HK CV-X2-106

S1-MBC IgG1 1-69

6

ATRKETTVTTSLVYGMDV

1

1-39

2

QQSYSTPYT

2

++

250

++

>250

HK CV-X2-107 X2-2 S1-MBC IgA1

3-66

4

ARGKVGATGFEY

15

3-20

2

QQYGSSPPMYT

8

9.14
n.exp.

HK CV-X2-108 X2-2 S1-MBC IgA1

3-66

4

ARGKVGATGFED

10

3-20

2

QQYGSSPPMYT

8

n.exp.

HK CV-X2-109

S1-MBC IgM

5-51

3

ARLAHYYDRSGYSRADDAFDV

7

3-15

2

QQYNNWPPVYT

2

6.81

HK CV-X2-117 X2-2 S1-MBC IgA1

3-66

4

ARGKVGATGFED

10

3-20

2

QQYGSSPPMYT

9

HK CV-X2-118

S1-MBC IgG1 3-30

4

AKTGGPYCSGGSCYSALMDY

0

1-33

1

QQYDNLPPT

0.08
n.exp.

HK CV-X2-123

S1-MBC IgA1

6

ARDRTREGYHDTLTGEFYFYGTDV

33

3-20

2

QQYAMSPVT

4-4

62

0
27 n.exp.

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

For clonality analysis mAbs from an identical donor were identified as clones when sharing the same V and J gene on both heavy and light
chain and showing similarities within amino acid sequences of both CDR3. S1 reactivity was determined as a normalized optical density
(OD) measured by SARS-CoV-2-S1 ELISA, with values above 0.5 considered as positive. From S1+ mAbs specificity to the RBD was
determined using an RBD-ELISA and noted as negative (-), positive (+) or strongly positive (++), when detectable at 10 ng/ml. All strongly
positive RBD+ mAbs were screened for neutralization of authentic SARS-CoV-2 (Fig. 1A), from which the IC50 was estimated.
Abbreviations: ASC = antibody-secreting cell, S1-MBC = S1-SARS-CoV2-enriched memory B cell, Ig = immunoglobulin, HC = heavy chain,
KC = kappa chain, LC = chain, IGHV/IGHJ = immunoglobulin heavy chain variable/joining gene, IGKV/IGKJ = immunoglobulin kappa chain
variable/joining gene, IGLV/IGLJ = immunoglobulin lambda chain variable/joining gene, CDR = complementarity-determining region, SHM =
somatic hypermutations, n.exp. = not expressed, n. t. = not tested.

63

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplementary Table ST3 | Public or common antibody response using VH3-53 and VH3-66 genes.
mAb

IGHV

IGHJ

CDR H3

IGKV/IGLV

IGKJ/IGLJ

CDR L3

RBD-494 (Cao et al.)

3-53

6

ARDLVVYGMDV

1-9

4

QQLNSYPFT

HK CV07-202

3-53*01

6*02

ARDLYYYGMDV

1-9*01

4*01

QQLNNYSVT

HL CV07-275

3-66*01

4*02

ARDYYDSSGYYSSGGLGY

2-8*01

1*01

SSYAGSNNFV

HL CV38-148

3-66*01

4*02

ARSAPLVGAYSGIYFDY

9-49*01

2*01

GADHGSGSNFVV

HK CV38-221

3-66*01

4*02

ARGFGDYYFDY

3-20*01

2*01

QQLYT

HK CV38-113

3-53*04

4*02

ARGGRLADAAGDY

1-33*01

2*02

QQYDNLPSWT

HK CV38-139

3-53*01

4*02

ARGHYDLFDY

1-9*01

3*01

QQLNSYPPGT

HL CV38-183

3-53*01

6*02

ARGDGWDNYYYGMDV

1-40*01

2*01

QSYDSSLSGSV

HK CV-X1-126
3-53*04 6*02
ARDLSEGGMDV
1-12*01
4*01
QQANGFSAL
Abbreviations: IGHV/IGHJ = immunoglobulin heavy chain variable/joining gene, IGKV/IGKJ = immunoglobulin kappa chain variable/joining
gene. IGLV/IGLJ = immunoglobulin lambda chain variable/joining gene, CDR = complementarity-determining region.

64

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplementary Table ST4 | Biophysical and functional characterization of the 18 most potent SARS-CoV-2
neutralizing mAbs.
mAb

EC50
(ng/ml)

Ka
(s-1)

Kd
(M-1s-1)

KD
(M)

IC50
(ng/ml)

ACE2 binding
reduction (%)

Tissue
reactivity

CV05-163

3.8

8.48 E+06

1.86 E-03

2.20 E-10

16.3

9.6

none

CV07-200

9.0

n/a

n/a

n/a

14.5

none

B / L*

CV07-209

4.1

2.40 E+07

1.44 E-04

6.00 E-12

3.1

73.9

none

CV07-222

5.5

2.98 E+07

2.07 E-04

6.97 E-12

7.8

36.9

B/L/C

CV07-250

8.7

4.05 E+06

2.28 E-04

5.64 E-11

3.5

59.9

none

CV07-255

4.8

n/a

n/a

n/a

14.5

51.6

L/H/C/K

CV07-262

12.1

4.27 E+06

3.37 E-04

7.90 E-11

7.1

25.5

none

CV07-270

14.2

n/a

n/a

n/a

82.3

7.5

L / H* / C

CV07-283

4.0

1.52 E+07

7.24 E-04

4.75 E-11

16.9

38.0

none

CV07-287

5.9

5.11 E+06

8.14 E-04

1.60 E-10

41.7

12.4

none

CV07-315

7.2

2.36 E+07

2.62 E-04

1.12 E-11

24.9

none

none

CV38-113

5.2

2.33 E+06

3.12 E-04

1.34 E-10

20.8

51.2

none

CV38-139

8.9

3.62 E+05

1.00 E-04

2.77 E-10

73.2

14.9

none

CV38-142

5.6

6.31 E+05

6.60 E-04

1.05 E-09

23.2

26.9

none

CV38-183

5.4

2.31 E+06

1.37 E-04

5.93 E-11

3.7

65.9

none

CV38-221

6.4

7.45 E+05

3.71 E-04

4.99 E-10

172.6

50.1

none

CV-X1-126

5.5

4.12 E+05

9.98 E-05

2.43 E-10

71.7

44.2

none

CV-X2-106

5.6

n/a

n/a

n/a

17.6

19.9

none

Abbreviations: EC50 = half-maximal effective concentration, Ka = association rate, Kd = dissociation rate, KD = equilibrium dissociation
constant, IC50 = half-maximal inhibitory concentration, B = brain, L = lung, H = heart, C = colon, K = kidney. An asterisk (*) indicates weak
binding.

65

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplementary Table ST5 | X-ray data collection and refinement statistics.
Data collection
CV07-250 + RBD

CV07-270 + RBD

Beamline

SSRL 12-1

SSRL 12-1

Wavelength (Å)

0.97946

0.97946

Space group

P 21 21 21

C121

68.0, 80.1, 153.7

157.0, 151.8, 66.0

Unit cell parameters
a, b, c (Å)
α, β, γ (°)

90, 90, 90

90, 95.4, 90

Resolution (Å) a

50.0–2.55 (2.59–2.55)

50.0–2.70 (2.75–2.70)

Unique reflections a

27,890 (2,659)

41,624 (2,089)

Redundancy a

8.8 (6.5)

4.7 (3.6)

Completeness (%) a

99.6 (98.9)

90.8 (90.8)

<I/σI> a

17.3 (1.1)

6.7 (1.1)

11.9 (94.6)

19.9 (80.6)

b

Rsym (%)

a

Rpimb (%) a

4.1 (38.9)

9.9 (50.5)

CC1/2c (%) a

99.5 (71.0)

97.6 (67.6)

Refinement statistics
Resolution (Å)

43.2–2.55

49.7–2.72

Reflections (work)

27,883

39,568

Reflections (test)

2,656

2,055

Rcrystd / Rfreee (%)

20.7/25.9

22.6/26.7

No. of atoms

4,525

9,233

Macromolecules

4,420

9,165

Glycans

28

28

Solvent

77

40

Average B-value (Å2)

52

44

Macromolecules

52

44

Fab

46

42

RBD

66

46

Glycans

100

77

Solvent

49

57

51

39

Wilson B-value (Å2)

RMSD from ideal geometry
Bond length (Å)

0.005

0.007

Bond angle (o)

0.74

1.27

Ramachandran statistics (%)
Favored

96.1

Outliers

0.2

96.8
0.0

PDB code

6XKQ

6XKP

a

Numbers in parentheses refer to the highest resolution shell.
Rsym = Σhkl Σi | Ihkl,i - <Ihkl> | / Σhkl Σi Ihkl,i and Rpim = Σhkl (1/(n-1))1/2 Σi | Ihkl,i - <Ihkl> | / Σhkl Σi Ihkl,i, where Ihkl,i is the scaled intensity of the ith
measurement of reflection h, k, l, <Ihkl> is the average intensity for that reflection, and n is the redundancy.
c
CC1/2 = Pearson correlation coefficient between two random half datasets.
d
Rcryst = Σhkl | Fo - Fc | / Σhkl | Fo | x 100, where Fo and Fc are the observed and calculated structure factors, respectively.
e
Rfree was calculated as for Rcryst, but on a test set comprising 5% of the data excluded from refinement.
b

66

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplementary Table ST6 | Hydrogen bonds and salt bridges identified at the antibody-RBD interface using the
PISA program.
CV07-250

Distance (Å)

SARS-CoV-2 RBD

Hydrogen bonds
H:TYR98[N]

3.0

A:ALA475[O]

H:ASN31[ND2]

3.4

A:SER477[OG]

H:ASN100C[ND2]

3.8

A:GLY485[O]

H:ASN100C[ND2]

2.9

A:PHE486[O]

H:ASN97[ND2]

2.8

A:ASN487[OD1]

H:ASN97[ND2]

2.7

A:TYR489[OH]

H:TYR100B[N]

3.5

A:TYR489[OH]

H:ASP96[OD1]

3.0

A:SER477[N]

H:ASP96[OD2]

2.7

A:SER477[OG]

H:ASP96[OD2]

3.5

A:THR478[N]

H:ASP96[OD2]

2.9

A:THR478[OG1]

H:SER95[OG]

2.9

A:ASN487[ND2]

H:PHE100[O]

3.4

A:TYR489[OH]

L:SER27A[OG]

3.2

A:TYR505[OH]

L:HIS31[N]

3.1

A:GLN493[OE1]

L:SER67[OG]

3.5

A:GLY446[O]

L:GLY68[N]

3.1

A:GLY446[O]

L:GLY68[N]

3.1

A:TYR449[OH]

L:ASN69[N]

3.8

A:GLN498[OE1]

L:ASN69[ND2]

3.7

A:GLN498[OE1]

L:TYR49[OH]

3.5

A:PHE486[N]

CV07-270

Distance (Å)

SARS-CoV-2 RBD

Hydrogen bonds
H:TYR100B[OH]

2.8

A:SER349[OG]

H:SER98[N]

3.2

A:GLY447[O]

H:SER98[OG]

3.8

A:GLY447[O]

H:SER98[OG]

3.2

A:ASN448[OD1]

H:ARG100G[NH2]

2.9

A:GLU484[OE1]

H:ARG100G[NH1]

3.2

A:GLU484[OE2]

H:ARG100G[NH2]

3.0

A:GLU484[OE2]

H:THR28[OG1]

3.2

A:LYS444[NZ]

H:ASP31[OD1]

2.7

A:ARG346[NH1]

H:ASP31[OD2]

2.7

A:LYS444[NZ]

H:SER98[O]

2.7

A:TYR449[N]

H:SER98[O]

3.3

A:ASN450[N]

3.6

A:SER349[N]

H:TYR100B[OH]

Salt bridges
H:ARG100G[NH2]

2.9

A:GLU484[OE1]

H:ARG100G[NH1]

3.2

A:GLU484[OE2]

H:ARG100G[NH2]

3.0

A:GLU484[OE2]

H:ASP31[OD1]

2.7

A:ARG346[NH1]

H:ASP31[OD1]

3.4

A:ARG346[NE]

H:ASP31[OD2]

2.7

A:LYS444[NZ]

67

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Macrophages

Neutrophils

Epithelial cell necrosis of bronchia

Bronchial inflammationa

Alveolar edemac

Perivascular edemac

Perivascular lymphocytic cuffing

Endotheliitis

a

b

c

1.0

0.0

1.0

1.0

0.0

0.0

0.0

1.0

0.0

0.0

0.0

1.0

0.0

0.0

0.0

0.0

P2

3

<5

1.0

1.0

1.0

1.0

0.0

0.0

0.0

1.0

0.0

0.0

0.0

1.0

0.0

0.0

0.0

0.0

P3

3

5

1.0

1.0

1.0

1.0

0.0

0.0

0.0

1.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

T1

3

10

1.5

1.0

1.0

1.0

0.0

0.0

0.0

1.0

0.0

0.0

0.0

1.0

0.0

0.0

0.0

0.0

T2

3

25

3.0

2.5

2.0

3.5

3.5

4.0

0.0

3.0

2.0

1.5

0.0

2.0

2.0

3.8

1.0

0.8

T3

3

15

2.0

2.0

2.0

2.0

0.0

0.0

0.0

2.0

1.0

0.0

1.0

1.0

0.0

0.0

0.5

0.5

C1

3

15

2.5

2.0

2.0

3.0

2,5

3.0

0.0

3.0

1.0

2.0

1.0

1.0

2.0

3.0

0.5

1.5

C2

3

20

2.5

2.5

2.0

2.5

2,5

3.0

0.0

2.0

1.0

0.0

3.0

1.5

2.0

3.0

0.5

1.5

C3

3

20

2.5

2.0

2,5

2,5

2.0

2.0

0.0

3.0

2.0

0.0

2.0

1.0

2.0

2.0

1.0

1.0

P4

5

5-10

2.0

2.0

2.0

1.5

0.0

0.0

0.0

2.0

2.0

0.0

1.5

1.0

0.0

0.0

1.0

0.8

P5

5

<5

1.0

1.0

1.0

1.0

0.0

0.0

0.0

1.0

0.0

0.0

1.0

1.0

0.0

0.0

0.0

0.5

P6

5

15

2.0

2.0

2.0

2.0

0.0

0.0

0.0

2.0

2.0

0.0

0.0

2.0

0.0

0.0

1.0

0.0

T4

5

5-10

2.0

2.0

1.5

1.0

0.0

0.0

0.0

1.0

2.0

0.0

0.0

2.0

0.0

0.0

1.0

0.0

T5

5

25

3.0

3.0

2.0

3.0

2.0

2.0

0.0

3.0

3.0

2.0

2.0

3.0

3.0

2.0

1.5

2.0

T6

5

0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C4

5

80

4.0

4.0

3.0

3.0

3.0

3.0

3.0

3.0

4.0

3.0

3.5

3.0

3.5

3.0

3.5

3.3

C5

5

15-20

2.5

3.0

2.5

2.0

2.0

2.0

1.5

2.0

2.0

2.5

0.0

3.0

2.0

2.0

1.8

1.3

C6

5

50

4.0

3.5

3.0

3.0

3.0

3.0

4.0

2.5

4.0

3.5

4.0

3.5

3.0

3.0

4.0

3.8

P7

13

20

2.0

2.0

2.0

1.0

0.0

0.0

0.0

1.5

0.0

1.5

0.0

1.5

0.0

0.0

0.8

0.8

P8

13

30

2.0

2.0

2.0

2.0

0.0

0.0

0.0

1.5

0.0

0.0

0.0

2.0

0.0

0.0

1.0

0.0

P9

13

30

2.0

2.0

2.0

2.0

0.0

1.0

1.0

1.5

0.0

0.0

0.0

2.0

0.0

0.5

1.5

0.0

T7

13

15

2.0

2.0

2.0

1.5

0.0

0.0

0.0

1.5

0.0

0.0

0.0

2.0

0.0

0.0

1.0

0.0

T8

13

5

1.0

1.5

1.0

1.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.0

0.0

0.0

0.5

0.0

T9

13

20

1.5

1.5

1.0

1.5

0.0

0.0

0.0

1.0

0.0

0.0

0.0

1.5

0.0

0.0

0.8

0.0

C7

13

5

1.0

1.0

1.0

1.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.5

0.0

0.0

0.8

0.0

C8

13

40

2.0

2.0

2.0

2.0

0.0

1.0

1.0

1.5

0.0

0.0

1.5

2.0

0.0

0.5

1.5

0.0

Alveolar epithelial cell necrosis

Animal number

Edema score

Lymphocytes

<5

Regeneration score

Degree of
inflammation*

3

Bronchitis score

% Affected lung
tissue

P1

|-------------- pneumonia ----------|

Hyperplasia of bronchial epithelia
cellsb

Time point (dpi)

Hyperplasia type II alveolar epithelial
cellsb

Supplementary Table ST7 | Histopathological scoring of lung tissue from COVID-19 hamster model.

C9
13
10
1.0
1.0
1.0
1.0
0.0
1.0
0.0
0.0
0.0
0.0
0.0
1.5
0.0
0.5
0.8
0.0
Histopathological scoring of formalin-fixed paraffin-embedded lung tissue from hamsters of experimental groups as abbreviated (P =
prophylactic, T = therapeutic, C = control) at indicated days post infection (dpi). Degree of inflammation

68

(*)

is scaled as (1) minimal, (2) mild,

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.15.252320; this version posted August 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

(3) moderate or (4) severe. For all other parameters rating refers to occurrence rate from (1) sporadic, (2) mild, (3) moderate to (4) severe.
Scores were assessed as means from parameters with corresponding letters as indicated.

69

